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ABSTRACT OF DISSERTATION 
 
 
 
 
 
ELUCIDATING PROTEASOME CATALYTIC SUBUNIT COMPOSITION AND ITS ROLE 
IN PROTEASOME INHIBITOR RESISTANCE 
 
Proteasome inhibitors bortezomib and carfilzomib are FDA-approved anticancer 
agents that have contributed to significant improvements in treatment outcomes.  However, 
the eventual onset of acquired resistance continues to limit their clinical utility, yet a clear 
consensus regarding the underlying mechanisms has not been reached. 
Bortezomib and carfilzomib are known to target both the constitutive proteasome 
and the immunoproteasome, two conventional proteasome subtypes comprising 
distinctive sets of catalytic subunits.  While it has become increasingly evident that 
additional, ‘intermediate’ proteasome subtypes, which harbor non-standard mixtures of 
constitutive proteasome and immunoproteasome catalytic subunits, represent a 
considerable proportion of the proteasome population in many cell types, less is known 
regarding their contribution to cellular responses to proteasome inhibitors.  Importantly, 
previous studies in murine models have shown that individual proteasome subtypes differ 
in sensitivity to specific proteasome inhibitors.  Furthermore, research efforts in our 
laboratory and others have revealed that proteasome catalytic subunit expression levels 
and activity profiles are altered when human cancer cells acquire resistance to 
proteasome inhibitors.  We therefore hypothesized that changes in the relative 
abundances of individual proteasome subtypes contribute to the acquired resistance of 
cancer cells to bortezomib and carfilzomib.   
A major obstacle in testing our hypothesis was a lack of chemical probes suitable 
for use in identifying distinct proteasome subtypes.  We addressed this by developing a 
series of bifunctional proteasome probes capable of crosslinking specific pairs of catalytic 
subunits colocalized within individual proteasome complexes and compatible with 
immunoblotting-based detection of the crosslinked subunit pairs.  We confirmed the utility 
of these probes in discerning the identities of individual proteasome subtypes in a multiple 
myeloma cell line that abundantly expresses catalytic subunits of both the constitutive 
proteasome and immunoproteasome.  Our findings indicate that constitutive proteasomes, 
immunoproteasomes, and intermediate proteasomes co-exist within these cells and 
support conclusions drawn from previous studies in other cell types.  
We also established non-small cell lung cancer cell line models of acquired 
bortezomib and carfilzomib resistance in which to test our hypothesis.  Using 
immunoblotting and proteasome activity assays, we discovered that changes in the 
expression levels and activities of individual catalytic proteasome subunits were 
associated with the emergence of acquired resistance to bortezomib or carfilzomib.  These 
changes were inhibitor-dependent and persisted after the selective pressure of the 
inhibitor was removed.  Finally, results obtained using our bifunctional proteasome probes 
suggest that the altered abundance of an intermediate proteasome subtype is associated 
with acquired proteasome inhibitor resistance.  Collectively, our results provide evidence 
linking changes proteasome composition with acquired proteasome inhibitor resistance 
and support the hypothesis that such changes are involved in resistance mechanisms to 
these inhibitors. 
 
Keywords: Proteasome Inhibitor, Bortezomib, Carfilzomib, Proteasome Subtype, 
Bifunctional Proteasome Probe 
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1 
1 INTRODUCTION 
1.1 Discovery and Characterization of the Ubiquitin-Proteasome Pathway 
The decades leading up to the discovery of ubiquitin-dependent protein 
degradation were characterized by marked paradigm shifts regarding the regulation of 
intracellular protein levels.  Until it was shown in the early 1940s that proteins are 
continuously turned over (i.e., degraded and resynthesized), they were regarded as stable 
entities [1, 2].  In the 1950’s, the discovery of the lysosome and its apparent protein-
degrading capabilities led many researchers to readily accept a new paradigm in which 
this organelle was solely responsible for cellular protein turnover [1, 2].  However, the 
unraveling of the ubiquitin-dependent pathway, beginning in the late 1970s and extending 
through the 1980s, provided a satisfying explanation for a number of observed properties 
of protein degradation that were seemingly incompatible with the acknowledged non-
selective, ATP-independent mechanism of lysosomal degradation—most notably, it 
explained why different cellular proteins are degraded at different rates, the differential 
effects of lysosomal protease inhibitors on distinct protein groups, as well as the ATP 
requirement for intracellular protein degradation.  Thus, a second major paradigm shift 
resulted in which ubiquitin-dependent proteolysis was deemed responsible for degrading 
the vast majority of cellular proteins [1, 2].  Largely in the pages of The Journal of Biological 
Chemistry and Proceedings of the National Academy of Sciences, Aaron Ciechanover, 
Avram Hershko, and Irwin Rose documented their discoveries that allowed them to 
elucidate this pathway, for which they were awarded the Nobel Prize in Chemistry in 2004 
[1, 2]. 
Targeting a protein for ubiquitin-dependent degradation, they found, involves its 
covalent linkage with a chain composed of multiple copies of the ubiquitin protein [3].  
Proteins are polyubiquitinated in a multistep process involving a series of three enzymes: 
an E1 ubiquitin-activating enzyme [4-6], an E2 ubiquitin-conjugating enzyme, and an E3 
ubiquitin ligase enzyme [7].  A K48-linked polyubiquitin chain, in which the C-terminal 
glycine residue of the incoming ubiquitin is linked with lysine at position 48 of the ubiquitin 
at the end of the growing chain, appears to serve as the earmark for degradation [8, 9].  
Additionally, a tetraubiquitin chain appears to be the minimal signal capable of targeting a 
protein for ubiquitin-dependent degradation [10] (Figure 1.1).  
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Figure 1.1 Ubiquitin proteasome pathway-mediated protein degradation 
A polyubiquitin chain is covalently linked to a target protein (substrate) via a series of three 
enzymes: an E1, an E2, and an E3. This polyubiquitin chain is recognized by the 
proteasome, which degrades the protein to short peptides and releases free ubiquitin. The 
19S caps are schematically depicted in yellow, and the 20S core in blue. 
 
Wilk, Pearce, and Orlowski were the first researchers to purify and characterize 
the endopeptidase we now know as the 20S proteasome, which serves as the degradative 
machinery of the ubiquitin-dependent pathway [11].  It was found to efficiently cleave 
bonds between leucine and the chromogenic group p-nitroaniline within the synthetic 
chromogenic substrates Cbz-Gly-Gly-Leu-pNA and Cbz-Gly-Gly-Tyr-Leu-pNA.  
Conversely, it was unable to hydrolyze model trypsin, chymotrypsin, carboxypeptidase, 
and aminopeptidase substrates [11].  Further studies with chromogenic peptide substrates 
revealed that the proteasome possesses three main catalytic activities—a chymotrypsin-
like (CT-L) activity, a trypsin-like (T-L) activity, and a peptidylglutamyl-peptide bond 
hydrolyzing (PGPH) activity—by which it cleaves peptide bonds on the carboxyl side of 
hydrophobic, basic, and acidic amino acids, respectively [12, 13].  The PGPH activity was 
later renamed the ‘caspase-like’ (C-L) activity when it was discovered that the active sites 
responsible for this activity prefer to hydrolyze peptide bonds after aspartates over those 
that follow glutamates [14].  Two additional catalytic activities were subsequently 
3 
discovered: a branched chain amino acid preferring (BrAAP) activity and a small neutral 
amino acid preferring (SNAAP) activity, which cleave on the carboxyl side of branched 
chain and small neutral amino acids, respectively [15]. 
 
1.2 Proteasome Structure and Proteasomal Degradation of Proteins 
Proteasomes interact with polyubiquitinated substrate proteins of the ubiquitin-
proteasome pathway (UPP) via ubiquitin-binding subunits of the 19S regulatory caps that 
associate with the ends of the 20S proteasome core [16-18] (Figure 1.1).  The 19S cap 
also contains components that remove the polyubiquitin chain to facilitate recycling of 
ubiquitin, unfold the protein, and assist entry of the unfolded protein into the 20S core [19-
23].  The core itself is an annular complex built of four axially stacked heptameric rings.  
Each outer or inner ring is composed of seven α-subunits or seven β-subunits, respectively.  
The seven α-subunits of the T. acidophilum 20S proteasome are all identical, as are the 
seven β-subunits [24, 25].  However, in eukaryotes, seven distinct α-subunits (α1-α7) and 
seven distinct β-subunits (β1-β7) comprise each α-ring and β-ring, respectively, with each 
of these subunits occupying a fixed position within the complex [16, 26, 27].  The N-
terminal tails of the α-rings form a gate that must be opened for a substrate to gain access 
to the 20S core, thereby providing one of several protective barriers against unregulated 
proteolysis.  Interactions between the 19S cap and the 20S core open this gate [28].  The 
catalytically active subunits, which are members of the N-terminal nucleophile (Ntn) 
hydrolase family [29], reside in the β-rings.  As all seven β-subunits of the T. acidophilum 
proteasome are identical, they are all catalytically active [30].  On the other hand, of the 
seven distinct β-subunits of eukaryotic proteasomes, only three—β1, β2, and β5—have 
proteolytic activities [31-33].  The active sites of the catalytic β-subunits are formed at 
subunit-subunit interfaces and are sequestered within the inner chamber of the core 
complex, providing further protection against uncontrolled degradation of cellular proteins 
[30, 33].  Additionally, the catalytic β-subunits are synthesized as precursors containing 
N-terminal propeptides; they become active only once their propeptides are removed to 
liberate the catalytic threonine residues of their new N-termini [34-37].  Removal of these 
propeptides occurs via an autocatalytic mechanism only within the fully assembled 
proteasome complex, providing yet another protective mechanism to ensure that these 
subunits cannot degrade proteins at random prior to their proteasome incorporation [36, 
38-41].  Upon entry of a substrate protein into the core particle, the active sites begin 
cleaving its peptide bonds, thereby degrading it to peptide fragments ~3-22 amino acids 
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in length [42, 43] (Figure 1.1).  Most of the products produced by proteasomal proteolysis 
are then further hydrolyzed by cytosolic peptidases to single amino acids [44].  
Alternatively, a small percentage of these products serve as antigens for presentation on 
MHC class I molecules, either directly or following further peptidase-mediated processing 
of their N-termini [43, 45-47]. 
By analyzing the hydrolysis of fluorogenic peptide model substrates by yeast 
mutants, Heinemeyer et al. were able to assign the C-L activity to β1, the T-L activity to 
β2, and the CT-L activity to β5 [31].  These conclusions were further supported by 
crystallography data, which identified amino acid 45 within the S1 specificity pocket of 
each of the yeast proteasome’s catalytic subunits as a major determinant of that subunit’s 
cleavage site preferences [33].  For example, Arg45 of β1’s S1 pocket explains the 
preference of this subunit for cleaving peptide bonds after acidic amino acids.  
Alternatively, Gly45 of β2 renders its S1 pocket quite spacious, and with Glu53 forming 
the bottom of this pocket, β2 prefers cleaving peptide bonds after large, basic residues.  
Finally, Met45 of β5 contributes to the preference of β5 for cleaving peptide bonds after 
hydrophobic amino acids [33, 48].  The nature of each S1 pocket is further modulated by 
amino acid residues of an adjacent subunit within the β-ring.  In addition to their C-L and 
CT-L activities, respectively, both β1 and β5 were concluded responsible for the BrAAP 
activity, and β5 for the SNAAP activity [49].  However, assessments made using 
fluorogenic peptide substrates may provide an oversimplified view of the cleavage site 
specificities of these subunits when they degrade longer peptides [50].  Proteasomes 
containing catalytic subunits β1, β2, and β5 appeared to be expressed in nearly all cell 
types and tissues examined and are therefore referred to as ‘constitutive proteasomes’ 
(Figure 1.2).   
It became evident soon after its discovery that the UPP mediates the degradation 
of short-lived and abnormal proteins [51-53].  Certain short-lived regulatory proteins were 
found to depend on the UPP for their timely degradation, revealing a key role of this 
pathway in regulating various cellular processes such as progression through the cell 
cycle and cell survival and differentiation [54-56].  As will be discussed further below, the 
development and discovery of selective inhibitors of the proteasome allowed these UPP 
functions to be confirmed and additional roles to be identified.  Furthermore, the 
contribution of the UPP to various pathological processes underlying human diseases has 
stimulated interest in targeting its components, particularly the proteasome, for therapeutic 
purposes.  
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Figure 1.2 Proteasome subtypes 
Five distinct proteasome subtypes that can be distinguished by their catalytic subunit 
compositions have been identified in mammalian cells. 
 
1.3 Immunoproteasome and Thymoproteasome 
1.3.1 Immunoproteasome 
In the 1980s, Monaco et al. discovered a previously uncharacterized class of 
murine proteins that could be immunoprecipitated from macrophages by an antiserum 
against the MHC H-2d haplotype, yet differed both biochemically and genetically from 
known MHC-encoded proteins.  They were found to range in molecular weight from ~15-
30 kDa and were thus named ‘low molecular weight proteins’ (or ‘LMPs’) [57].  High levels 
of the LMPs were detected in macrophages, and lower levels in lymphocytes and 
fibroblasts [57].  They were shown to exist in a large (580 kDa) complex held together by 
noncovalent bonds.  A similar complex was also detected in the human U937 cell line [58].  
The genes encoding two of the LMPs, initially named LMP-2 and LMP-7, mapped to the 
MHC class II complex in close proximity to the TAP1 and TAP2 genes [59, 60], whose 
products transport cytoplasmic peptides into the endoplasmic reticulum (ER) for assembly 
on newly-generated MHC class I molecules.  The resulting MHC class I-peptide 
complexes are transported via the Golgi apparatus to the cell surface, where the antigen 
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is presented for recognition by cytotoxic (CD8+) T cells of the adaptive immune system 
[61, 62].  In 1991, Brown et al. provided evidence indicating that the LMP complex was in 
fact a subtype of the proteasome [60].  Based on the high level of LMPs in antigen-
presenting cells and the ability of the immunomodulatory cytokine IFNγ to upregulate the 
MHC-encoded LMPs as well as TAP1 and TAP2, these researchers proposed that the 
LMP-2- and LMP-7-containing proteasome complex may function in the processing of 
foreign antigens, producing antigenic peptides for subsequent transport by TAP1 and 
TAP2 and, finally, presentation to T cells [59, 60].   
Findings from a subsequent study conducted by Brown et al. led them to propose 
a model in which distinct subtypes of proteasomes are formed by the incorporation of 
unique subunits into a core complex otherwise comprising subunits common to all 
proteasomes, permitting proteasome functionality to adapt as needed to meet cellular 
demands [63].  This was further supported by the results of subsequent studies, which 
showed that the IFNγ-inducible subunits replaced their ‘constitutive subunit’ homologs 
upon de novo proteasome biogenesis.  Among the first of these was conducted by Aki et 
al., who demonstrated that the levels of LMP-2 and LMP-7 in intact proteasome complexes 
strongly increased in human SW620 colon carcinoma cells following IFNγ treatment, while 
a strong decrease in the levels of subunits ‘X’ and ‘Y’ occurred concomitantly [64].  X and 
Y were identified as previously-reported constitutive subunits β5 and β1, which bear high 
homology to LMP-7 and LMP-2, respectively [65].  Based on these observations, IFNγ 
was concluded to cause a replacement of the β5 and β1 subunits by LMP-2 and LMP-7 
to form a proteasome complex termed the ‘immunoproteasome’, a name chosen due to 
its IFNγ-inducibility and its proposed role in producing antigenic peptides for presentation 
on MHC class I molecules [65].  Current nomenclature refers to LMP-2 as ‘β1i’ and LMP-
7 as ‘β5i’.  Additional evidence for such subunit replacement was provided by Früh et al., 
who showed that an increase in proteasome-incorporated β1i led to a selective decrease 
in the incorporation of β1, whereas an increase in incorporated β5i led to a decrease only 
in incorporation of β5.  They concluded that these changes likely resulted from a 
competition between two homologous subunits for a single position within the assembling 
proteasome complex, with the relative concentration of each competitor determining the 
outcome [66].  
IFNγ stimulation of cells was also found to alter the catalytic activities of 
proteasome complexes.  Specifically, it increased the CT-L and T-L activities and 
decreased the C-L activity.  It was therefore proposed that the IFNγ-induced incorporation 
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of β1i and β5i into proteasome complexes may result in the functional changes observed 
[64, 67].  These changes indicated that, in comparison with constitutive proteasomes, 
immunoproteasomes would less efficiently produce peptides with acidic C-termini and 
more efficiently produce those with basic and hydrophobic C-termini.  As MHC class I 
molecules preferentially bind peptides with basic and hydrophobic C-termini, this further 
supports a role for immunoproteasomes in adaptive immune responses [64, 67].   
To more precisely identify how the incorporation of each of the IFNγ-inducible 
subunits (referred to hereafter as ‘immunosubunits’) impacted these catalytic activities, a 
series of experiments with transfected cell lines was conducted.  Transfecting 
lymphoblasts or HeLa cells with β5i increased the proteasome’s CT-L activity, but its C-L 
activity remained unaltered, whereas transfecting with β1i decreased proteasomal C-L 
activity while leaving the CT-L activity unaltered.  Transfecting these cells with either β5i 
or β1i led to an increase in the proteasome’s T-L activity [68]. 
Alternatively, transfecting HeLa cells with β1 increased C-L activity but left the T-L 
and CT-L activities unchanged [69].  Together with the opposing results obtained with the 
β1i transfectant [68], this indicates that β1 bears the C-L activity of the proteasome, and 
that its decreased presence in proteasomes leads to the reduced C-L activity observed 
following β1i transfection or IFNγ stimulation [68, 69].  Likewise, transfecting a lymphoblast 
cell line with β5 resulted in decreased CT-L and T-L activity, but left the C-L activity 
unaltered [69], contrasting what was observed for the β1i and β5i transfectants [68].  
These results indicate that the reduced β5 levels in intact proteasomes following β5i 
transfection or IFNγ stimulation leads to the increased CT-L and T-L activities that were 
observed under these conditions [68, 69]. 
A third immunosubunit, ‘multicatalytic endopeptidase complex-like 1’ (‘MECL-1’), 
was later found to replace β-subunit ‘Z’ in mouse and human proteasomes following IFNγ 
stimulation [70, 71].  Unlike β1i and β5i, the gene encoding MECL-1 is located outside of 
the MHC [72].  Based on the homology of Z to yeast β2, it is now more commonly called 
‘β2’, and its immunosubunit homolog, MECL-1, is called ‘β2i’.  It was speculated that these 
subunits modulate the proteasome’s T-L activity [70].  These three subunit exchanges (β1i 
for β1, β5i for β5, and MECL-1 for Z) were the only three noted following IFNγ stimulation 
[70]; thus, pure immunoproteasomes contain the three immunosubunits in place of their 
constitutive homologs (Figure 1.2).  Similar observations were made in mouse H6 
hepatoma cells [73].  Evidence indicating that these three constitutive subunits and their 
IFNγ-inducible counterparts are catalytically active, while the remaining β-subunits are not, 
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suggested that the mammalian proteasome has evolved towards a reduced number of 
catalytically active subunits and an increase in the diversity of these subunits, imparting a 
high degree of functional versatility [70]. 
Crystallography data for the mammalian constitutive proteasome and 
immunoproteasome provided structural explanations for the observed differences in 
catalytic activities between these two proteasome subtypes [74, 75].  In comparison with 
that of β1, β1i’s S1 specificity pocket has a reduced size and polarity, leading to a shift 
away from C-L activity towards CT-L and BrAAP activity [74, 75].  Major structural 
differences between the S1 pockets of β2 and β2i were not observed, in accordance with 
both having T-L activity [74, 75].  Finally, differences in the conformation of Met45 between 
β5 and β5i’s S1 pockets result in a smaller S1 pocket in β5 and a larger one in β5i.  
Therefore, although both subunits have CT-L activity, β5 has an increased preference for 
cleaving after small hydrophobic residues such as Ala, while β5i has a stronger preference 
for cleaving after larger hydrophobic residues [75].  These differences facilitated the recent 
development of fluorogenic peptide substrates that are selectively hydrolyzed by individual 
constitutive subunits or immunosubunits [76].    
Early studies in which the expression levels of the immunosubunits were examined 
across various cell lines and tissues yielded results consistent with the proposed roles of 
these subunits in adaptive immunity.  β1i, β2i, and β5i mRNA levels were high in mouse 
thymus, spleen, and lymph nodes, moderate in lung, and substantially lower in other non-
lymphoid tissues (e.g., liver, kidney, heart, brain, and muscle) [77, 78].  Levels of the 
mRNAs encoding each constitutive subunit and its immunosubunit counterpart across the 
various tissues were inversely correlated [78].  Consistent with the high mRNA levels 
detected, mouse spleen contained an exceptionally high proportion of immunosubunit-
containing proteasomes, while the proportion of these proteasomes was lower in heart, 
kidney, and liver [77].  Mouse thymus also contained high levels of immunosubunit-
containing proteasomes, and lung was found to contain an intermediate level of 
immunosubunits [78].  Constitutive expression of the β2i protein was also detected in 
freshly isolated human white blood cells [79].   
In line with their constitutive expression predominantly in tissues involved in the 
immune system, the immunosubunits were found to be most highly expressed in cells of 
hematopoietic origin.  β1i and β5i mRNA levels were high in mouse RMA T cell and RHW 
macrophage cell lines.  Lower levels were detected in mouse NIH 3T3 fibroblasts and 
human hepatocytes, although also in the human CEM T cell line [77].  Additionally, higher 
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β2i mRNA levels were detected in human B cell lines IM9 and Reh than in human HeLa 
cervix carcinoma and MCF7 breast adenocarcinoma cells [79], and β2i protein levels were 
undetectable in HeLa, HeLa S3, human Caco-2 colon adenocarcinoma cells, and human 
ECV304 endothelial cells prior to IFNγ stimulation [79].  Conversely, although basal 
expression of β1i and β5i mRNAs was not detectable in the SW620 colon carcinoma cell 
line, it was also not detected in the J111 monocytic leukemia cell line.  Furthermore, basal 
expression of β5i mRNA was detected in two renal carcinoma cell lines (ACHN and KPK-
1), whereas basal β1i mRNA expression was only detected in ACHN (and not KPK-1) cells 
[64].  In agreement with their mRNA levels, higher basal amounts of the β5i protein were 
detected in the renal carcinoma cell lines than in the SW620 and J111 cell lines.  These 
results indicate that the basal expression of β1i and β5i is cell type-specific [64], and, at 
least in cancer cells, not necessarily restricted to immune-related cells.  However, 
immunosubunit protein levels are not always consistent with the levels of their 
corresponding mRNAs.  For example, despite the relatively high β1i and β5i mRNA levels 
in liver, this tissue was found to have a low proportion of β1i- and β5i-containing 
proteasomes.  It was suggested that the high mRNA levels in liver might allow proteasome 
composition to be readily adjusted when required [77].  Additionally, although stimulation 
of mouse RMA T cells with IFNγ led to a marked increase in β1i and β5i mRNA levels, β5i 
protein levels (which were already readily detectable prior to stimulation) remained 
relatively unchanged [77]. 
IFNγ was shown to induce expression of immunosubunit mRNAs in human SW620 
colon carcinoma, J111 monocytic leukemia, and KPK-1 and ACHN renal carcinoma cell 
lines [64, 71] and in the mouse H6 hepatoma cell line [73], whereas the other proteasome 
α- and β-subunit-encoding mRNAs examined were not significantly affected [64, 71, 73].  
Additionally, IFNγ stimulation increased β2i mRNA in HeLa cervix carcinoma and MCF7 
breast adenocarcinoma cells, but increased it to a much lesser extent in B cell lines IM9 
and Reh in which it was already constitutively expressed at higher levels [79].  β2i protein 
expression also increased following IFNγ treatment in HeLa, HeLa S3, Caco-2 colon 
adenocarcinoma, and ECV304 endothelial cells; in ECV304 cells, this was associated with 
the incorporation of β2i into proteasome complexes [79].  The basal and IFNγ-inducible 
levels of the processed β2i protein in the Reh and Daudi cells matched relatively well with 
the mRNA levels observed in these B cell lines [79]. 
Proteasomes are known to produce most of the antigenic peptides presented on 
MHC class I molecules [80, 81], and many of the observations described above led 
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researchers to propose that immunoproteasomes specifically function in producing such 
peptides.  This notion was further supported by demonstrations that immunoproteasomes 
produce immunodominant epitopes derived from ovalbumin [43] or a lymphocytic 
choriomeningitis viral protein [82] more efficiently than constitutive proteasomes.  
Overexpressing all three immunosubunits in mouse fibroblast cells increased the 
presentation of the latter epitope to CD8+ T cells [82].   
Studies conducted with immunosubunit-deficient mice provided additional 
evidence suggesting that immunoproteasomes produce MHC class I ligands more 
efficiently than constitutive proteasomes.  β5i-deficient mice displayed reduced cell 
surface levels of MHC class I molecules and ineffectively presented a peptide derived 
from an endogenous antigen, indicating defective production of antigenic peptides [83].  
In line with these results, β5i-deficient mice were unable to survive Toxoplasma gondii 
infection under conditions that spared wild-type mice, which was speculated to result from 
defects in antigen processing [84].  Furthermore, antigen presenting cells isolated from 
β1i-deficient mice appeared to present an influenza A viral epitope less efficiently than 
those obtained from wild-type mice.  Accordingly, the anti-influenza CD8+ T cell response 
is inferior in β1i-deficient mice [85].  In contrast to β5i-deficient mice [83, 86], β1i-deficient 
mice had fewer CD8+ T cells than wild-type mice [85].  β2i-deficient mice also had fewer 
CD8+ splenocytes as well as a defective CD8+ T cell response to two lymphocytic 
choriomeningitis viral protein-derived epitopes, with the reduced response to one epitope 
being attributable to an altered T cell repertoire [87].  β1i may also protect against 
tumorigenesis by assisting the antitumor immune response [88].  Alternatively, a study 
assisted by mice lacking both β2i and β5i expression revealed a potential protective role 
of immunosubunit upregulation in peripheral tissues under inflammatory conditions 
against the development of CD8+ T cell-mediated autoimmune diseases [89]. 
However, while these observations seemed to indicate that immunoproteasomes 
specifically function in producing MHC class I ligands, other findings indicated that they 
are actually dispensable for this process.  For example, in cell lines lacking the genes 
encoding β1i, β5i, TAP1, and TAP2, reintroducing TAP1 and TAP2 is sufficient to restore 
MHC class I-mediated antigen presentation to normal levels [90, 91].  Later studies 
demonstrated that the impact of a given constitutive subunit or immunosubunit on antigen 
presentation depends on the sequence of each particular antigenic epitope [92-95].  In 
fact, some antigenic peptides are actually better produced by constitutive proteasomes, 
due to either the poor efficiency with which immunoproteasomes produce the correct  
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C-terminus or the tendency of immunoproteasomes to internally cleave the peptide [95-
97].  In line with these results, the CD8+ T cell response against infection with Sendai virus 
was not reduced in β1i-deficient mice in comparison with wild-type mice, contrasting the 
impaired response to influenza infection [85].  CD8+ T cell responses to lymphocytic 
choriomeningitis virus were also largely unimpaired, as was the immunodominance 
hierarchy, in mice lacking β1i or β5i expression [98].  These findings indicate that 
understanding which peptides are efficiently and inefficiently produced by each 
proteasome subtype is beneficial for tumor immunotherapy and vaccine development [95, 
96]. 
The immunosubunits appear to contribute to the adaptive immune system in other 
ways as well.  They have, for example, been found to hold regulatory roles in T cell survival 
and proliferation [86, 87, 93, 99, 100], T helper cell differentiation [101, 102], and pro-
inflammatory cytokine production [101, 103-106].  However, constitutive expression of 
immunosubunits has also been observed in immunoprivileged tissues, including the retina 
[107] and brain [107-109], as well as in other non-hematopoietic cells such as aortic 
endothelial cells [110], suggesting roles for these subunits aside from immune responses.  
Indeed, immunosubunits appear to be important for the efficient elimination of oxidatively-
damaged proteins under conditions of oxidative stress [111, 112] and for regulating 
cardiac muscle mass [113].  They are also upregulated in response to injury of the retina 
and brain, suggesting that they may help repair cellular damage to protect against injury 
[107].  β1i was found to play a role in cell signaling, as it appeared to be important for 
proteolytic processing events involved in activating the transcription factor NF-κB [88, 114], 
although this has been disputed by findings obtained in our laboratory and elsewhere [115-
118].  
 
1.3.2 Thymoproteasome 
Functional proteasomes are essential for the survival of yeast [119].  Because the 
human T2 cell line, which contains a homozygous deletion of the MHC class II region 
containing the genes encoding the immunosubunits [120], can survive without expressing 
immunosubunits, Ortiz-Navarrete et al. suggested that human cells may express multiple 
specialized proteasome complexes, with the one containing the immunosubunits being 
better suited for antigen processing [121].  Further supporting this idea of specialized 
proteasomes, Murata et al. identified a third homolog of the β5 subunit that incorporates 
into otherwise immunoproteasomes (containing β1i and β2i).  The resulting proteasome 
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complexes were termed ‘thymoproteasomes’ due to the exclusive expression of this 
newly-identified β5 subunit, ‘β5t’, in cortical thymic epithelial cells [122] (Figure 1.2).  In 
contrast to the S1 specificity pockets of β5 and β5i, which include Met45 and are largely 
composed of hydrophobic residues, β5t’s S1 pocket includes Thr45 and is predominantly 
composed of hydrophilic amino acids, indicating that the CT-L activity of β5t should be 
less pronounced than that of β5 and β5i.  Indeed, these β5t-containing proteasome 
complexes were shown to have lower CT-L activity than those containing either β5 or β5i, 
making them less effective in producing peptides with hydrophobic C-termini, which tend 
to bind tightly to MHC class I molecules.  These low-affinity MHC class I-binding peptides 
appear to play an important role in the positive selection of developing CD8+ T cells, a 
critical process that determines which of these cells will continue on in the developmental 
program [122].   
Immature thymocytes develop into mature T cells in the thymus, during which they 
undergo both negative and positive selection processes to ensure that only 
immunocompetent T cells are released into the peripheral lymphoid organs.  During 
positive selection, self peptides complexed with self MHC molecules are presented on the 
surface of cortical thymic epithelial cells to immature thymocytes as they move through 
the thymic cortex.  Those thymocytes bearing T cell receptors capable of appropriately 
interacting with these complexes are positively selected to continue their development, as 
they will be able to interact with self MHC molecules in the periphery, and the remaining 
thymocytes undergo programmed cell death.  In the subsequent process of negative 
selection, self peptides complexed with MHC molecules are again presented to the 
developing thymocytes on medullary thymic epithelial cells and other antigen-presenting 
cells in the thymic medulla, although, in this case, apoptosis is induced in thymocytes that 
interact with the self peptide-MHC complexes too intensely to eliminate these autoreactive 
cells from the body.  
Thymoproteasomes appear to produce a unique array of MHC class I-binding 
peptides with distinctive properties important for the positive selection process [123-125].  
As thymoproteasomes have a higher propensity to produce peptides that bind to MHC 
class I molecules with relatively low affinity, the looser interaction between these peptide 
products and MHC class I molecules on the surface of cortical thymic epithelial cells may 
dampen the intensity with which thymocytes interact with these complexes, helping to 
ensure that the positively-selected thymocytes will not further mature into T cells that will 
then react with normal self peptide-MHC complexes encountered in the periphery [122, 
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126].  Additionally, it has been proposed that the presentation of this thymoproteasome-
specific set of peptides during positive selection may safeguard against mature T cells 
mounting autoimmune responses against these same peptides in the periphery [127].  
Indeed, CD8+ T cells of thymoproteasome-deficient mice tend to be more reactive against 
self peptides [124].  Whatever the mechanism, thymoproteasomes are obviously crucial 
for CD8+ T cell development.  β5t-deficient mice have substantially fewer CD8+ thymocytes 
than wild-type mice and are unable to survive an influenza virus infection that is not lethal 
to control mice [122-124], stressing that differences in proteasome composition can have 
major biological consequences. 
 
1.4 Development of Proteasome Inhibitors 
To further examine the catalytic activities and cellular functions of the proteasome, 
researchers sought to develop small molecules capable of inhibiting its activity more 
specifically.  Most of the proteasome inhibitors that have been developed to date are 
composed of a short peptide sequence followed by a C-terminal pharmacophore that 
reacts with the catalytic threonine residues of the proteasome’s active sites.  Interactions 
between the side chains of such inhibitors and the specificity pockets of each active site 
determine their subunit binding preferences.  Therefore, the amino acid sequence of a 
given inhibitor largely determines whether it will act as a broad-spectrum proteasome 
inhibitor that targets most or all of the active sites, or a subunit-selective one that 
selectively targets the active site of a single subunit and/or its constitutive subunit or 
immunosubunit homolog.  The five main classes of inhibitors include the peptide 
aldehydes, peptide boronates, β-lactones, peptide vinyl sulfones, and peptide 
epoxyketones (Figure 1.3).    
 
1.4.1 Peptide Aldehydes 
Peptide aldehydes were the first synthetic proteasome inhibitors to be developed 
[128] (Figure 1.3 A).  These inhibitors reversibly bind the proteasome’s active sites by 
forming hemiacetal adducts with their catalytic threonine residues [30, 33].  Peptide 
aldehyde inhibitors were used to make many important discoveries regarding the 
functional roles of proteasomes.  These studies revealed, for example, that proteasomes 
are responsible for degrading most intracellular proteins and producing most antigenic 
peptides presented on MHC class I molecules [80].  Additionally, they were used to 
demonstrate that the tumor suppressor protein p53 [129] and the cyclin-dependent kinase  
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Figure 1.3 Representative members of the five major classes of proteasome 
inhibitors 
A) Peptide aldehydes. Leupeptin (a natural product that selectively inhibits the 
proteasome’s T-L activity) and ALLN and MG132 (synthetic inhibitors that selectively 
inhibit its CT-L activity) are shown. MG132 targets the proteasome more selectively than 
do leupeptin and ALLN. B) Peptide boronates. MG262, the boronate analog of MG132, 
is shown. C) β-lactones. The natural products clasto-lactacystin β-lactone (together with 
its precursor, lactacystin) and marizomib are shown. D) Peptide vinyl sulfones. Z-L3VS 
and NLVS selectively inhibit the proteasome’s CT-L activity. Ada-Ahx3L3VS is an N-
terminally extended peptide vinyl sulfone that operates as a broad spectrum proteasome 
inhibitor. E) Peptide epoxyketones. The natural products eponemycin and epoxomicin 
are shown. Eponemycin preferentially targets β1i, β5, and β5i, and epoxomicin β5, β5i, 
β2, and β2i. 
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inhibitor p27Kip1 [130] are proteasome substrates, confirming an important role of the 
proteasome in regulating the cell cycle.  Further studies revealed a role of the proteasome 
in regulating apoptosis [131, 132].  Peptide aldehydes were also found to block activation 
of NF-κB by preventing the proteolytic processing of the inactive NF-κB precursor protein 
p105 and the TNFα-induced degradation of the NF-κB inhibitor IκBα, demonstrating that 
the proteasome is essential for the activation of this important transcription factor [133].  
As NF-κB regulates the expression of numerous genes involved in inflammation, immune 
responses, and protection from apoptosis, these observations suggest that proteasome 
inhibitors may be of therapeutic benefit in treating inflammatory diseases as well as 
cancers [133, 134].  Consistent with a potential anticancer effect, inhibiting proteasome 
activity via peptide aldehyde inhibitors was shown to induce apoptosis in cancer cells [135-
139].  Perhaps the most widely used inhibitor of this class is MG132 [140, 141] (Figure 1.3 
A).  Other notable peptide aldehyde proteasome inhibitors include the natural product 
leupeptin, which selectively inhibits the proteasome’s T-L activity [12], and the synthetic 
inhibitor ALLN [80] (Figure 1.3 A).  However, the use of peptide aldehyde inhibitors is 
limited by their off-target inhibition of cysteine and serine proteases, instability, and low 
bioavailability [142, 143].   
 
1.4.2 Peptide Boronates 
Peptide boronates were developed as a second class of synthetic, reversibly-
binding proteasome inhibitors and are more potent than their aldehyde counterparts [142] 
(Figure 1.3 B).  The empty p-orbital of the boronate pharmacophore can readily accept a 
lone pair of electrons from the oxygen atom of the proteasome’s catalytic threonine 
residue to form a stable tetrahedral adduct [142, 144].  Although peptide boronates are 
known to inhibit serine proteases, hydrogen bonding between a boronate hydroxyl group 
and the N-terminal amino group of the proteasome’s catalytic threonine further stabilizes 
the tetrahedral adduct, thereby giving rise to the high affinity of this class of inhibitors for 
the proteasome’s active sites and contributing to their selectivity for the proteasome over 
serine proteases [142, 145].  Notable peptide boronates include the boronate analog of 
MG132, known as MG262 (Figure 1.3 B) [142], and, of special interest, bortezomib, which 
was the first proteasome inhibitor to receive FDA approval [146] (Figure 1.9).  
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1.4.3 β-Lactones 
Natural products have also served as important proteasome inhibitors.  Initial 
interest in the Streptomyces metabolite lactacystin was piqued after the discovery of its 
abilities to block cell cycle progression and stimulate neurite outgrowth [147] (Figure 1.3 
C).  Results of a subsequent study identified the proteasome as the cellular target of this 
inhibitor [148].  Lactacystin, which converts to its active form, clasto-lactacystin β-lactone, 
via spontaneous hydrolysis in aqueous solution [149], was found to preferentially bind to 
the β5 subunit and, accordingly, to inhibit the proteasome’s CT-L activity (Figure 1.3 C).  
It also inhibited the T-L and C-L activities at slower rates [148].  Accordingly, 100 μM 
lactacystin was shown to covalently modify all of the constitutive and immunosubunits [81].  
β-lactone inhibitors inactivate the catalytic threonine by esterifying its hydroxyl [33].  
However, they were also found to inhibit some serine proteases [150, 151].  Lactacystin 
was used to confirm the proteasome’s role in degrading intracellular proteins and 
producing peptides presented on MHC class I molecules [81].  In fact, treatment of cells 
with nontoxic doses of lactacystin and the peptide epoxyketone proteasome inhibitor 
epoxomicin could alter the presentation of specific antigenic epitopes, suggesting that 
proteasome inhibitors may be useful therapeutics for autoimmune diseases [152].  Like 
peptide aldehydes and peptide boronates, lactacystin was shown to induce apoptosis in 
malignant cells [153-156].  A second natural product β-lactone, marizomib (also known as 
salinosporamide A or NPI-0052), is currently in clinical development [157] (Figure 1.9). 
 
1.4.4 Peptide Vinyl Sulfones 
Peptide vinyl sulfones comprise a class of synthetic, irreversibly-binding 
proteasome inhibitors (Figure 1.3 D).  A Michael addition reaction between the hydroxyl 
group of the catalytic threonine residue and the double bond of the vinyl sulfone 
pharmacophore serves as the mechanistic basis for inhibition [158].  An initial report 
described the peptide vinyl sulfone carboxybenzyl-LLL-vinyl sulfone (Z-L3VS) and its 125I-
labeled nitrophenol derivative (125I-NIP-L3VS (or 125I-NLVS)) as cell-permeable inhibitors 
that preferentially target the CT-L activity but inhibit the remaining activities at higher 
concentrations [158] (Figure 1.3 D).  Peptide vinyl sulfones proved useful for studying how 
the peptide sequence of an inhibitor influences its subunit binding preferences [159, 160].  
Furthermore, the vinyl sulfone pharmacophore itself was shown to confer enhanced 
binding selectivity toward the β5 subunit over epoxyketone inhibitors of the same peptide 
sequence [161].  Due to their ability to form irreversible covalent bonds with the 
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proteasome’s catalytic threonine residues along with their ease of synthesis and 
amenability to modification, peptide vinyl sulfone inhibitors, including the broad-spectrum 
proteasome inhibitor Ada-Ahx3L3VS [162] (Figure 1.3 D), have often been converted to 
activity-based probes for use in purifying or visualizing active proteasome subunits [158, 
163].  However, as they were initially developed as cysteine protease inhibitors, they tend 
to react with these proteases in addition to the proteasome [158, 161, 164]. 
 
1.4.5 Peptide Epoxyketones 
Natural products eponemycin and epoxomicin are members of the peptide 
epoxyketone class of proteasome inhibitors [165, 166] (Figure 1.3 E).  These inhibitors 
were isolated from a Streptomyces or Actinomycete strain, respectively, and identified as 
compounds with antitumor activity against B16 murine melanoma [167, 168], with their 
biological activity later being attributed to proteasome inhibition [165, 166].  Inhibitors of 
this class target the proteasome’s catalytic activities irreversibly and with an unparalleled 
degree of specificity [166, 169].  Upon binding of the epoxyketone pharmacophore to the 
catalytic threonine, a six-membered morpholino ring is formed, which requires both the 
catalytic threonine’s hydroxyl group and its free α-amino group [170].  Such an adduct 
cannot be formed with serine and cysteine proteases because their catalytic residues lack 
a free α-amino group, providing the basis for the remarkable proteasome specificity of this 
class of inhibitors [170].  Specific structural differences in eponemycin and epoxomicin 
contribute to their differential subunit binding preferences [171]: eponemycin preferentially 
binds β1i, β5, and β5i [165, 171], while epoxomicin targets β5, β5i, β2, and β2i [166].  As 
will be discussed below, many synthetic peptide epoxyketones have been developed for 
use as research tools, and, ultimately, as therapeutic agents.  Carfilzomib, the second 
proteasome inhibitor to receive FDA approval for use as an anticancer agent, belongs to 
this inhibitor class [172] (Figure 1.9). 
 
1.4.6 Subunit-Selective Proteasome Inhibitors 
While proteasome researchers had begun to better understand the substrate 
binding preferences of each of the proteasome’s catalytic subunits, the contribution to the 
proteolytic process or unique cellular functions of each individual subunit remained largely 
undefined.  This prompted the design and synthesis of a variety of subunit-selective 
inhibitors (Figures 1.4 and 1.5).  The development of these inhibitors also provided the  
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Figure 1.4 Inhibitors that selectively target homologous pairs of catalytic 
proteasome subunits 
A) β5/β5i-selective inhibitors. The peptide epoxyketone inhibitors YU-101 and NC-005 
are shown. B) β1/β1i-selective inhibitors. The peptide epoxyketone inhibitors YU-102 
and NC-001 are shown. While YU-102 was initially found to selectively inhibit the 
proteasome’s C-L activity, our laboratory later revealed its preference for binding 
immunosubunit β1i over constitutive subunit β1. C) β2/β2i-selective inhibitors. The 
peptide epoxyketone inhibitors NC-012 and NC-022, and the peptide vinyl sulfone inhibitor 
LU-102, are shown. 
 
tools required to challenge the prevailing notion that inhibiting the proteasome’s CT-L 
activity was of exclusive importance in mediating proteasome inhibitor-induced cytotoxicity. 
 
a. β5/β5i-Selective Inhibitors 
The second-generation tetrapeptide epoxyketone YU-101 was synthesized in 
effort to develop a proteasome-specific inhibitor that potently and selectively targets the 
CT-L activity [173] (Figure 1.4 A).  The potency and selectivity of YU-101 was found to 
exceed that of epoxomicin, dihydroeponemycin, bortezomib, clasto-lactacystin β-lactone, 
and NLVS [173].  Furthermore, YU-101 was found to have anti-proliferative and anti-
inflammatory effects [173].  Derivatization of this inhibitor would later yield the second 
FDA-approved proteasome inhibitor carfilzomib [174].  Subsequently, Britton et al. sought 
to develop a proteasome inhibitor with even greater selectivity for the CT-L activity than 
YU-101.  To this end, they used a previously-reported CT-L-selective peptide aldehyde 
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inhibitor [175] as a reference compound in designing the peptide epoxyketone inhibitor 
NC-005 (Figure 1.4 A).  This inhibitor was concluded to inhibit the CT-L activity with similar 
potency as YU-101, but with greater selectivity, allowing the CT-L activity to be inhibited 
almost completely without inhibiting the C-L or T-L activities [176].  However, the cytotoxic 
effects of NC-005 in most of the cancer cell lines tested were optimal at concentrations at 
which the T-L and/or C-L activity was co-inhibited, demonstrating that inhibiting the CT-L 
activity alone is not sufficient to achieve maximal anticancer activity [176]. 
 
b. β1/β1i-Selective Inhibitors 
Another second-generation epoxyketone proteasome inhibitor, YU-102, was 
initially concluded to selectively inactivate the C-L activity of the bovine reticulocyte 20S 
proteasome [177] (Figure 1.4 B).  Later work with this inhibitor in our laboratory revealed 
that YU-102’s preferred target is the immunosubunit β1i, followed by the constitutive 
subunit β1 [178].  YU-102 inefficiently stabilized the proteasome reporter substrate UbG76-
GFP in transfected HeLa cells and had poor anti-proliferative activity, suggesting that 
selectively inhibiting the β1-type subunits is insufficient to markedly impact protein 
degradation [177].  Several years later, van Swieten et al. reported a β1/β1i-selective 
peptide vinyl sulfone inhibitor (Ac-APnLL-VSPhOH) that appeared to inhibit β1i more 
potently than β1 [179].  An epoxyketone analog of this inhibitor, NC-001, was subsequently 
synthesized and shown to be a cell-permeable yet potent and selective inhibitor of the β1 
and β1i subunits [176] (Figure 1.4 B).  Exclusively inhibiting the C-L activity with NC-001 
was not cytotoxic to multiple myeloma cells but, at concentrations inhibiting at least 90% 
of the C-L activity, sensitized these cells to the cytotoxic effects of the β5/β5i-selective 
inhibitor NC-005, further demonstrating the importance of inhibiting more than one type of 
proteasome activity for optimal anticancer activity [176].   
 
c. β2/β2i-Selective Inhibitors 
Mirabella et al. developed three T-L-selective peptide epoxyketone proteasome 
inhibitors [180].  The first, NC-002 (Ac-LLR-ek), is the epoxyketone derivative of the 
peptide aldehyde cysteine protease inhibitor leupeptin (Figure 1.3 A), which, in the context 
of the proteasome, selectively inhibits its T-L activity [12].  The second, NC-012 (Ac-RLR-
ek) (Figure 1.4 C), is an epoxyketone derivative of the T-L-selective fluorogenic peptide 
substrate, Ac-RLR-AMC [181].  The third, NC-022 (Hmb-VSR-ek) (Figure 1.4 C), was 
designed using a peptide vinyl-ester that was previously reported to inhibit the 
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proteasome’s T-L activity [182] as a reference compound.  All three of these compounds 
were found to selectively inhibit β2 and β2i [180].  Among these three inhibitors, NC-012 
was found to inhibit the T-L activity of purified 26S proteasomes most potently and 
selectively but displayed the weakest impact on this activity when tested in a multiple 
myeloma cell line, presumably reflecting low cell-permeability. Instead, NC-022 was 
chosen as the most potent cell-permeable T-L-selective inhibitor for use in further cell-
based studies.  These studies demonstrated that selectively inhibiting the T-L activity is 
not toxic to multiple myeloma cells but sensitizes these cells to the cytotoxic effects of 
inhibiting the CT-L activity with equivalent or greater efficacy compared with the C-L-
selective inhibitor NC-001, indicating that the T-L active sites may be better co-targets for 
drugs than the C-L ones [180].   
Due to the low synthetic yields, apparently inconsistent degrees of cell permeability 
across multiple cell lines, and chemical instability of the arginine-containing T-L-selective 
peptide epoxyketones, these researchers subsequently developed a new β2/β2i-selective 
inhibitor, LU-102 [183] (Figure 1.4 C).  In comparison with the peptide epoxyketones, this 
peptide vinyl sulfone inhibitor is easier to synthesize, is more cell-permeable, and more 
potently inhibits the proteasome’s T-L activity [183].  Like NC-022, LU-102 was not toxic 
to multiple myeloma cells but sensitized them to the cytotoxic effects of bortezomib and 
carfilzomib [183, 184].  However, this compound also inhibits cathepsins and therefore its 
use requires further experimental controls to validate that any observed biological effects 
result from inhibiting the proteasome’s T-L activity [183]. 
 
d. β5-Selective Inhibitors 
The β5-selective peptide epoxyketone inhibitor PR-825 was discovered in a 
medicinal chemistry effort to develop orally bioavailable carfilzomib analogs and was 
shown to be 14-fold selective for β5 over β5i [185] (Figure 1.5 A).  PR-825 was 
subsequently used to differentiate the effects of selective inhibition of β5 versus β5i on the 
production of pro-inflammatory cytokines by activated PBMCs and on disease progression 
in a mouse model of rheumatoid arthritis [101], and to demonstrate the importance of 
inhibiting β5i, but not β5, in producing therapeutic effects in a mouse model of multiple 
sclerosis [106]. 
PR-893 (also referred to as CPSI) was the second β5-selective peptide 
epoxyketone to be reported (Figure 1.5 A).  This compound inhibits β5 over β5i and β1i 
with 21-fold and 13-fold selectivity, respectively.  Higher concentrations also inhibit β1, β2,  
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Figure 1.5 Subunit-selective proteasome inhibitors 
A) β5-selective inhibitors. The peptide epoxyketone inhibitors PR-825 and PR-893 are 
shown. B) β1i-selective inhibitors. The peptide epoxyketone inhibitor UK-101 and the 
peptide aldehyde inhibitor IPSI-001 are shown. IPSI-001 is also a calpain inhibitor. C) β5i-
selective inhibitors. The peptide epoxyketones ONX 0914 and PR-924 are shown. 
 
and β2i [186].  Using PR-893 as a research tool to evaluate the cellular consequences of 
selective β5 inhibition revealed that, in contrast with dual inhibition of β5 and β5i, inhibiting 
β5 alone was insufficient to induce proteasome substrate accumulation or cytotoxicity in 
hematologic cancer cells [186].  Furthermore, in contrast to dual inhibition or inhibition of 
β5i alone, selectively inhibiting β5 with PR-893 did not substantially inhibit IFNα production 
by bone marrow cells [187]. 
 
1.4.7 Immunosubunit-Selective Inhibitors 
Although the immunoproteasome was initially believed to primarily function in 
producing antigenic peptides for presentation on MHC class I molecules, the results of 
other studies suggested that it was, in fact, not required for MHC class I-mediated antigen 
presentation [90, 91] and, as discussed above, may have additional cellular functions.  
These observations fueled efforts to generate immunosubunit-selective inhibitors for use 
as molecular probes to investigate the functional roles of immunoproteasomes and their 
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individual catalytic subunits.  Additionally, findings implicating the immunosubunits in the 
pathogenesis of autoimmune diseases [101, 104, 188-191] and cancers [192-195], and 
the low levels of these subunits in many non-diseased cells, stimulated interest in 
examining whether immunosubunit-selective inhibitors could make effective therapeutic 
agents. 
 
a. β1i-Selective Inhibitors 
Building upon knowledge gained form evaluating the structure-activity 
relationships of natural product peptide epoxyketones epoxomicin and eponemycin, our 
laboratory developed the first immunosubunit-selective inhibitor to be reported: the β1i-
selective peptide epoxyketone inhibitor UK-101 [192] (Figure 1.5 B).  Cancer cells with 
high β1i-levels were found to be more sensitive to the antiproliferative effects of UK-101 
than those deficient in this immunosubunit, suggesting that β1i may play an important 
growth-regulatory role in cancer cells in which it is abundantly expressed [192].  UK-101 
was also found to significantly inhibit tumor growth in a mouse xenograft model of prostate 
cancer [195]. 
The dipeptide aldehyde calpain inhibitor IPSI-001 (also known as calpeptin) was 
also found, in the context of the proteasome, to selectively inhibit β1i [193] (Figure 1.5 B).  
This inhibitor, which exhibited a 100-fold selectivity towards the CT-L activity of the 
immunoproteasome over that of the constitutive proteasome, was shown to induce 
apoptosis in bortezomib-sensitive and -resistant multiple myeloma cell lines and patient 
samples, and in samples from patients with other hematologic cancers, while having less 
pronounced effects than bortezomib on the viability of non-hematopoietic cells.  Its pro-
apoptotic activity was attributed to proteasome—rather than calpain—inhibition.  Because 
of its aldehyde pharmacophore and low potency, further optimization of IPSI-001 will be 
required to obtain a β1i inhibitor suitable for clinical development [193].  
 
b. β5i-Selective Inhibitors 
The tripeptide epoxyketone PR-957 (now known as ONX 0914) was the first β5i-
selective inhibitor to be reported [101] (Figure 1.5 C).  When tested for its subunit binding 
preferences in a human leukemia cell line expressing both constitutive subunits and 
immunosubunits, ONX 0914 was found to display 20- and 40-fold selectivity for β5i over 
secondary targets β5 and β1i, respectively, while also inhibiting β2, β2i, and β1 at high 
concentrations.  In PBMCs, which predominantly express immunosubunits, greater than 
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80% β5i inhibition was achievable by ONX 0914 treatment without substantially inhibiting 
β1i or β2i [101].  ONX 0914 was shown to inhibit the production of pro-inflammatory 
cytokines by activated monocytes, as well as the activation and differentiation of T helper 
cells, indicating that β5i is a potential therapeutic target for treating inflammatory diseases.  
This was further corroborated by the anti-inflammatory efficacy of ONX 0914 in mouse 
models of rheumatoid arthritis, in contrast to the β5-selective inhibitor PR-825, which 
lacked efficacy, and the β5/β5i-selective inhibitor carfilzomib, which was only moderately 
effective [101].  ONX 0914 also reduced disease severity and/or suppressed disease 
progression in mouse models of colitis [104], lupus [187], and multiple sclerosis [106], 
further supporting the potential therapeutic benefits of β5i inhibitors in treating 
autoimmune diseases.   
A second β5i-selective peptide epoxyketone proteasome inhibitor, PR-924 (also 
referred to as IPSI), was subsequently reported [186] (Figure 1.5 C).  This inhibitor was 
found to display 130-fold selectivity towards β5i over β5.  It also inhibited β1i at higher 
concentrations but was not found to substantially inhibit β1, β2, or β2i within the 
concentration range examined [186].  Experimental results obtained using this compound 
demonstrated that, similarly to inhibiting β5 alone, inhibiting β5i alone was incapable of 
inducing proteasome substrate accumulation or producing cytotoxic effects in hematologic 
cancer cells; inhibiting both subunits was required [186].  Conversely, Singh et al. found 
PR-924 to inhibit growth and induce apoptosis in multiple myeloma cells without 
significantly reducing the viability of normal PBMCs [194].  PR-924 was also well-tolerated, 
exerted antitumor activity, and prolonged survival in mouse xenograft models.  The results 
of the latter study, therefore, provided a rationale for the clinical development of PR-924 
for anti-myeloma therapy [194]. 
 
1.4.8 Bifunctional Proteasome Inhibitors 
Several bifunctional compounds containing two reactive groups have also been 
developed in effort to obtain potent and/or subunit-selective proteasome inhibitors.  
Among the first of these was Mal-βAla-Val-Arg-H, a peptide aldehyde inhibitor designed 
to selectively target the T-L activity [196] (Figure 1.6 A).  Like other peptide aldehydes, the 
aldehyde warhead was intended to react with β2’s catalytic threonine residue, while the 
N-terminal maleinimide moiety was expected to react with the thiol group of Cys118 of  
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Figure 1.6 Bifunctional proteasome inhibitors 
A) Mal-βAla-Val-Arg-H is an inhibitor comprising two functional groups designed to 
covalently modify distinct residues of the β2 active site. The aldehyde pharmacophore 
targets the catalytic threonine, while the N-terminal maleinimide moiety targets a cysteine 
residue unique to the β2 active site. B) A heterobifunctional compound comprising a β5-
selective (LLnL-H) and a β2-selective (RLR-H) inhibitor coupled by a polydisperse PEG 
linker. C) A homobifunctional inhibitor derived from a linear mimic of the noncovalent 
proteasome inhibitor TMC-95A. The two inhibitor moieties were coupled via a 
monodisperse polyaminohexanoic acid linker. 
 
β3—which protrudes into β2’s S3 specificity pocket—to further increase the inhibitor’s 
concentration in the β2 active site.  The ethylene spacer was selected based on the 
optimal spacer length determined via molecular modeling, and the Val-Arg sequence was 
chosen based on the Bz-Phe-Val-Arg-AMC substrate used to selectively measure the 
proteasome’s T-L activity [196].  As anticipated, Mal-βAla-Val-Arg-H inhibited the T-L 
activity of the yeast proteasome with an IC50 value of 0.5 μM, exhibiting a more than 200-
fold selectivity over the CT-L and C-L activities [196].  Activity assay and crystal structure 
data indicate that the P1 Arg first interacts with the S2 specificity pocket of β2, leading to 
the reaction of the aldehyde group with β2’s catalytic threonine residue.  This positions 
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the maleinimide group for reaction with Cys118’s thiol within the S3 specificity pocket of 
this subunit, which results in the sustained presence of the inhibitor in the β2 active site 
[196]. 
This same research group subsequently reported bifunctional compounds 
comprising two peptide aldehyde proteasome inhibitors N-terminally coupled via 
poly(ethylene glycol) (PEG) linkers.  These included both homobifunctional inhibitors 
containing two identical inhibitory moieties, which were intended to simultaneously inhibit 
the two identical active sites on opposing β-rings within a single 20S proteasome complex, 
and a heterobifunctional inhibitor, which was designed to simultaneously inhibit two 
different active sites [197].  The crystal structure-derived distances between individual 
active sites within the yeast proteasome complex were used to select a linker of the 
appropriate length to facilitate simultaneous binding of the two inhibitory moieties to the 
desired active sites.  PEG was chosen as a spacer because its flexibility and linearity 
allows it to mimic an unfolded polypeptide chain and therefore gain entry into the 20S 
proteasome core while, in contrast to an actual polypeptide chain, being resistant to 
proteolysis [197].  The two homobifunctional inhibitors developed met the intended goal 
of increasing inhibitory potency towards the targeted catalytic subunits.  One 
homobifunctional inhibitor, which was derived from the peptide aldehyde Ac-LLnL-H and 
designed to target the two β5 subunits within a 20S proteasome complex, was found to 
inhibit the CT-L activity of the yeast proteasome with an IC50 value of 17 nM, and another, 
derived from Ac-RVR-H and designed to target the two β2 subunits, inhibited the T-L 
activity with an IC50 of 71 nM.  These values represent potency increases of more than 
100-fold over the respective PEGylated monomeric inhibitors, which was achieved while 
avoiding detectable inhibition of the non-targeted catalytic activities (IC50 values >100 μM).  
The heterobifunctional compound, which was constructed from the same monomeric 
inhibitors and designed to simultaneously target β5 and β2, was found to inhibit the CT-L 
and T-L activities with IC50 values of 31 and 97 nM, respectively, without substantially 
inhibiting the C-L activity (IC50 >100 μM) [197] (Figure 1.6 B).  Although the crystallography 
data obtained did not allow the simultaneous binding of two active sites to be confirmed, 
the inhibitory potency of the heterobifunctional compound toward the CT-L and T-L 
activities was increased to a similar extent as that of the homobifunctional compounds if 
the stoichiometry of the inhibitory moieties is considered (i.e., the heterobifunctional 
inhibitor is ~2-fold less potent against a given activity than the homobifunctional inhibitor 
targeting that activity) [197].   
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A second research group extended this approach to develop homobifunctional 
inhibitors built from two linear mimics of a noncovalent proteasome inhibitor known as 
TMC-95A [198, 199].  The more active of the two bifunctional compounds described in the 
initial report, in which the two inhibitors were coupled via a polydisperse PEG linker, 
inhibited the CT-L activity of the rabbit 20S proteasome with 783-fold increased potency 
(IC50 value of 0.18 μM) compared with the reference compound [198].  Alternatively, the 
homobifunctional inhibitors described in the second report were composed of two units of 
a different linear TMC-95A mimic coupled by monodisperse polyaminohexanoic acid 
linkers [199] (Figure 1.6 C).  These compounds potently inhibited both the CT-L (IC50 
values between 19.1 and 25.9 nM) and T-L (IC50 values between 12.4 and 20.2 nM) 
activities of purified human constitutive proteasomes, while the C-L activity was targeted 
more weakly (IC50 values between 336 and 590 nM).  These values indicate 123-167-fold 
(CT-L), 355-577-fold (T-L), and 19-34-fold (C-L) increases in inhibitory potency relative to 
the monomeric reference compound.  Four of these bifunctional inhibitors were also found 
to inhibit the CT-L activity in HEK-293 cells more potently (IC50 values ranging from 0.472-
0.756 μM) than the reference compound (IC50 value of 7.97 μM) [199].  Collectively, these 
results indicate that applying the principle of multivalency to proteasome inhibitor design 
can successfully improve the potency of proteasome inhibitors towards multiple active 
sites.   
 
1.4.9 Activity-Based Probes 
By attaching a reporter group to an inhibitor that binds covalently and irreversibly 
to the proteasome’s catalytic threonine residues, many researchers have converted 
existing proteasome inhibitors to activity-based probes (ABPs) for use in functional studies 
[163].  Various reporter groups, such as biotin, radioisotopes, or fluorophores, can be 
attached to enable probe-bound proteasome subunits to be purified by affinity 
chromatography or visualized by techniques such as western blotting, in-gel fluorescence, 
or fluorescence microscopy (Figure 1.7).  Both active and inactive forms of the 
proteasome’s catalytic subunits are often present in cells; as only active subunits can be 
bound by ABPs, the use of these probes ensures that only the active forms of these 
subunits are detected when working with complex biological samples.  This approach, 
therefore, overcomes a major limitation of traditional antibody-based approaches, since 
antibodies bind to both inactive and active forms of catalytic proteasome subunits [163]. 
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Figure 1.7 Activity-based probes and their utility 
Structural representation of an ABP, which is composed of a targeting sequence that 
directs the probe to the targeted enzyme, a reactive chemical warhead which binds 
irreversibly to the enzyme’s catalytic residues, and a tag for identification or visualization 
of probe-bound enzymes. Biotin-tagged ABPs can be used for affinity purification and 
mass spectrometry-based identification of probe targets, as well as for visualization of 
these targets by streptavidin affinity blotting. Radiolabeled and fluorescent ABPs can be 
used to visualize target proteins by in-gel fluorescence. Additionally, cell-permeable 
fluorescent ABPs can be used to monitor enzyme activity in living cells or tissue samples 
via fluorescence microscopy. This figure was published in our previous report [163]. 
 
125I-labeled peptide vinyl sulfones were among the first proteasome-targeting 
ABPs to be developed [158].  They were used alongside fluorogenic peptide substrates in 
determining which catalytic subunits of the mammalian proteasome were responsible for 
each of its distinct activities [159, 160] and in examining the influence of inhibitor 
substituents on their subunit-selectivity profiles [159, 160, 162].  Many peptide vinyl 
sulfone- and peptide epoxyketone-based ABPs have since been developed, most of which 
were derived from broad-spectrum inhibitors that generally target all of the proteasome’s 
active sites and contain fluorophores and/or biotin rather than radiolabels as reporter  
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Figure 1.8 Proteasome-targeting activity-based probes 
A) Broad-spectrum activity-based probes. DansylAhx3L3VS and MV151 are peptide 
vinyl sulfones labeled with the dansyl-sulfonamidohexanoyl hapten or the fluorophore 
Bodipy TMR, respectively. Catalytic proteasome subunits covalently modified by the 
former can be detected via immunoblotting with antibodies directed against the dansyl 
moiety, whereas those modified by the latter can be detected via in-gel fluorescence or 
fluorescence microscopy. B) Immunosubunit-selective activity-based probes. 
Fluorescent derivatives of the β1i-selective inhibitor UK-101 and the β5i-selective inhibitor 
LKS01 were previously developed in our laboratory. These probes allow catalytically 
active β1i or β5i to be visualized via in-gel fluorescence or fluorescence microscopy. 
UK101-B660 and LKS01-B650 are labeled with the near-infrared Bodipy 650/665 
fluorophore and may therefore be compatible with in vivo imaging. 
 
groups [163].  Perhaps the most widely utilized among these probes include dansyl-
Ahx3L3VS [200] and Bodipy TMR-Ahx3L3VS (known as MV151) [201], the latter of which 
can be used in in vivo studies [201] (Figure 1.8 A).  The most common application of the 
broad-spectrum ABPs has been to examine the subunit binding preferences of both 
existing and newly-developed proteasome inhibitors [158-162, 180, 192, 200-207].  
Results from such investigations have assisted the development of both subunit-selective 
and broad-spectrum proteasome inhibitors and ABPs [159-162, 180, 192, 206].  
Proteasome-targeting ABPs may also be useful in evaluating the clinical efficacy of 
proteasome inhibitors [204, 208].   
The utility of these probes in monitoring proteasome activity profiles also renders 
them suitable for use in investigating proteasome functions.  Results obtained with peptide 
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vinyl sulfone-based ABPs demonstrated that proteasome activity patterns vary 
substantially across primary leukemia samples and that proteasome activity increases 
when cell lines acquire bortezomib resistance, thereby enabling higher residual activity to 
be maintained following bortezomib treatment [184, 204, 209].  Additional studies in which 
proteasome-targeting ABPs were utilized uncovered a relationship between Bcr-Abl-
mediated malignant transformation and proteasome activity in cell line models [210] and 
indicated roles of the proteasome in programmed cell death and defense responses in 
Arabidopsis plants [205].  Another study showed that disease-associated prion protein 
aggregates inhibit proteasome activity [211].  Finally, findings obtained with peptide 
epoxyketone- and peptide vinyl sulfone-based ABPs confirmed that the thymoproteasome 
subunit β5t has catalytic activity and demonstrated that this subunit differs from β5 and 
β5i in its substrate and inhibitor binding preferences.  These results support the hypothesis 
that β5t is involved in generating peptides for the positive selection of developing T cells 
[212]. 
In addition to the broad-spectrum probes discussed above, subunit-selective ABPs 
have also been developed. Some of these bind both a particular constitutive subunit and 
its immunosubunit counterpart [176, 179, 180], while others can selectively bind a 
particular immunosubunit.  Probes of the latter sort can be used to assess the functions 
of immunosubunit-containing proteasomes in normal and diseased cells.  β1i- and β5i-
selective ABPs developed in our laboratory facilitate the subcellular localization of the 
catalytically active forms of these immunosubunits via fluorescence microscopy, and those 
containing a near-infrared (NIRF) fluorophore may be suitable for use in animal studies 
[213, 214] (Figure 1.8 B).  The high β1i levels detected in multiple cancer types [192, 193, 
195] suggest its potential to serve as a tumor biomarker; therefore, β1i-selective ABPs 
may be useful as imaging probes for cancer screening or monitoring disease progression 
[213].   
The use of ABPs has allowed researchers to obtain valuable information regarding 
proteasome function and inhibitor efficacy.  Importantly, results obtained from such studies 
continue to provide insight into ways in which clinical responses to proteasome inhibitor 
therapy can be improved.  A more detailed discussion of proteasome-targeting ABPs can 
be found in our review article [163]. 
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1.5 Proteasome Assembly 
Proteasomes are assembled in an ordered, chaperone-assisted process that 
begins with the formation of the α-rings.  A heterodimeric chaperone complex comprising 
proteasome assembling chaperones-1 and -2 (PAC1-PAC2) serves as a scaffold upon 
which α-rings are built to prevent improper α-subunit aggregation [215].  A second 
heterodimeric chaperone complex, PAC3-PAC4, also assists in α-ring formation [216, 
217].  Fully-assembled α-rings then serve as scaffolds for β-ring assembly.  During this 
process, β2 and the assembly chaperone proteasome maturation protein (POMP) first 
associate with an α-ring.  β3 is incorporated next, and the PAC3-PAC4 complex is 
concomitantly released [217].  Additional β-subunits continue to incorporate—β4, then β5, 
then β6, then β1, and finally β7—to form a half proteasome, with the propeptides of β2 
and β5 and β2’s C-terminal tail acting as intramolecular chaperones to aid in this process 
[217].  POMP, together with β7’s C-terminal tail, then facilitate the dimerization of two half 
proteasomes, the propeptides of β1, β2, β5, β6, and β7 are removed, and POMP, PAC1, 
and PAC2, serving as the first substrates of the now fully-assembled 20S proteasome 
complex, are degraded [216, 217].  In mammals, the propeptides of the catalytically active 
β-subunits appear to be removed in a two-step autocatalytic mechanism, with an initial 
trans-autocatalytic step in which a neighboring β-subunit trims the propeptide to a specific 
length and a final cis-autocatalytic step involving Thr1 Oγ and Lys33 of the subunit 
undergoing processing [39].  As mentioned above, removing the propeptides from the 
catalytically active subunits only upon completion of 20S proteasome assembly serves as 
a safety mechanism to protect against unregulated cleavage of cellular proteins by these 
subunits that may otherwise occur prior to their incorporation into the complex [36, 38-41].   
Immunosubunits can, alternatively, become incorporated in place of their 
constitutive counterparts during the β-ring assembly process.  Unlike incorporation of β1, 
which occurs at a relatively late step, co-incorporation of β1i and β2i was concluded to be 
the initial step in immunoproteasome β-ring assembly [217-219].  This is followed by 
incorporation of β3.  Either β4 or β5i can be incorporated immediately after β3, followed 
by the incorporation of the other.  Bai et al. suggested that the addition of β5i prior to β4 
may contribute to the preferential assembly of immunoproteasomes over constitutive 
proteasomes when all six catalytic subunits are simultaneously expressed [219].  Addition 
of β6, and, finally, β7, complete the assembly of the immunoproteasome β-ring.  Assembly 
chaperones were concluded to play the same roles in immunoproteasome assembly as in 
constitutive proteasome assembly [219].   
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While it has been concluded that cooperative assembly mechanisms encourage 
the assembly of pure constitutive proteasomes or pure immunoproteasomes, assembly of 
intermediate proteasome subtypes comprising mixtures of constitutive proteasome and 
immunoproteasome catalytic subunits has also been reported [220-223].  However, there 
seem to be restrictions governing which combinations of constitutive proteasome and 
immunoproteasome catalytic subunits can be co-incorporated into a single 20S 
proteasome complex.  For example, it was found that β2i is not incorporated into 
proteasomes independently of β1i, indicating that all β2i-containing proteasome 
complexes also contain β1i [220, 221, 223].  Additionally, proper maturation of β1i- and 
β2i-containing proteasomes requires incorporation of β5i, indicating that β5i is present in 
all mature 20S proteasome complexes that contain any of the immunosubunits [221].  
Conversely, β1i can incorporate into proteasome complexes without co-incorporation of 
β2i [223].  Furthermore, β5i can incorporate into proteasome complexes containing either 
constitutive subunits or immunosubunits [220-223].  Collectively, these findings suggest 
that the formation of four distinct 20S proteasome subtypes—pure constitutive 
proteasomes composed of β1, β2, and β5, pure immunoproteasomes composed of β1i, 
β2i, and β5i, and two subtypes of intermediate proteasomes composed of β1, β2, and β5i 
or β1i, β2, and β5i—is permitted, whereas the formation of subtypes comprising β2i with 
constitutive subunits or β5 with immunosubunits is precluded [223] (Figure 1.2). 
  
1.6 Intermediate Proteasomes 
An initial clue to the existence of intermediate proteasomes was obtained via 
immunoprecipitation experiments conducted by Brown et al.  The P388D1 murine 
macrophage cell line simultaneously harbored proteasomes either containing or lacking 
immunosubunit β1i, both of which also contained β5i, demonstrating that intermediate 
proteasome subtypes containing β5i without β1i can form in these cells [63].  The H6 
hepatoma cell line, conversely, exclusively contained proteasomes lacking β1i, but these 
differed from the β1i-deficient subtype identified in P388D1 cells by their lack of β5i as well 
as a third component, which was present in both subtypes from P388D1 cells.  Additionally, 
while β1i-containing proteasomes were detected in H6 cells following IFNγ stimulation, 
these subtypes also differed from the β1i-containing proteasomes of P388D1 cells in the 
continued absence of this component.  Therefore, at least four distinct subtypes of 
proteasomes were identified [63].  Whether or not additional proteasome subtypes aside 
from these four existed could not be determined in this study due to a lack of appropriate 
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research tools.  However, the difference in the proportion of β1i+ and β1i- proteasome 
subtypes between the two cell lines and the differential extent to which the β1i+ subtypes 
could be upregulated by IFNγ (they were only weakly upregulated in P388D1 cells under 
these conditions) led the authors to suggest that proteasome subtypes with unique subunit 
compositions have specialized biological functions [63].     
A subsequent report by Dahlmann et al. described the detection of intermediate 
proteasome subtypes in murine tissues [224].  Although rat muscle tissue predominantly 
contained constitutive proteasomes, substantial amounts of intermediate proteasomes of 
composition β1-β2-β5i and β1/β1i-β2-β5i were detected.  While only low levels of pure 
immunoproteasomes were detected in muscle, this was the most abundant subtype 
present in rat spleen.  Intermediate proteasomes of subtype β1-β2i-β5i and β1/β1i-β2i-β5i 
were also detected in spleen [224].  Since then, results of many studies have indicated 
the presence of intermediate proteasomes in various non-diseased tissues and cancer 
cells derived from both murine and human sources [186, 225-229].  For example, ELISA-
based quantification demonstrated that normal human tissues contain considerable 
quantities of intermediate proteasomes; intermediate proteasome subtypes of catalytic 
subunit composition β1-β2-β5i or β1i-β2-β5i constituted between one-third and one-half 
of the total proteasomes in liver, kidney, small intestine, and colon.  They were also found 
to comprise 9-17% of the total proteasomes in melanoma cell lines (most of which were 
of catalytic subunit composition β1-β2-β5i) and ~20% of proteasomes in NCI-H460 non-
small cell lung carcinoma and L363 myeloma cell lines (most or all of which were of 
composition β1i-β2-β5i) [226]. 
Consistent with the notion that individual subtypes may be specialized to assist in 
specific cellular functions, each subtype seems to differ from the rest in its activity profile 
and tissue and subcellular distribution patterns [224-235].  With regards to antigen 
presentation, results from several studies indicate that intermediate proteasome subtypes 
support the enhanced diversification of antigenic peptides presented on MHC class I 
molecules [226, 236-238].  Importantly, specific intermediate proteasome subtypes are 
indispensable for the production of certain tumor antigens; therefore, identifying which 
proteasome subtypes are present in cells should be helpful for the development of 
immunotherapy-based approaches [226].  Distinguishing proteasome compositions have 
also been associated with diseases such as Crohn’s disease and ulcerative colitis, 
suggesting their potential to serve as disease biomarkers [191].  Finally, as distinct 
proteasome subtypes appear to differ in their sensitivities to specific proteasome inhibitors 
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[231, 232], identifying which proteasome subtypes are present in diseased cells could 
ultimately guide the selection of the appropriate proteasome inhibitor to selectively target 
those subtypes more effectively while minimizing toxicity to healthy cells [232, 239].   
 
1.7 Development of Proteasome Inhibitors for Clinical Use 
Initial interest for developing proteasome inhibitors for clinical use was sparked by 
the finding that excessive UPP activity was a substantial contributor to muscle wasting in 
rodent disease models.  It was reasoned that inhibiting the proteasome may be able to 
prevent muscle wasting in human patients suffering from various diseases [240].  
Additionally, the discovery of the proteasome’s role in activating the transcription factor 
NF-κB, a key contributor to inflammation and cancer [133], indicated that proteasome 
inhibitors could be of therapeutic benefit in inflammatory diseases and cancers.  However, 
due to the critical roles of the proteasome in normal cellular function, the potential for 
proteasome inhibitors to be overly toxic to non-diseased cells remained a prominent 
concern [240].  Fortunately, several research groups began to discover that proteasome 
inhibitors were selectively cytotoxic to malignant cells over healthy ones [136-138, 155, 
241, 242].  For example, the β-lactone inhibitor lactacystin was shown to preferentially 
induce apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells over normal 
lymphocytes [241], and patient-derived multiple myeloma cells were found to be more 
susceptible to the growth inhibitory effects of bortezomib than peripheral blood 
mononuclear cells (PBMCs) isolated from healthy donors [242].  These findings suggested 
a therapeutic window for proteasome inhibitors in treating cancers; thus, clinically, they 
have largely been developed as anticancer agents. 
 
1.7.1 Bortezomib 
Bortezomib (formerly known as PS-341 and now marketed as Velcade®), a 
peptide boronate, was the first proteasome inhibitor to receive FDA approval [134] (Figure 
1.9 A).  Bortezomib preferentially targets the β5 and β5i subunits [174, 180, 207, 243-245], 
but also targets β1 and β1i at clinically achievable concentrations [200, 204, 207, 243].  
Conversely, an increase in T-L activity is frequently observed following bortezomib 
treatment [145, 203, 207, 243, 245, 246].  Bortezomib induces apoptotic cell death via 
both caspase-8 and caspase-9-dependent pathways [247].  Activation of caspase-4-
dependent apoptosis, which is induced by ER stress, has also been noted following 
treatment with bortezomib [248]. 
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Figure 1.9 Proteasome inhibitors that are FDA-approved or in clinical trials 
A) FDA-approved proteasome inhibitors. The peptide boronate bortezomib, the peptide 
epoxyketone carfilzomib, and the peptide boronate ixazomib were granted FDA approval 
in 2003, 2012, and 2015, respectively.  The peptide boronic ester prodrug of ixazomib, 
ixazomib citrate, is also shown. B) Proteasome inhibitors in clinical trials. The peptide 
boronate delanzomib, the β-lactone marizomib, and the peptide epoxyketone oprozomib 
are shown. 
 
Bortezomib was evaluated in the National Cancer Institute’s in vitro screen and 
found to produce significant cytotoxic effects in multiple cell lines derived from diverse 
tumor types.  Bortezomib-mediated proteasome inhibition in PC-3 prostate cancer cells 
led to elevated levels of the cyclin-dependent kinase inhibitor p21 and induced G2/M-
phase cell cycle arrest and apoptosis [134].  The inhibitor also achieved broad tissue 
distribution in rats and significant antitumor activity in a mouse xenograft model of prostate 
cancer [134].  Maximum achievable CT-L inhibition following bortezomib administration, 
as measured in patient blood samples, was found to be ~70-80% [249-253].  Maximal 
inhibition was detected within 5 minutes following bortezomib treatment, with recovery of 
activity beginning as early as 4 hours following treatment [252].  Complete recovery was 
observed within 72 hours following treatment [249, 250, 252].  Since bortezomib-mediated 
proteasome inhibition is reversible, recovery of proteasome activity can occur via 
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bortezomib dissociating from the proteasome’s active sites, or via new proteasomes being 
produced by the cell [174].    
Based on promising clinical trial results, bortezomib was approved by the FDA in 
2003 for treating relapsed or refractory multiple myeloma [254].  It has since been 
approved for use as a first line agent in treating multiple myeloma and mantle cell 
lymphoma [255].  Clinical trials of bortezomib for other applications are ongoing [157]. 
Despite its clinical success, bortezomib-treated patients experience several severe 
side effects.  Peripheral neuropathy is a dose-limiting side effect of bortezomib treatment 
that may result from off-target inhibition of the neuronal prosurvival serine protease 
HtrA2/Omi [256].  Intrinsic and acquired resistance are also clinical challenges observed 
with bortezomib-based therapy [257-260].  Furthermore, while bortezomib is active against 
solid tumor cells in vitro and in xenograft models [134], it has had limited success in 
treating solid cancers in the clinic [261].  These observations prompted the development 
of second-generation proteasome inhibitors with improved activity, reduced toxicity, and 
efficacy in treating bortezomib-resistant cancers.  Such inhibitors include second-
generation peptide boronates as well as inhibitors falling into other classes.  So far, two 
second-generation inhibitors have received FDA approval: carfilzomib and ixazomib. 
 
1.7.2 Carfilzomib 
Modifying the N-terminus of the synthetic epoxomicin analog YU-101 to improve 
its water solubility later gave rise to the second FDA-approved proteasome inhibitor 
carfilzomib (formerly called PR-171 and now marketed as Kyprolis®) [174] (Figure 1.9 A).  
This inhibitor was approved in 2012 for treating relapsed or refractory multiple myeloma 
[172].  In comparison with bortezomib, carfilzomib inhibits the proteasome’s CT-L activity 
more selectively [174], and slightly differs from bortezomib in its secondary targets; β1i 
and β2i are the next preferred targets of carfilzomib, which, in contrast to bortezomib, 
exhibits a distinct aversion to binding β1 [262].  Another difference is that, in contrast to 
bortezomib, carfilzomib does not substantially cross-react with non-proteasomal 
proteases [256].  The more selective proteasome inhibitory profile, together with the 
unparalleled proteasome specificity of the epoxyketone pharmacophore, are potential 
reasons behind carfilzomib’s lower in vivo toxicity relative to that of bortezomib [174].  
Notably, the incidence of treatment-emergent peripheral neuropathy is substantially lower 
in carfilzomib-treated patients than those treated with bortezomib [263-268] consistent 
with the notion that this side effect results from the off-target activity of bortezomib [256].   
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Carfilzomib’s more favorable toxicity profile permits consecutive-day dosing, which 
prevents complete recovery of proteasome activity between consecutive day doses and 
therefore achieves a more robust and sustained proteasome inhibition [174, 263, 264, 
266].  Applying the consecutive-day dosing schedule to xenograft models of human 
cancers produced greater anticancer activity than bortezomib (or carfilzomib) 
administered on bortezomib’s clinical dosing schedule (biweekly day 1/day 4, which allows 
proteasome activity to recover between bortezomib doses) [174, 249, 250, 252].  
Furthermore, in comparison with bortezomib, carfilzomib’s irreversible binding mechanism 
also facilitates a more sustained proteasome inhibition following a single, brief exposure, 
as recovery of proteasome activity following carfilzomib treatment requires de novo 
proteasome production [174].  This has been suggested to contribute to its enhanced 
anticancer efficacy over that of bortezomib [174, 262] and its ability to overcome 
bortezomib resistance [262, 263, 266, 267].  However, resistance is still a major clinical 
challenge, as ~50% of multiple myeloma cases fail to respond to initial treatment with 
bortezomib or carfilzomib [259, 265], and, as for bortezomib, acquired resistance to 
carfilzomib emerges in initially responsive patients [269]. 
Although it was hoped that the advantages offered by carfilzomib over bortezomib 
would lead to enhanced clinical activity against solid tumors, results of a clinical trial with 
carfilzomib in this setting were disappointing [268].  However, its tolerable toxicity profile 
makes it worthwhile to investigate its therapeutic efficacy in higher doses or in combination 
with other chemotherapeutic agents in patients with solid cancers [268], and further clinical 
trials are exploring such possibilities [157]. 
 
1.7.3 Ixazomib and Delanzomib 
A suggested consequence of bortezomib’s slowly irreversible binding to the 
proteasome’s active sites is that proteasomes in red blood cells may act as a sink for this 
inhibitor following its intravenous administration, therefore limiting its tissue distribution 
and, consequently, its activity in solid tumors.  This provided the rationale for the 
development of ixazomib citrate (previously known as MLN9708), a prodrug which is 
hydrolyzed to its active form, ixazomib (previously called MLN2238 and now marketed as 
NINLARO®), in aqueous solution or plasma [270] (Figure 1.9 A).  Ixazomib is an N-capped 
dipeptide boronic acid that preferentially inhibits β5 (IC50 value of 3.4 nM).  Higher 
concentrations are required to inhibit the C-L and T-L active sites, with IC50 values of 31 
nM and 3,500 nM, respectively [270].  In comparison with bortezomib, ixazomib has an 
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~6-fold shorter proteasome dissociation half-life, which was suggested to largely 
contribute to its superior tissue distribution [270].  Unlike bortezomib and carfilzomib, 
ixazomib is orally bioavailable [270], and, unlike bortezomib, it lacks activity against the 
neuronal protease HtrA2/Omi [271].  Ixazomib has a similar subunit selectivity profile to 
that of bortezomib, but inhibited the proteasome’s CT-L activity in tumor tissue more 
strongly and displayed greater antitumor activity in xenograft models of both hematologic 
and solid cancers [270, 271].  It was also active in multiple myeloma cells obtained from 
bortezomib-resistant patients and in a cell line model of acquired bortezomib resistance 
[271].  Ixazomib was recently approved (in November of 2015) by the FDA for use, in 
combination with lenalidomide and dexamethasone, in treating multiple myeloma in 
patients who have received at least one prior therapy [272].  A second orally-bioavailable 
peptide boronate, delanzomib (also known as CEP-18770), has also been assessed in 
clinical trials [245] (Figure 1.9 B).  This inhibitor has a subunit selectivity profile similar to 
that of bortezomib and ixazomib [245, 270].  In a phase I clinical study, CT-L activity in 
blood was inhibited by only ~45% at the maximum tolerated dose [273].  Further clinical 
trials of delanzomib were initiated but have since been terminated [157]. 
 
1.7.4 Marizomib 
A β-lactone proteasome inhibitor is also in clinical development.  This inhibitor, 
marizomib (also known as salinosporamide A or NPI-0052), is a natural product produced 
by the marine gram-positive actinomycete Salinospora tropica [202] (Figure 1.9 B).  Its 
subunit selectivity profile differs from that of bortezomib: marizomib is more potent than 
bortezomib against the CT-L and T-L activities of purified erythrocyte proteasomes, but is 
less potent than bortezomib against the C-L activity.  Marizomib was found to be more 
cytotoxic than bortezomib to multiple myeloma cells derived from bortezomib-resistant 
patients, but was less cytotoxic than bortezomib to non-malignant cells [202].  When these 
inhibitors were administered intravenously to mice at the maximum tolerated doses, 
marizomib achieved complete inhibition of the CT-L activity in whole blood, which was 
sustained for at least 72 hours following administration, whereas bortezomib inhibited this 
activity less completely, with recovery already beginning to occur 24 hours following 
administration.  Conversely, bortezomib inhibited the C-L activity more strongly than 
marizomib, which was sustained for at least 72 hours following administration [202].  
Importantly, marizomib inhibited the T-L activity by ~50%, whereas a persistent 
bortezomib-mediated stimulation of this activity was observed; elevated T-L activity 
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remained detectable 168 hours after treatment [202].  Like the second-generation peptide 
boronates described above, marizomib is also orally bioavailable.  Additionally, marizomib 
and bortezomib were found to have synergistic cytotoxic activity in multiple myeloma cells 
[202].  However, like bortezomib, marizomib can also inhibit non-proteasomal proteases 
[202].  Several clinical trials of marizomib, as a single agent or in combination with others, 
remain open [157].      
 
1.7.5 Oprozomib 
Finally, the tripeptide epoxyketone inhibitor oprozomib (formerly known as PR-047 
or ONX 0912) is an orally bioavailable carfilzomib analog that is currently in clinical trials 
[185] (Figure 1.9 B).  Like carfilzomib, oprozomib selectively inhibits β5 and β5i over the 
remaining catalytic proteasome subunits and does so with similar potency [185, 274].  
Additionally, oprozomib was cytotoxic to multiple myeloma cells, including primary cells 
derived from bortezomib-resistant patients, but was not significantly cytotoxic to 
nonmalignant PBMCs even at high doses [274].  Administering oprozomib orally on two 
consecutive days per week at doses that inhibit the CT-L activity by >80% in blood and in 
the peripheral tissues examined was well-tolerated in mice and, in mouse xenograft 
models of hematologic and solid cancers, had similar antitumor activity to that of 
intravenously administered carfilzomib and prolonged survival [185, 274].  Proteasome 
activity recovered in adrenal and liver within 24-72 hours following oral administration of 
oprozomib, while no recovery was observed in blood [185].  As observed for a 
marizomib/bortezomib combination [202], combined treatment of multiple myeloma cells 
with oprozomib and bortezomib produced synergistic cytotoxic effects [274].  Oprozomib 
is currently being examined in clinical trials in patients with both hematologic and solid 
cancers, both as a single agent and in combination regimens [157]. 
 
1.8 Proteasome Inhibitor Resistance 
Clinical resistance has emerged as a major limitation associated with bortezomib 
therapy, although the mechanisms responsible remain unclear.  Both intrinsic and 
acquired proteasome inhibitor resistance mechanisms have been investigated in 
laboratory settings, and wide-ranging conclusions have been drawn.  Resistance to a 
catalytic β-subunit-targeting proteasome inhibitor such as bortezomib could theoretically 
be conferred by several mechanisms.  First, the activity of drug efflux transporters or 
metabolic enzymes in cancer cells may lead to suboptimal intracellular inhibitor 
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concentrations and, therefore, to an insufficient extent of proteasome inhibition to promote 
growth arrest and apoptotic cell death.  Second, proteasome substrates may be rerouted 
to an alternative proteolytic system for degradation, thus mitigating the cytotoxic effects of 
proteasome inhibition.  Third, aberrant apoptotic/survival signaling downstream of 
proteasome inhibition may allow cells to withstand proteasome inhibitor-induced 
accumulation of polyubiquitinated proteins.  Finally, various mechanisms involving the 
proteasome complex itself may confer proteasome inhibitor resistance.  Of course, these 
mechanisms are not mutually exclusive; multiple mechanisms may operate 
simultaneously to confer resistance.  Additionally, mechanisms may be inhibitor-specific 
and therefore capable of being overcome by applying an alternative proteasome inhibitor 
with different inhibitory properties.  A summary of the previously-reported mechanisms of 
proteasome inhibitor resistance—predominantly focusing on acquired resistance—will 
ensue. 
 
1.8.1 Role of Drug Efflux Transporters 
a. ALLN Resistance 
Perhaps the first report of a cell line model of acquired resistance to a proteasome 
inhibitor came from Sharma et al., who cultured the Chinese hamster ovary cell line CHO-
K1 in the presence of gradually increasing concentrations of the synthetic peptide 
aldehyde inhibitor ALLN (Figure 1.3 A) until it adapted to grow under continuous exposure 
to 50 μg/mL ALLN [275].  This process was undertaken to understand the apparent 
contribution of the protease(s) inhibited by ALLN to the degradation of the rate-limiting 
cholesterol biosynthetic enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, and it was hoped that the mechanism by which ALLN resistance was acquired 
would involve amplifying the protease-encoding gene(s) to facilitate this study.  However, 
the resulting cell line, ALLNr50, instead acquired ALLN resistance by amplifying and 
overexpressing the multidrug resistance gene mdr1, which encodes the drug efflux 
transporter P-glycoprotein (P170) [275].  Overexpression of this ATP-hydrolyzing 
transmembrane transporter confers resistance to various structurally and functionally 
diverse chemotherapeutic agents.  The multidrug resistance phenotype of ALLNr50 cells 
was exemplified by their more than 10-fold upregulation of P-glycoprotein, cross-
resistance to P-glycoprotein substrates doxorubicin, colchicine, and etoposide, and a 
reduction in their 50-fold ALLN resistance by treatment with the competitive P-glycoprotein 
inhibitor verapamil.  It was therefore concluded that ALLN is a P-glycoprotein substrate, 
40 
and that, in ALLNr50 cells, overexpression of P-glycoprotein contributes to ALLN resistance 
by extruding the inhibitor and, consequently, lowering the steady-state ALLN levels 
available for binding its intracellular targets.  Further support for this conclusion was 
provided by the substantially higher ALLN concentrations required to inhibit the 
degradation of a chimeric reporter protein in ALLNr50 than in parental CHO-K1 cells [275].  
In contrast to the results of this study, de Jong et al. found that A2780 ovarian cancer cells 
selected for 10 μM ALLN resistance overexpressed multidrug resistance-associated 
protein (MRP)1 instead of P-glycoprotein [276].  Other transporter proteins, including 
MRP2, 3, 5, breast cancer resistance protein (BCRP), and the lung resistance protein 
(LRP), were not overexpressed in these cells [276]. 
 
b. Epoxomicin Resistance 
While ALLN inhibits the proteasome [128], it also inhibits other cellular proteases 
[277].  However, a multidrug resistance phenotype was also observed in a derivative of 
the KMS-11 multiple myeloma cell line selected for resistance to the proteasome-specific 
inhibitor epoxomicin [278].  The resulting cell line, KMS11R, remained viable in the 
presence of 20 nM epoxomicin but maintained similar bortezomib sensitivity to that of 
parental KMS-11 cells.  Although KMS11R cells exhibited reduced CT-L activity relative 
to parental KMS-11 cells and lacked mutations in the PSMB5 gene encoding the catalytic 
proteasome subunit β5, epoxomicin, unlike bortezomib, was unable to significantly inhibit 
the proteasome’s CT-L activity in KMS11R cells.  However, treatment of lysates of 
parental and epoxomicin-resistant KMS-11 cells led to similar dose-dependent inhibition 
of proteasome activity in both cell lines, suggesting that epoxomicin’s ability to bind the 
proteasomes of KMS11R cells was not impaired [278].  KMS11R cells incubated in both 
the absence and presence of epoxomicin for 24 hours were shown to express P-
glycoprotein, while parental cells incubated under these same conditions did not, 
indicating that P-glycoprotein expression was associated with the mechanism of acquired 
epoxomicin resistance.  Overexpression of P-glycoprotein in KMS11R cells led to a 3-5-
fold lower uptake of doxorubicin—a known P-glycoprotein substrate—in comparison with 
parental KMS-11 cells [278].  Treatment with the P-glycoprotein inhibitor verapamil 
restored epoxomicin sensitivity and doxorubicin uptake to KMS11R cells, further 
emphasizing a causative role of P-glycoprotein overexpression in epoxomicin resistance 
and identifying epoxomicin as a P-glycoprotein substrate.  Conversely, the lack of cross-
resistance of KMS11R cells to bortezomib implies that bortezomib is not a P-glycoprotein 
41 
substrate [278].  Results of a study by Ohkawa et al. also suggested that epoxomicin is a 
P-glycoprotein substrate [279].  In contrast to the findings of Gutman et al. [278], however, 
the mechanism by which A431 squamous cell carcinoma cells acquired resistance to 12 
nM epoxomicin apparently did not involve P-glycoprotein overexpression [279].  
 
c. Carfilzomib/Peptide Epoxyketone Inhibitor Resistance 
Based on the above-mentioned studies in support of epoxomicin as a P-
glycoprotein substrate, it is unsurprising that the structurally-related proteasome inhibitor 
carfilzomib was also found to be a substrate of this transporter [280].  CEM T cell leukemia 
cells overexpressing P-glycoprotein (CEM/VLB) were highly resistant to carfilzomib as well 
as to the structurally-related proteasome inhibitors ONX 0914 and (to a lesser extent) 
oprozomib.  Slight bortezomib resistance was also observed [280].  The reduced 
sensitivity of CEM/VLB cells to these inhibitors was associated with the requirement of 
higher inhibitor concentrations to induce a similar suppression of proteasomal CT-L 
activity, and resistance and inhibitory efficacy towards the CT-L activity were largely 
reversed and restored, respectively, by the P-glycoprotein inhibitor reversin 121 (P121).  
These findings further implicated P-glycoprotein-mediated drug efflux in the causative 
resistance mechanism [280].  Conversely, cell lines overexpressing the drug transporters 
MRP1-5 were not significantly resistant to these proteasome inhibitors, and the transporter 
BCRP was also ruled out as a contributor to resistance, indicating that P-glycoprotein is 
the major transporter with resistance-conferring potential with respect to these agents 
[280].  Even the low basal levels of P-glycoprotein’s transport activity observed in PBMCs 
from rheumatoid arthritis patients and healthy controls were sufficient to slightly but 
significantly reduce the ex vivo inhibitory efficiency of carfilzomib and ONX 0914 against 
the proteasome’s CT-L activity, as demonstrated by the stronger suppression of this 
activity by both inhibitors in the presence of reversin 121.  However, these effects were 
not observed for oprozomib or for bortezomib [280]. 
Furthermore, H23 lung adenocarcinoma and DLD-1 colon adenocarcinoma cell 
line models of acquired carfilzomib resistance were found by our laboratory to overexpress 
P-glycoprotein at both the mRNA and protein levels, which was shown to contribute to the 
resistance phenotype by a substantial loss of resistance upon treatment with the P-
glycoprotein inhibitor verapamil [281].  These cell lines acquired the ability to grow in 
culture medium containing 500 nM (H23/Carf) or 1,000 nM (DLD-1/Carf) carfilzomib and 
exhibited marked cross-resistance to the carfilzomib analog YU-101 and the known 
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P-glycoprotein substrate paclitaxel but retained parental levels of bortezomib sensitivity.  
Peptide analogs of carfilzomib lacking the epoxyketone pharmacophore were shown to 
resensitize the carfilzomib-resistant cell lines to carfilzomib, suggesting that such analogs 
may be useful in combating P-glycoprotein-mediated drug resistance [281].  Consistent 
with the results obtained in our laboratory [281], KMS-34 multiple myeloma cells cultured 
for 4 weeks in the presence of a low concentration (6 nM) of carfilzomib exhibited reduced 
carfilzomib sensitivity that could be restored by inhibiting P-glycoprotein with reversin 121 
[282].  Although this cell line already expressed high basal levels of P-glycoprotein mRNA 
prior to carfilzomib exposure, its reduced carfilzomib sensitivity following culture in 
carfilzomib-containing medium was associated with increased levels of P-glycoprotein on 
the cell surface [282].  Furthermore, gene expression profiling detected increased 
expression of P-glycoprotein mRNA in drug-refractory cells obtained from a multiple 
myeloma patient following carfilzomib relapse, suggesting the contribution of this 
transporter to carfilzomib resistance may be of clinical relevance [282].  Additional studies 
will be required to definitively determine whether P-glycoprotein overexpression is a 
clinically important mediator carfilzomib resistance.     
P-glycoprotein overexpression was also concluded to contribute to the acquired 
resistance of head and neck squamous cell carcinoma cell line models to 1 μM carfilzomib 
(R-UMSCC-1 and R-Cal33) [283].  While parental cells did not express detectable levels 
of P-glycoprotein, both of the resistant cell lines overexpressed this transporter, and the 
finding that a partial restoration of carfilzomib sensitivity could be achieved by reversin 
121 treatment demonstrated that P-glycoprotein overexpression contributes to carfilzomib 
resistance in these cell lines.  However, additional factors must also contribute, as the R-
Cal33 cell line expressed much higher levels of P-glycoprotein than did the R-UMSCC-1 
cell line but was more sensitive to carfilzomib [283].  In line with this, Bcl-2 was also 
upregulated in R-UMSCC-1 cells but not in R-Cal33 cells.  Furthermore, co-treatment with 
carfilzomib and the Bcl-2/Bcl-XL inhibitor ABT-737 led to an ~50% decrease in the 
carfilzomib IC50 in R-UMSCC-1 cells, in contrast to R-Cal33 cells.  The authors suggested 
that elevated levels of Bcl-2 may contribute to the higher degree of acquired carfilzomib 
resistance exhibited by the R-UMSCC-1 cells, and, therefore, that adding a Bcl-2 inhibitor 
may be of therapeutic utility in such instances [283].  Additionally, although these 
carfilzomib-resistant cell lines were highly cross-resistant to oprozomib, they were only 
moderately cross-resistant to bortezomib, suggesting that bortezomib may be effective in 
treating carfilzomib- and oprozomib-resistant cancers [283]. 
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d. Bortezomib Resistance 
The above mentioned reports by Gutman et al. and Ao et al. demonstrated that 
bortezomib sensitivity was maintained in P-glycoprotein-overexpressing epoxomicin- and 
carfilzomib-resistant lines [278, 281], indicating that bortezomib may not be a P-
glycoprotein substrate.  However, results of other studies on whether or not bortezomib is 
a substrate of this transporter have yielded mixed results.  Verapamil did not influence the 
sensitivity of P-glycoprotein-overexpressing K562 cells toward bortezomib, but did 
increase their sensitivity toward the P-glycoprotein substrate daunorubicin, suggesting 
that the activity of bortezomib is not significantly impacted by P-glycoprotein 
overexpression [284].  Additionally, results of studies of various cell line models of 
bortezomib resistance indicated that P-glycoprotein-mediated efflux of bortezomib did not 
serve as an underlying resistance mechanism [209, 246, 285-290].  Conversely, slight 
(4.5-fold) bortezomib resistance was observed by Verbrugge et al. in the P-glycoprotein-
overexpressing CEM/VLB cell line [280].  Likewise, P-glycoprotein overexpression was 
shown to reduce bortezomib sensitivity only slightly (2-fold) in HL60/VCR and 8226/Dox6 
MDR cell lines relative to parental HL60 and 8226 cells, an effect that was deemed unlikely 
to be relevant in vivo [291].  Bortezomib sensitivity was not affected by overexpression of 
MRP1, BCRP, or LRP [291]. 
Results of a study by Rumpold et al. also demonstrated that siRNA-mediated 
knockdown of P-glycoprotein in the P-glycoprotein-overexpressing cell line K562/Dox 
resulted in an ~6-fold increase in sensitivity to bortezomib-induced cytotoxicity, whereas 
sensitivity to the bortezomib analog MLN273 was increased to a greater extent (~26-fold) 
[292].  Consistent with this divergence, more pronounced differences were observed in 
the extent of MLN273-mediated inhibition of the proteasome’s CT-L activity in the cells in 
which P-glycoprotein was knocked down versus left intact than those observed for 
bortezomib-mediated inhibition.  These results suggested that, while both inhibitors can 
be transported by P-glycoprotein, MLN273 is more efficiently transported than is 
bortezomib [292]. 
O’Connor et al. also concluded bortezomib to be a substrate of P-glycoprotein.  
This was based on the reduced sensitivity to bortezomib observed in the P-glycoprotein-
overexpressing DLKP-A cell line in comparison with the DLKP parental cell line, which did 
not overexpress P-glycoprotein, and the synergism with which bortezomib reduced cell 
viability in combination with the P-glycoprotein inhibitor elacridar in the former cell line 
[293].  Synergistic effects of this drug combination were also observed in other 
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P-glycoprotein-mediated multidrug resistant cell lines, including the NCI-Adr/res ovarian 
cancer and RPMI-Dox40 multiple myeloma cell lines [293].  O’Connor et al. suggested 
that the degree to which P-glycoprotein is overexpressed may dictate the ability of 
bortezomib to serve as a P-glycoprotein substrate, as the DLKP-A cell line, with higher P-
glycoprotein expression, was less sensitive to bortezomib relative to its parental cell line, 
but the differences between the sensitivities of the A549-taxol cell line, with lower P-
glycoprotein expression, and its parental cell line were much less pronounced.  
Additionally, the synergistic effects of the bortezomib-elacridar combination were greater 
in the cell line with higher P-glycoprotein expression than in the cell line with lower P-
glycoprotein expression [293].  Consistent with the results of Minderman et al. [291], 
bortezomib was not found to be a substrate of MRP1 or BCRP [293]. 
NF-κB activity can induce P-glycoprotein expression in cancer cells [294].  Since 
proteasome inhibitors attenuate NF-κB signaling, they could potentially block upregulation 
of P-glycoprotein and thereby reduce the MDR phenotype.  In fact, the proteasome 
inhibitors MG132 and bortezomib were found to reduce expression of P-glycoprotein, 
increase intracellular accumulation of doxorubicin, and synergize with doxorubicin and 
paclitaxel in P-glycoprotein-overexpressing MCF7 breast cancer cells (MCF7/ADR); 
treatment with these inhibitors also caused an increase in cytosolic IκBα levels and a 
decrease in NF-κB DNA binding [295].  O’Connor et al. also found P-glycoprotein 
expression in both RPMI-Dox40 and DLKP-A cells, and P-glycoprotein’s transport activity 
in the former, to decrease following treatment with bortezomib, presumably due to a 
suppressed NF-κB-mediated induction of P-glycoprotein expression [293].  Alternatively, 
Fujita et al. attributed the reduced P-glycoprotein levels observed in MCF7/ADR cells 
following treatment with MG132 and bortezomib to increased signaling through the c-Jun 
pathway, which has been shown to inhibit P-glycoprotein expression in MDR cells, 
together with decreased and unaltered signaling through the ERK1/2 MAPK and p38-
MAPK pathways, respectively, which have been suggested as contributors to the MDR 
phenotype [295]. 
 
1.8.2 Role of Altered Drug Metabolism 
After concluding that P-glycoprotein overexpression mediated ALLN resistance in 
their original ALLN-resistant cell line [275], Inoue et al. generated a second ALLN-resistant 
CHO cell line, this time also adding verapamil to the culture medium in effort to block P-
glycoprotein overexpression.  These cells adapted to grow in the presence of 100 μM 
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ALLN and displayed 30-fold increased ALLN resistance in comparison with the parental 
CHO cell line [296].  They were also cross-resistant to the ALLN analog ALLM but not to 
the dipeptide aldehyde protease inhibitor calpeptin or E-64-d, a cysteine protease inhibitor 
which lacks an aldehyde group.  Importantly, this cell line was not cross-resistant to 
doxorubicin, etoposide, or colchicine, demonstrating that the selection protocol did, in fact, 
prevent the development of the multidrug resistance phenotype [296].  Instead, the newly-
generated ALLN-resistant cells were found to overexpress an aldo-keto reductase, which 
was accompanied by elevated levels of aldo-keto reductase activity.  Aldo-keto reductases 
are capable of reducing a variety of carbonyl compounds, including xenobiotic aldehydes; 
thus, the observed aldo-keto reductase upregulation was presumed to contribute to the 
resistance phenotype by reducing ALLN’s aldehyde pharmacophore to a 
pharmacologically inactive alcohol [296].  As observed for the P-glycoprotein-
overexpressing ALLN-resistant cell line [275], higher concentrations of ALLN were 
required to inhibit the degradation of a reporter substrate in the aldo-keto-reductase-
overexpressing ALLN-resistant cell line than in the parental cell line, which, in this case, 
was concluded to result from metabolic inactivation of ALLN [296].  The ALLN-resistance 
phenotype of these cells was found to be stable over a 1 month period in the absence of 
ALLN, whereas the levels of the aldo-keto reductase began to decrease 2 months 
following removal of the inhibitor [296]. 
As for bortezomib, Xu et al. demonstrated that DII1-mediated activation of the 
Notch signaling pathway led to reduced sensitivity of murine and human multiple myeloma 
cells to the inhibitor, an effect that was attributed to the increased expression of the 
cytochrome P450 enzyme CYP1A1 and could be abrogated by Notch pathway inhibition 
[297].  Conversely, microarray data led researchers to conclude that an increase in 
cytochrome P450-mediated oxidative deboronation of bortezomib was unlikely to 
contribute to the acquired bortezomib resistance of THP-1 myelomonocytic leukemia and 
HT-29 colorectal adenocarcinoma cell line models [246, 298].   
   
1.8.3 Role of Alternative Proteolytic Pathways 
Culturing EL4 mouse lymphoma cells in the presence of the peptide vinyl sulfone 
proteasome inhibitor NLVS led to the selection of an NLVS-resistant cell population in 
which an alternative, AAF-AMC-hydrolyzing, NLVS-insensitive proteolytic complex 
capable of taking over proteasome functions was concluded to help facilitate continued 
survival and proliferation under these conditions [299].  Subsequently, Geier et al. 
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identified tripeptidyl peptidase II (TPPII) as an AAF-AMC-hydrolyzing proteolytic complex 
with increased activity in EL4 cells selected for resistance to a 6 μM dose of the β-lactone 
proteasome inhibitor lactacystin and suggested that it may play a role in degrading 
proteasome substrates when proteasome activity is inhibited [300].  However, as TPPII 
activity was also detected in parental EL4 cells, Geier et al. concluded it to be most likely 
that multiple factors, including increased TPPII activity, simultaneously contribute to the 
lactacystin-resistant phenotype of these cells [300]. 
Indeed, TPPII was deemed capable of protecting against the cytotoxic effects of 
NLVS in the NLVS-resistant EL4 cell line by helping to degrade polyubiquitinated proteins 
[301].  Although Wang et al. discovered that proteasome activity was incompletely 
inhibited by the concentration of NLVS applied, residual proteasome activity (primarily of 
the β2 and β2i subunits) alone was concluded to be inadequate for protecting these cells 
against NLVS-induced cytotoxicity [301].  However, findings of a separate study refuted 
these conclusions and instead suggested that continued polyubiquitinated protein 
degradation via residual proteasome activity was essential for the NLVS-resistant cells to 
survive NLVS exposure [302].  Additionally, the results of several more studies suggested 
that TPPII was not involved in mechanisms of acquired bortezomib resistance [246, 285, 
287].  Whether TPPII actually plays a role in conferring acquired proteasome inhibitor 
resistance, therefore, remains unresolved. 
On the other hand, it may seem much more likely that compensatory activity of the 
main non-proteasomal proteolytic pathway—that is, the lysosomal/autophagy pathway—
would contribute to proteasome inhibitor resistance.  In fact, a number of studies have 
revealed that autophagy can compensate for diminished proteasome activity, which can 
contribute to insensitivity of cancer cells to proteasome inhibitors [303-305].  Enhanced 
prosurvival autophagy was identified as a contributor to acquired carfilzomib resistance in 
two multiple myeloma cell lines selected for resistance to 12 nM carfilzomib—one of which 
overexpressed P-glycoprotein and one which did not [306].  The results generated in this 
study supported a model in which the pluripotency reprogramming transcription factor 
KLF4—which was upregulated in the carfilzomib-resistant cell lines—mediates 
upregulation of sequestosome 1/p62, a ubiquitin-binding adaptor protein that can direct 
ubiquitinated proteins to either the proteasomal or the autophagic degradative pathway.  
This thereby allows ubiquitinated proteasome substrates to be rerouted to 
autophagosomes for clearance via prosurvival autophagy when proteasome activity is 
inhibited.  Treatment with the autophagy inhibitor chloroquine sensitized both of these 
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carfilzomib-resistant cell lines to carfilzomib, further implicating this pathway in mediating 
carfilzomib resistance [306].  Activation of autophagy has also been associated with 
acquired bortezomib resistance [290].  These findings indicate that targeting both the 
proteasome and autophagy may be a more effective treatment strategy than targeting the 
proteasome alone [303-305]. 
 
1.8.4 Role of Proteasome-Mediated Mechanisms 
The cellular effects of proteasome inhibitors have been shown to be concentration-
dependent.  For example, while a high concentration of the proteasome inhibitor MG132 
induced apoptosis in AT3 prostate carcinoma cells, a lower concentration was not toxic 
and instead protected against apoptosis induced by Sindbis virus infection, demonstrating 
that proteasome inhibitors can induce or protect against apoptosis, depending on the 
concentration applied.  These concentration-dependent effects are presumably due to 
differential degrees of proteasome inhibition achieved at a low versus high inhibitor 
concentration [307].  In line with this, a 24 hour treatment of human umbilical cord vein 
cells (HUVECs) with nontoxic doses of the proteasome inhibitors MG132 and MG262 
inhibited the CT-L activity of the proteasome by 80%, while the C-L and T-L activities were 
inhibited by less than 50%.  Alternatively, toxic doses inhibited the CT-L activity by 90-
97%, the C-L activity by >50%, and the T-L activity by >70% [308].  Furthermore, similar 
bortezomib-mediated inhibition of proteasome activities did not similarly inhibit protein 
degradation in a panel of myeloma cell lines, with stronger inhibition of protein degradation 
leading to greater sensitivity to bortezomib.  In most of the myeloma cell lines studied, a 
>90% reduction in viability by bortezomib required >95% inhibition of the proteasome’s 
CT-L activity, co-inhibition of the C-L activity, and an ~50% inhibition in protein degradation.  
Unfortunately, this exceeds clinically achievable levels of bortezomib-mediated inhibition 
[309]. 
Alternatively, bortezomib’s inhibitory efficacy against the CT-L activity was found 
to differ between two non-small cell lung cancer (NSCLC) cell lines, which was considered 
to be a contributing factor to their differential sensitivities to this inhibitor [310].  Basal CT-
L proteasome activity was slightly lower and was more substantially inhibited by a lower 
concentration of bortezomib in the intrinsically bortezomib-sensitive NSCLC cell line 
SW1573 than in the intrinsically bortezomib-resistant H460 NSCLC cell line.  Accordingly, 
G2/M arrest and apoptosis were induced by a lower concentration of bortezomib in 
SW1573 than in H460 NSCLC cells [310].  However, at higher doses of bortezomib that 
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similarly inhibited CT-L activity in both cell lines and induced G2/M arrest in H460 cells, a 
higher percentage of apoptotic H460 than SW1573 cells was observed.  Although the 
extent to which the C-L and T-L activities were inhibited by bortezomib in these cell lines 
was not reported, these results suggested that induction of apoptosis in NSCLC cells 
requires sufficient inhibition of proteasome activity to induce G2/M arrest, and, once G2/M 
arrest has been induced, resistance to apoptosis must be overridden [310].   
Collectively, these results (and others described above) suggest that, while 
mechanisms downstream of the proteasome are probably involved as well, cellular 
mechanisms leading to suboptimal inhibition of the proteasome’s catalytic activities are 
likely to contribute to proteasome inhibitor resistance.  Mutations in the β5-encoding 
PSMB5 gene and altered expression levels and activity profiles of the catalytic 
proteasome subunits have been shown to produce such effects. 
 
a. Bortezomib Resistance 
Proteasome Inhibitor Resistance-Conferring PSMB5 Mutations 
1. Impact on bortezomib binding 
Lu et al. were the first to report a cell line model of acquired proteasome inhibitor 
resistance in which a mutation in the PSMB5 gene contributes to the resistance phenotype 
[311].  In their initial publication, they described two mutations in this gene that they had 
identified in bortezomib-resistant Jurkat T lymphoblastic lymphoma/leukemia cells: a 
homogenous yet silent T192C mutation, and a G322A mutation encoding an Ala49Thr 
amino acid substitution in the β5 subunit.  This latter mutation was initially heterogeneous, 
but became homogenous following further selection with higher bortezomib 
concentrations, perhaps indicating that the heterogeneity originally observed resulted from 
polyclonality of the initial culture rather than heterozygosity.  Similar results were obtained 
with three additional bortezomib-resistant cell lines derived from the parental Jurkat cell 
line, suggesting that the Ala49Thr β5 mutant provides a growth advantage to these cells 
under bortezomib exposure [311].  Measuring the CT-L activity following bortezomib 
treatment in parental and bortezomib-resistant cell lines revealed that bortezomib’s 
inhibitory efficacy towards this activity was significantly lower in the bortezomib-resistant 
cell lines, leading the authors to conclude that the Ala49Thr mutation in the β5 subunit 
plays a key role in bortezomib resistance by reducing the efficiency with which bortezomib 
inhibits its activity [311].  In line with this conclusion, introducing the mutant PSMB5 gene 
into parental Jurkat cells led to significantly reduced bortezomib-mediated inhibition of the 
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proteasome’s CT-L activity and conferred bortezomib resistance [311].  Overall, the results 
of this study are consistent with a resistance mechanism in which bortezomib’s binding 
affinity for the conformationally-altered β5 subunit is reduced, leading to reduced 
bortezomib-mediated inhibition of CT-L activity and, consequently, suppressed G2 cell 
cycle arrest and apoptosis [311]. 
Further study of Jurkat sublines adapted to 1,000 nM bortezomib uncovered two 
additional PSMB5 mutations: C323T and C326T, leading to Ala49Val and Ala50Val 
substitutions, respectively, in the β5 subunit [312].  One of these sublines initially 
contained a mixture of the G322A and C323T mutations, but, upon repeated rounds of 
selection, the C323T mutation became homogenous.  Similarly, two additional sublines 
were found to contain a mixture of the C323T mutation and a G322A, C3236T conjoined 
mutation, with the conjoined mutation becoming homogenous upon further rounds of 
selection.  These results led Lu et al. to hypothesize that, when challenged with a high 
dose (1,000 nM) of bortezomib, the G322A, C326T conjoined mutation provided a growth 
advantage over the C323T mutation, while this C323T mutation in turn provided a growth 
advantage over the G322A mutation [312].  Supporting this hypothesis, cells harboring the 
G322A, C326T conjoined mutation were the most resistant to bortezomib-induced 
cytotoxicity, those with the C323T mutation were intermediately resistant, and those 
containing the G322A mutation were the least resistant.  This rank order also held true for 
resistance to bortezomib-mediated inhibition of the proteasome’s CT-L activity [312].  As 
crystallographic studies previously showed that active site constituent amino acids Ala49 
and Ala50 of the functional β5 protein are involved in a hydrogen bonding network with 
the carbonyl oxygen of bortezomib’s pyrazine-2-carboxyl side chain [145], amino acid 
substitutions at these positions likely reduce the number of stabilizing interactions that can 
occur between bortezomib and the β5 active site, thereby leading to the reduced inhibitory 
efficacy observed, and, consequently, to bortezomib resistance [311, 312].  Additionally, 
computational modeling suggested that the Ala49Thr mutation leads to structural changes 
in the β5 subunit that may lower bortezomib’s binding affinity [311].  The G322A point 
mutation has subsequently been identified in other bortezomib-resistant cell line models, 
including those derived from the THP-1 myelomonocytic leukemia [246], RPMI 8226 [313], 
KMS-11, and OPM-2 [314] multiple myeloma, and H460 and A549 NSCLC [289] cell lines, 
while the C323T mutation was also identified in bortezomib-resistant CCRF-CEM acute 
lymphoblastic leukemia cells [313]. 
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The bortezomib-resistant THP-1 cell line gained an additional G311T mutation in 
the PSMB5 gene while undergoing selection for resistance to 500 nM bortezomib, leading 
to a second, Met45Ile, substitution in the β5 active site [313].  A heterozygous G311T 
mutation in the PSMB5 gene was associated with acquired bortezomib resistance in JY 
human B lymphoblast cells as well [315].  Franke et al. also observed PSMB5 mutations 
in bortezomib-resistant derivatives of the CCRF-CEM and RPMI 8226 cell lines [313].  
CCRF-CEM cells selected for resistance to 7 nM bortezomib harbored a G332T point 
mutation in this gene, leading to a Cys52Phe substitution in the S1 specificity pocket of 
the β5 active site [313].  The G332T mutation was also detected in SW1573 NSCLC cells 
resistant to 30 or 150 nM bortezomib [289]. 
Although Met45 plays an important role in defining the specificity of β5’s S1 pocket 
[33], the Met45Ile substitution was not found by in silico modeling to directly impact 
bortezomib binding [313].  Analyzing the crystal structure of the bortezomib-bound yeast 
proteasome revealed that the position of its side chain shifts upon bortezomib binding to 
allow the S1 pocket to accommodate the P1 leucine side chain [145].  Met45 substitutions 
may alter the specificity and flexibility of the S1 pocket and, therefore, the dynamics of 
bortezomib binding [313].  Additionally, although Cys52 may not be directly involved in 
bortezomib binding, it is located near Met45 [145].  In silico modeling indicated that 
Cys52Phe would slightly repel bortezomib from β5’s S1 specificity pocket [313].   
In addition to the G332T mutation, CCRF-CEM cells selected for resistance to a 
higher concentration (200 nM) of bortezomib gained the C323T mutation in the PSMB5 
gene previously observed by Lu et al. [312], leading to a second amino acid substitution, 
Ala49Val, in the β5 subunit [313].  While the additional methyl groups contributed by the 
Ala49Val substitution did not, based on in silico modeling, appear to provide a direct steric 
barrier to bortezomib binding, this substitution was previously suggested to render β5’s 
S1 pocket less accessible [313, 316]. 
RPMI 8226 cells selected for resistance to 7 nM bortezomib also contained an 
A247G PSMB5 mutation, encoding a Thr21Ala substitution in the β5 subunit.  This 
mutation was initially heterozygous, but became homozygous under continuous 
bortezomib exposure [313].  Thr21 was also previously concluded to play a direct role in 
bortezomib binding to β5 [145].  In silico modeling demonstrated that the Thr21Ala 
substitution causes a hydrogen bond between β5 and bortezomib to be lost, likely resulting 
in decreased affinity of bortezomib for β5 [313].  The heterozygous A247G mutation of the 
bortezomib-resistant RPMI 8226 cells was ultimately replaced by a homozygous G322A 
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mutation (encoding Ala49Thr) during dose escalation to 100 nM bortezomib [313].  When 
Franke et al. introduced the Ala49Thr substitution into their in silico model, they observed 
steric clashes with bortezomib’s backbone or a constriction of the entrance into the S1 
pocket—depending on how the Thr side chain was oriented—that may hinder bortezomib 
binding [313]. 
Interestingly, different PSMB5 mutations were detected in independently-
generated bortezomib-resistant CCRF-CEM and THP-1 cell lines [313].  An A310G 
mutation emerged in the new bortezomib-resistant THP-1 cell line, leading to a Met45Val 
substitution in the β5 subunit.  Alternatively, a G322A mutation was detected in the new 
bortezomib-resistant CCRF-CEM cell line, resulting in the Ala49Thr substitution observed 
in the RPMI 8226 and THP-1 cell lines selected for resistance to 100 nM bortezomib.  
These results led the authors to conclude that β5 mutations are acquired de novo 
consequent to long-term exposure to bortezomib [313].  The A310G mutation was also 
identified in A549 cells resistant to 40 nM bortezomib, while a second, G322A, mutation 
was additionally detected in this cell line following selection for resistance to 100 nM 
bortezomib [289].  The elevated basal levels and suppressed bortezomib-induced 
accumulation of Mcl-1 and NOXA seen in the A549 cells resistant to 40 nM bortezomib 
were suggested as potential consequences of alterations in the degradation of specific 
proteins imposed by the β5 Met45Val substitution [289].   
Ri et al. also observed heterozygous G322A (Ala49Thr-encoding) point mutations 
in the PSMB5 gene in their bortezomib-resistant KMS-11 and OPM-2 cell lines [314].  
However, the resulting amino acid substitutions were not accompanied by upregulation of 
the β5 protein in these cell lines [314], contrasting the results of other studies of 
bortezomib-resistant cell lines in which the G322A mutation was found [246, 289, 313].  
The Ala49Thr substitution was concluded to result in a slightly impaired bortezomib-
mediated inhibition of the CT-L activity in these bortezomib-resistant cell lines, thereby 
suppressing the bortezomib-induced accumulation of polyubiquitinated proteins and 
facilitating the evasion of a fatal ER stress response [314].   
Acquired bortezomib resistance in HT-29 colorectal adenocarcinoma cell line 
models was also associated with PSMB5 mutations [298].  Two PSMB5 mutations were 
identified: one encoding a Cys63Phe substitution in the mature β5 protein, and another 
encoding an Arg24Cys substitution in the β5 propeptide [298].  Cys63 resides outside of 
the β5 active site but on the same α-helix containing the active site residues Ala49 and 
Ala50, which are involved in bortezomib binding [145].  Molecular modeling predicted that 
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the Cys63Phe substitution alters the position of this helix relative to the active site, 
especially in the bortezomib-bound state, causing bortezomib to adopt an unfavorable 
conformation in in the β5 active site [298].  The accelerated recovery of the proteasome’s 
CT-L activity following its bortezomib-mediated inhibition in the bortezomib-resistant cell 
lines suggests that the Cys63Phe substitution may increase bortezomib’s dissociation 
constant with respect to the β5 active site.  Conversely, the Cys63Phe substitution was 
not predicted to substantially impact the binding of epoxomicin to the β5 active site, which 
was in line with the largely retained sensitivity of the bortezomib-resistant HT-29 cell lines 
to the epoxomicin analog carfilzomib [298].  On the other hand, the Arg24Cys substitution 
results from a naturally-occurring polymorphism observed more frequently in patients with 
multiple myeloma than in the general population [317].  Suzuki et al. proposed that this 
substitution may contribute to the faster recovery of CT-L activity following its inhibition by 
bortezomib by influencing propeptide processing [298].  In addition, a mutation in the 
PSMB8 gene, encoding a Phe50Ile substitution in the β5i propeptide, was observed in 
HT-29 cells resistant to 200 nM bortezomib, but how this may contribute to bortezomib 
resistance was not further discussed [298]. 
 
2. Impact on β5’s Catalytic Activity 
Many of the PSMB5 mutations identified in the bortezomib-resistant cell lines 
described above were also concluded to impair β5’s catalytic activity.  For example, the 
observed discrepancy between the strong overexpression of the Ala49Thr mutant β5 
subunit and the relatively minor increase in basal CT-L activity detected in the bortezomib-
resistant THP-1 cell lines described by Oerlemans et al. [246] may have resulted from a 
reduced ability of the P1 tyrosine of Suc-LLVY-AMC—the substrate used to measure 
proteasomal CT-L activity in this study—to access the S1 specificity pocket of the mutant 
β5 subunit, leading to a weaker hydrolysis of this substrate than observed with wild-type 
β5 [313].  Similarly, de Wilt et al. suggested that the β5 amino acid substitutions identified 
in their bortezomib-resistant NSCLC cell lines resulted in the reduced CT-L activity 
observed, despite β5 upregulation [289].  The Ala49Thr substitution was also concluded 
to reduce the efficiency of β5 labeling by the ABP Bodipy FL-Ahx3L3VS, as this labeling 
appeared to be prominently reduced in cells selected for resistance to 30 nM bortezomib 
but rebounded somewhat in cells selected for higher levels of resistance in which greater 
upregulation of the mutant β5 was observed [246].   
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Franke et al. used in silico modeling to evaluate how the amino acid substitutions 
in the β5 active site observed in their bortezomib-resistant cell lines may impair Suc-LLVY-
AMC hydrolysis [313].  This analysis indicated that, when Cys52 is replaced by Phe, it 
displaces the P1 tyrosine side chain of the Suc-LLVY-AMC substrate from β5’s S1 
specificity pocket, thereby decreasing its binding affinity.  The Cys52Phe mutation may 
also hamper the conformational change in Met45 that is required for substrate binding 
[313].  Thr21 was not shown by in silico modeling with wild-type β5 to play a direct role in 
Suc-LLVY-AMC binding, but, due to its proximity to Suc-LLVY-AMC’s peptide backbone, 
a hydrogen bond may form between the two upon minor shifts in conformation, which may 
explain the negative impact of the Thr21Ala substitution on Suc-LLVY-AMC hydrolysis 
[313].  The Ala49Thr substitution alters β5’s S1 pocket, and in silico modeling suggested 
it may impair the P1-S1 interaction between Suc-LLVY-AMC and β5, as predicted for 
bortezomib [313].  The Ala49Val, Cys52Phe and Met45Ile, Ala49Thr double substitutions 
were predicted to lead to a greater repulsion of Suc-LLVY-AMC’s P1 side chain from β5’s 
S1 specificity pocket than the Cys52Phe or Ala49Thr substitution, respectively, alone [313].  
Based on their results, Oerlemans et al. and Franke et al. suggested that, as the identified 
amino acid substitutions in the β5 subunit appear to impair proteasomal CT-L activity, 
overexpression of the mutant β5 subunits in the bortezomib-resistant cells serves to 
maintain acceptable levels of this activity [246, 313].  In support of this notion, bortezomib-
resistant cells with homozygous β5 mutations showed greater β5 upregulation relative to 
cells with heterozygous mutations [313].  Verbrugge et al. also suggested that 
upregulation of the Met45Ile mutant β5 subunit in their bortezomib-resistant JY cells likely 
reflected this compensatory mechanism [315]. 
In contrast to the various mutations identified in the β5-encoding gene (and the 
mutation identified by Suzuki et al. in the β5i-encoding gene), no mutations were detected 
in the genes encoding β1 or β2 in the bortezomib-resistant CCRF-CEM or RPMI 8226 
cells reported by Franke et al. [313].  Additionally, no mutations were detected in the genes 
encoding β1 or β6 in the bortezomib-resistant multiple myeloma cell lines reported by Ri 
et al. [314], in the genes encoding β1, β7, or β1i in the bortezomib-resistant HT-29 cell 
lines reported by Suzuki et al. [298], or in the gene encoding β5i in the bortezomib-
resistant JY cells reported by Verbrugge et al. [315]. 
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3. Impact on Cross-Resistance to Alternative Proteasome Inhibitors 
In addition to contributing to bortezomib resistance, the amino acid substitutions in 
the β5 subunit observed in bortezomib-resistant cell lines may also lower the inhibitory 
efficiency of, and thereby confer cross-resistance to, other active site-targeting 
proteasome inhibitors.  THP-1 cells resistant to up to 200 nM bortezomib and harboring 
Ala49Thr mutant β5 subunits were cross-resistant to reversibly-binding proteasome 
inhibitors, including tripeptide aldehydes ALLN and MG-132 and MG-132’s boronate 
analog, MG-262 [246].  THP-1 cells resistant to 50 and 500 nM bortezomib, which harbor 
only an Ala49Thr substitution or both Ala49Thr and Met45Ile substitutions, respectively, 
in the β5 active site, were also cross-resistant to the irreversibly-binding proteasome 
inhibitors ONX 0912, ONX 0914, and carfilzomib, indicating that PSMB5 mutations 
contribute to a general resistance to β5/β5i-targeting inhibitors due to an impaired ability 
of these inhibitors to bind to the β5 active site [280].  Furthermore, bortezomib-resistant 
cell lines harboring mutant β5 subunits were less sensitive than their parental counterparts 
to both the β5-inhibitory and cytotoxic effects of PR-924, consistent with a negative impact 
of these amino acid substitutions on PR-924 binding to β5 and in line with the finding that 
the cytotoxic effects of this β5i-selective inhibitor require co-inhibition of β5 [186, 318].  
Additionally, the observed cross-resistance of bortezomib-resistant NSCLC cell lines to 
the proteasome inhibitors MG132, carfilzomib, and ONX 0912 was concluded to support 
a causative role of PSMB5 mutations in cases of acquired bortezomib resistance [289]. 
Despite these conclusions, bortezomib-resistant cell lines typically displayed much 
greater resistance to bortezomib than to alternative reversibly- and irreversibly-binding 
inhibitors [246, 280, 289, 318].  Furthermore, while introducing the mutant PSMB5 into 
parental KMS-11 cells led to suppressed polyubiquitinated protein accumulation, a 
weakened terminal ER stress response, and protection against growth inhibition and 
apoptosis following treatment with bortezomib, it conferred a lesser degree of resistance 
than that observed in the bortezomib-adapted KMS-11 cells [314].  These findings imply 
that other factors besides amino acid substitutions in the β5 subunit also contribute to the 
resistance of these cell lines to bortezomib [246, 280, 289, 314, 318].  Finally, although 
PSMB5 mutations have been identified in a variety of proteasome inhibitor (predominantly 
bortezomib)-resistant cell line models, such mutations have not yet been linked to clinical 
cases of proteasome inhibitor resistance [313, 314, 317, 319-321].   
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Altered Proteasome Subunit Expression Levels 
As overexpression of target proteins can confer resistance to targeted therapeutic 
agents, perhaps an increase in the levels of proteasome subunits can mediate 
proteasome inhibitor resistance.  The observed feedback upregulation of proteasome 
components following proteasome inactivation in yeast [322, 323], Drosophila [324], and 
mammalian [247, 325-327] cells supports this notion, and, in fact, this response was 
shown to be important in compensating for impaired proteasome activity [322, 323, 326-
328].  Thus, mRNA and/or protein levels of proteasome subunits were often evaluated in 
cell line models of acquired proteasome inhibitor resistance.   
 
1. mRNA Levels 
The PSMB5 gene encodes the catalytic proteasome subunit β5—the primary 
constitutive subunit targeted by bortezomib.  Of the mRNAs encoding catalytic 
proteasome subunits, the levels of PSMB5 mRNA were most frequently reported, and 
were often found at odds with the β5 protein levels detected in the same cell lines.  For 
example, among a series of bortezomib-resistant THP-1 myelomonocytic leukemia cell 
lines selected for varying degrees of bortezomib resistance, PSMB5 mRNA levels ranged 
from reduced to relatively similar to parental levels in those selected for resistance to 30-
200 nM bortezomib, and were only increased in cells resistant to 500 nM bortezomib—the 
highest concentration applied in this study.  This contrasted the β5 protein levels in these 
cell lines, which were elevated by as much as 60-fold, leading the authors to conclude that 
the massive upregulation of β5 occurred at the post-transcriptional level [246].  Although 
this is the most extreme example, similar disparities were also noted by others [209, 288, 
329].  Additionally, despite a greater upregulation of PSMB5 mRNA in RPMI 8226 multiple 
myeloma cells selected for resistance to 100 nM bortezomib than in those selected for 
resistance to only 7 nM of the inhibitor, these two cell lines contained similar levels of the 
β5 protein, again suggesting post-transcriptional control of cellular β5 levels [313].  
Conversely, increased levels of PSMB5 mRNA were observed in bortezomib-resistant 
CCRF-CEM acute lymphoblastic leukemia [313], RPMI 8226 multiple myeloma [330], JY 
B lymphoblast [315] and HT-29 colorectal adenocarcinoma cell lines [298], which 
corresponded to the increased β5 protein levels detected [298, 313, 315, 330]. 
The upregulation of PSMB5 mRNA observed in bortezomib-resistant cell lines can 
be a transient effect of bortezomib exposure.  For example, Lu et al. found PSMB5 mRNA 
to be increased up to 7-fold in an initial study of bortezomib-resistant Jurkat T 
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lymphoblastic lymphoma/leukemia cell lines, which was associated with an increase in the 
proteasome’s CT-L activity of up to 6-fold [286].  However, in a subsequent study in which 
bortezomib-resistant Jurkat cells were withdrawn from bortezomib for more than two 
months, the levels of both PSMB5 mRNA and CT-L activity were found to be similar to 
those detected in parental Jurkat cells, suggesting that PSMB5 upregulation had been 
reversed during prolonged culture in the absence of bortezomib [312].  Similarly, both 
PSMB5 mRNA and β5 protein levels decreased time-dependently in bortezomib-resistant 
THP-1 cells following bortezomib withdrawal, further suggesting that the upregulation of 
these species can be reversed once the selective pressure of bortezomib is removed [246]. 
PSMB6 (β1-encoding) and PSMB7 (β2-encoding) mRNA levels were also 
evaluated in several of these studies.  Like PSMB5 mRNA, the regulation of these species 
were often found to inadequately represent that of the respective proteins [209, 246, 298].  
For instance, while PSMB6 and PSMB7 mRNAs were increased above parental levels in 
bortezomib-resistant HL-60 myeloid leukemia cells, only β2, and not β1, was upregulated 
at the protein level [209].  This contrasts the results of Suzuki et al., who found that PSMB7, 
but not PSMB6, mRNA was upregulated in bortezomib-resistant HT-29 cells, but that both 
subunits were upregulated 3-4-fold at the protein level [298].  On the other hand, increases 
in PSMB6 and PSMB7 mRNA levels were observed in bortezomib-resistant CCRF-CEM  
[313] and JY [315] cells, which corresponded to increases in the protein levels of β1 and 
β2 [313, 315].  However, despite the greater increases in PSMB6 and PSMB7 mRNAs in 
bortezomib-resistant RPMI 8226 cells compared with those observed in bortezomib-
resistant CCRF-CEM cells, no major changes were observed in β1 and β2 expression at 
the protein level [313]. 
Only three of the above-mentioned reports addressed the levels of mRNAs 
encoding the immunosubunits.  In the bortezomib-resistant THP-1 cells described by 
Oerlemans et al., PSMB8 and PSMB9 mRNAs (which encode β5i and β1i, respectively) 
were the only β-subunit mRNAs that were substantially downregulated, whereas the levels 
of PSMB10 mRNA (which encodes β2i) remained relatively unaltered.  However, the 
protein levels of these subunits were not evaluated for comparison [246].  Verbrugge and 
colleagues, as well as Suzuki and colleagues, alternatively, did examine immunosubunit 
expression at both the mRNA and protein levels [298, 315].  In the former case, a slight 
increase in immunosubunit mRNAs relative to parental levels was observed in bortezomib-
resistant JY cells, which was not associated with changes in the levels of the 
immunosubunit proteins [315].  In the latter case, conversely, no major changes in 
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immunosubunit mRNA levels were observed in bortezomib-resistant HT-29 cells, whereas, 
at the protein level, although β1i expression did in fact appear to remain unaltered, β5i 
and β2i levels were increased 8-fold and 3-4-fold, respectively [298]. 
Collectively, these findings demonstrate that the levels of the mRNAs encoding the 
various catalytic proteasome subunits are often poorly predictive of their corresponding 
protein levels, as previously discussed [331], stressing the importance of evaluating 
proteasomal protein levels and activity profiles directly rather than using mRNA levels as 
a surrogate. 
 
2. Protein Levels 
As was the case for PSMB5 mRNA, the protein expression levels of β5 were most 
frequently examined in bortezomib-resistant cells.  Downregulation of this subunit at the 
protein level was never observed, but, in a few bortezomib-resistant cell lines, it was 
concluded to remain unchanged from parental levels [287, 290, 314].  However, its levels 
were increased in almost all bortezomib-resistant cell lines [209, 246, 280, 285, 288, 289, 
298, 313, 315, 329, 330, 332, 333]. 
Many of these studies also assessed the protein levels of constitutive catalytic 
subunits β1 and β2.  It was concluded that the expression of only β1 (in bortezom ib-
resistant HL-60 myeloid leukemia and ARH-77 plasmacytoid lymphoma cells [209]) or 
both β1 and β2 (in bortezomib-resistant RPMI 8226 [313] and U266 multiple myeloma 
[290] and I-45 mesothelioma [287] cells) remained unaltered in several bortezomib-
resistant cell lines.  Ri et al. also concluded that β1 and β2 levels were unaltered in 
bortezomib-resistant KMS-11 and OPM-2 multiple myeloma cell lines cultured in the 
absence of bortezomib [314].  β2 expression was slightly increased in these cell lines 
following reintroduction of 10 nM bortezomib, contrary to the slight decrease in the levels 
of this subunit in the parental cell lines under these conditions.  However, no such 
bortezomib-induced changes were noted for β1 or β5 in the parental or bortezomib-
resistant cell lines [314].  Conversely, the levels of β2, as well as those of β1 and β5, 
whether altered with respect to those of the parental cells or not, were concluded to be 
uninfluenced by whether or not bortezomib-resistant HL-60 myeloid leukemia, ARH-77 
plasmacytoid lymphoma, AMO-1 multiple myeloma [209] or I-45 mesothelioma [287] cells 
were cultured in the presence or absence of bortezomib.  For bortezomib-resistant HL-60, 
ARH-77, and AMO-1 cells, this was suggested to reflect adaptive and not reactive 
changes in proteasome catalytic subunit content [209].  Irrespective of these findings, β1 
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and β2 expression, like that of β5, was found to increase when bortezomib resistance was 
acquired in most cell line models in which it was examined [209, 246, 280, 285, 289, 298, 
313, 315, 330, 332].   
More varied results were observed in the handful of studies for which 
immunosubunit levels were reported.  All three were found to be reduced in bortezomib-
resistant Namalwa Burkitt lymphoma [285], THP-1 myelomonocytic leukemia, RPMI 8226 
multiple myeloma, and CCRF-CEM acute lymphoblastic leukemia [280, 332] cell lines, but 
were increased in bortezomib-resistant H460 and A549 NSCLC cell lines [289].  De Wilt 
et al. suggested that, while the increased immunosubunit levels detected in their 
bortezomib-resistant H460 and A549 cell lines contrast the results of Busse et al., who 
showed that elevated immunosubunit levels were associated with increased (albeit 
intrinsic) bortezomib sensitivity [334], their finding may be in agreement with the ability of 
immunoproteasomes to efficiently degrade oxidized proteins [112], which are known to 
accumulate following bortezomib treatment; thereby, immunoproteasomes may serve a 
protective role against bortezomib-mediated induction of apoptosis [289].  Alternatively, 
Niewerth et al. proposed that the increased formation of intermediate proteasomes 
containing β5i together with β1 and β2 or β1i and β2 following bortezomib withdrawal may 
be capable of compensating for the weakened CT-L activity of mutant β5 subunit-
containing proteasomes [332].  Conversely, no major changes in immunosubunit levels 
were reported for bortezomib-resistant HL-60 myeloid leukemia [209], JY B lymphoblast 
[315], or SW1573 NSCLC [289] cells, and, in bortezomib-resistant HT-29 colorectal 
adenocarcinoma cell lines, β5i and β2i were increased (8- and 3-4-fold, respectively), but 
β1i remained unaltered from parental levels [298].  The lack of a concerted increase in all 
three immunosubunits in the bortezomib-resistant HT-29 cells may suggest an increase 
in intermediate proteasome levels [298].  Lastly, an increase in proteasome-incorporated 
β5i was observed in the initial study of bortezomib-resistant CCRF-CEM cells, while a 
decrease was observed in bortezomib-resistant RPMI 8226 cells [313]. 
In addition to the catalytic subunits of the 20S proteasome, up- or downregulation 
of other proteasome components was observed in bortezomib-resistant cell lines.  An 
increase in structural 20S proteasome subunits α3, β4 and β6, 19S cap subunits Rpt5 and 
Rpn2, and in the proteasome maturation protein POMP was observed in bortezomib-
resistant Namalwa cells, which, together with the increased β5, β1, and β2 levels detected, 
suggested a general upregulation of proteasome components and elevated assembly of 
proteasome complexes [285].  On the other hand, as was observed for the three 
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immunosubunits, the PA28β subunit of the IFNγ-inducible 11S proteasome activator—an 
alternative regulatory complex that can associate with the 20S proteasome in place of the 
19S cap at either or both ends [335, 336]—was downregulated.  This led Fuchs et al. to 
suggest that the inducible proteasome subunits, unlike the constitutive subunits, are not 
required for the survival of this cell line in the continuous presence of bortezomib [285].  
Conversely, although expression of the three immunosubunits was unaltered in 
bortezomib-resistant HL-60 cells in comparison with parental HL-60 cells, expression of 
the PA28α subunit of the 11S activator was elevated, as were the levels of 11S-20S 
complexes [209].  Furthermore, the increased levels of structural 20S proteasome subunit 
α7 in bortezomib-resistant NSCLC cell lines was in agreement with the increased levels 
of assembled proteasome complexes detected [289].  However, while increases in the 
levels of α7 and assembled proteasome complexes were also detected in bortezomib-
resistant CCRF-CEM cells, no major changes in these properties were observed in 
bortezomib-resistant RPMI 8226 cells [313].  Although THP-1 cells selected for resistance 
to 100 nM bortezomib did not show substantially elevated α7 levels [246], a later study 
showed that THP-1 cells selected for resistance to a higher concentration (200 nM) of 
bortezomib had higher levels of assembled proteasomes than did parental THP-1 cells 
[332].  Finally, no major changes were observed in the levels of structural 20S proteasome 
subunit α4 or 19S cap subunit Rpn1 in bortezomib-resistant HL-60 cells [209].   
In summary, altered levels of the various proteasome components were commonly 
detected in cancer cell lines upon acquisition of bortezomib resistance, yet the specific 
changes observed often differed cell line-dependently.  This may suggest that proteasome 
complexes can adapt in multiple unique ways to allow cancer cells to survive bortezomib 
exposure.  This notion is further evidenced by the findings discussed below.  
 
Altered Proteasome Activities  
The levels of individual catalytic activities of the proteasome were also evaluated 
in many bortezomib-resistant cell line models.  The proteasome’s CT-L activity was 
increased in many of these cell lines relative to that of the parental cells [246, 285, 286, 
298, 313, 329, 333].  Alternatively, in some cases, no increase [289, 290] or reduced [287, 
288, 313] CT-L activity was observed.  In the initial study of bortezomib-resistant Jurkat 
cells, upregulation of PSMB5 mRNA and the associated increase in CT-L activity were 
concluded to lead to the high levels of bortezomib resistance established [286].  IκB levels 
were decreased in a time-dependent manner following bortezomib treatment in one of 
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these bortezomib-resistant cell lines, indicating that activation of NF-κB under these 
conditions may also contribute to their resistance phenotype [286].  Subsequently 
published findings obtained with the bortezomib-resistant Jurkat cells revealed, however, 
that point mutations in the PSMB5 gene contributed to the impaired ability of bortezomib 
to inhibit the CT-L activity of the β5 subunit—whether PSMB5 mRNA levels and CT-L 
activity were increased or not—and, therefore, to their reduced bortezomib sensitivity [311, 
312].  Conversely, despite the large (up to 60-fold) upregulation of the β5 protein in 
bortezomib-resistant THP-1 cells, their basal CT-L activity was only increased 1.3-1.4-fold 
over parental levels, presumably due to the negative impact of the β5 active site 
substitution identified in these cells on their CT-L activity [246, 313].   
Additionally, in agreement with the reduced immunosubunit levels observed in 
bortezomib-resistant THP-1, RPMI 8226, and CCRF-CEM cells, basal β5i and β1i 
activities were decreased in these cell lines [318, 332].  On the other hand, despite the 
presence of active site-mutant β5 subunits, the increased expression of constitutive 
catalytic subunits detected in these cell lines was accompanied by 2-4-fold higher basal 
β5 activity [318, 332].  Based on these results and those obtained from experiments 
involving IFNγ-mediated immunosubunit upregulation and siRNA-mediated 
immunosubunit downregulation, the authors concluded that downregulation of β5i is a 
major factor contributing to the acquired resistance of these cell lines to the cytotoxic 
effects of bortezomib, and that IFNγ-mediated upregulation of immunosubunits could 
increase the sensitivity of bortezomib-resistant leukemia cells to bortezomib, carfilzomib, 
and the β5i-selective inhibitor ONX 0914 [332].  They speculated that, since IFNγ 
increases the levels of both oxidant-damaged proteins, which are in need of proteasomal 
degradation, and immunoproteasomes, which degrade these substrates more efficiently 
than do constitutive proteasomes, inhibiting immunoproteasome activity in bortezomib-
resistant cells under these conditions ensures the accumulation of polyubiquitinated 
proteins, providing an explanation for the increased accumulation of these species and 
enhanced cytotoxicity observed following combined IFNγ stimulation and proteasome 
inhibition, particularly when ONX 0914 was used as the inhibitor [332].   
Increases in proteasomal C-L and T-L activities were also observed in several 
studies [246, 285, 298, 329], although these activities were concluded to be reduced [333] 
or largely unaltered [290] in some bortezomib-resistant cell lines.  In bortezomib-resistant 
Namalwa cells, the <1.5-fold increase in the three major proteolytic activities poorly 
reflected the marked β1, β2, and β5 upregulation observed, leading Fuchs et al. to 
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conclude that proteasomes in these cells possessed lower levels of these specific 
activities [285].   
The CT-L activity in bortezomib-resistant cell lines was frequently found to be less 
susceptible to bortezomib-mediated inhibition than that of the parental cells.  This has 
been attributed to increased basal expression and activity of the β5 subunit and/or amino 
acid substitutions in or near the β5 active site [246, 289, 313, 314].  However, the reduced 
sensitivities of other proteasome activities to bortezomib-mediated inhibition noted for 
bortezomib-resistant cell lines harboring PSMB5 mutations suggest that factors aside from 
these mutations also underlie their bortezomib-resistant phenotypes.  For example, 
Oerlemans et al. observed a reduced inhibitory efficacy of bortezomib against not only the 
CT-L activity, but also the C-L and T-L activities, in their bortezomib-resistant THP-1 cell 
lines.  They suggested that, in particular, the enhanced (rather than reduced) T-L activity 
observed in these cell lines upon exposure to their selective concentrations of bortezomib 
may compensate for the substantially suppressed CT-L and C-L activities observed under 
these conditions [246].  Similar conclusions were drawn from results obtained with 
bortezomib-resistant CCRF-CEM cells [337].  De Wilt et al. also found that higher 
concentrations of bortezomib were required to inhibit the CT-L and C-L activities of 
bortezomib-resistant NSCLC cell lines to a comparable extent to that achieved with lower 
bortezomib doses in the corresponding parental cell lines.  Furthermore, even a high 
concentration (500 nM) of bortezomib did not inhibit the T-L activity of the bortezomib-
resistant cell lines, and, as observed for the parental cell lines, low concentrations 
stimulated the T-L activity [289].  In line with these findings, higher concentrations of 
bortezomib were required to induce a similar degree of polyubiquitinated protein 
accumulation in the bortezomib-resistant cell lines to that attained with lower bortezomib 
concentrations in the parental cell lines; higher bortezomib concentrations were also 
required to induce G2/M arrest and cell death in the bortezomib-resistant cells than in the 
parental cells [289].  Doses exceeding the selective bortezomib concentrations were also 
required to induce polyubiquitinated protein accumulation in bortezomib-resistant THP-1 
[246], CCRF-CEM, RPMI 8226 [313], and JY [315] cells.  Consistently, higher 
concentrations of bortezomib were required to provoke loss of mitochondrial membrane 
potential and apoptosis in bortezomib-resistant THP-1 cells, yet apoptosis was induced by 
etoposide with similar efficiency in the parental and bortezomib-resistant cells.  This 
suggests that the bortezomib-resistant cells do not display general resistance to apoptosis; 
only proteasome inhibitor-induced apoptosis is suppressed [246]. 
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Bortezomib also inhibited proteasome activity less efficiently in bortezomib-
resistant cell lines devoid of PSMB5 mutations.  The elevated levels of constitutive 
catalytic subunit expression in bortezomib-adapted AMO-1, HL-60, and ARH-77 cells were 
consistent with the increased basal levels of active proteasome subunits detected via ABP 
labeling [204, 209].  These changes were concluded to result in the ability of the 
bortezomib-resistant cells to retain higher levels of active β5/β1-type subunits in the 
presence of 20 nM bortezomib than those found in the parental cells under these 
conditions [204, 209], reflecting an important role of maintaining sufficient levels of active 
β5- and β1-type subunits in surviving bortezomib exposure [204].  Furthermore, the 
increased relative β2 activity in bortezomib-resistant AMO-1 cells in comparison with that 
of parental AMO-1 cells [209, 338] was suggested to indicate that, as previously proposed 
by Oerlemans et al. [246], maintaining sufficiently high β2 activity in the presence of 
bortezomib may compensate for the bortezomib-mediated suppression of β1/β1i and 
β5/β5i activities, thereby allowing cells to bypass the cellular repercussions of bortezomib 
treatment [338].  This, in turn, is consistent with the ability of β2/β2i-selective inhibitors to 
sensitize cancer cells, including those with acquired proteasome inhibitor resistance, to 
the cytotoxic effects of bortezomib and carfilzomib [180, 184].  However, bortezomib did 
still inhibit β1, β1i, β5, and β5i activities, and to a lesser extent β2 and β2i activities, dose-
dependently in bortezomib-adapted AMO-1 cells, consistent with the established 
bortezomib inhibition profile [338], with a similar proportion of the basal levels of active 
proteasome subunits being inactivated in the parental and bortezomib-adapted cell lines 
[184].  These findings indicated to the authors that mutations in the β1/β5 active sites that 
impede bortezomib binding did not contribute to the bortezomib resistance mechanisms 
of these cells [209, 338], which was later confirmed directly [184].  As observed for other 
cell line models both with and without PSMB5 mutations [246, 289, 313, 315, 330], 
bortezomib-induced accumulation of polyubiquitinated proteins was suppressed in 
bortezomib-resistant HL-60 cells in comparison with parental HL-60 cells [209].  
Additionally, genes encoding several proteins involved in ER stress and the unfolded 
protein response (UPR) were found to be downregulated in bortezomib-resistant HL-60 
cells [209].  
In bortezomib-resistant Namalwa cells, the CT-L activity became resistant to the 
inhibitory effects of even 50 nM bortezomib, which inhibited most of the CT-L activity in 
the parental cell line [285].  Conversely, while lactacystin suppressed the CT-L, C-L, and 
T-L activities in the parental cells, it selectively inhibited the CT-L activity in the bortezomib-
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resistant cells.  The ability of lactacystin, but not bortezomib, to inhibit the CT-L activity in 
the bortezomib-resistant cells was suggested to possibly result from the irreversible 
binding mechanism of this inhibitor to the β5 subunit [285].  Whether or not this cell line 
harbored a PSMB5 mutation was not reported. 
Alternatively, in addition to their elevated β5 levels and proteasome activities, 
bortezomib-resistant JEKO and HBL2 mantle cell lymphoma cell lines could successfully 
withstand a greater bortezomib-mediated reduction in their CT-L activity than could 
parental cells [329].  Although the extent to which C-L and T-L activities were inhibited by 
bortezomib in these cell lines was not reported, the authors concluded that these results 
may suggest that other cellular mechanisms aside from increased proteasome activity are 
also important contributors to the bortezomib resistance seen.  Indeed, it was concluded 
that, along with the above-mentioned properties, plasmacytic differentiation played an 
important role in the adaptation of these cells to the presence of bortezomib [329].  All of 
these factors were concluded to contribute to the enhanced ability of the bortezomib-
resistant mantle cell lymphoma cells to deal with the increased protein load placed on the 
proteasome by bortezomib treatment, thus, in the absence of the increased 
immunoglobulin synthesis associated with fully-differentiated plasma cells, rendering them 
less susceptible to bortezomib-induced cytotoxicity [329]. 
 
Faster Recovery from Proteasome Inhibition 
While inferior inhibition of proteasome activity by a given dose of bortezomib may 
be one important factor contributing to bortezomib resistance, faster recovery of 
proteasome activity following an initially similar extent of bortezomib-mediated inhibition 
appears to be another.  Despite the increased β5 expression detected in a bortezomib-
resistant RPMI 8226 cell line reported by Kuhn et al., bortezomib maintained the ability to 
suppress their CT-L activity, suggesting that active site mutations in the β5 subunit do not 
contribute to the resistance mechanism in these multiple myeloma cells [288].  This was 
confirmed by sequencing the active site region of the PSMB5 gene.  Although CT-L activity 
was inhibited by 10 nM bortezomib to a similar extent in both the parental and resistant 
cell lines at early timepoints, this activity recovered more quickly following bortezomib 
addition in the latter cell line than in the former [288].  However, while it was acknowledged 
that multiple mechanisms may contribute to the emergence of bortezomib resistance, the 
focus of this study was turned to the contribution of elevated IGF-1/IGF-1R signaling, 
which was concluded to potentially play a key role in bortezomib resistance in multiple 
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myeloma cells and to possibly be an interesting co-target to examine for bortezomib-based 
combination regimens.  It was suggested that such regimens could ultimately overcome 
or prevent clinical resistance to proteasome inhibitors in multiple myeloma patients [288]. 
Similar findings to those obtained by Kuhn et al. were reported for bortezomib-
resistant HT-29 colorectal adenocarcinoma cell lines [298].  Despite the elevated 
expression levels and activities of catalytic proteasome subunits detected in these cell 
lines, CT-L activity was inhibited to a similar extent in both parental and bortezomib-
resistant HT-29 cells following treatment with bortezomib but recovered faster from 
bortezomib-mediated inhibition.  The faster recovery could not be attributed to the 
expedited production of new proteasomes, since recovery was actually more rapid in the 
presence of the protein synthesis inhibitor cycloheximide.  These results were concluded 
to suggest that bortezomib’s dissociation constant with respect to the β5 active site was 
increased in the bortezomib-resistant cell line, attributable to the presence of a Cys63Phe 
mutation near the β5 active site [298].  Conversely, while the CT-L activity was also 
similarly inhibited in both the parental and bortezomib-resistant cells following treatment 
with carfilzomib, it recovered more slowly and at similar rates in both cell lines.  In this 
case, recovery was largely prevented by inhibiting protein synthesis, consistent with new 
proteasome synthesis being required for substantial recovery of proteasome activity in 
both the parental and bortezomib-resistant cells following exposure to irreversibly-binding 
inhibitors such as carfilzomib [298].  Additionally, the similar recovery rates of the CT-L 
activity in parental and bortezomib-resistant cells from carfilzomib-mediated inhibition 
indicate that β5 mutations that impair bortezomib binding do not necessarily impair binding 
of carfilzomib to the β5 active site.  Consistent with this, computational modeling indicated 
that the Cys63Phe mutation should not impact epoxomicin binding.  Accordingly, the 
bortezomib-resistant cells remained largely sensitive to carfilzomib; their 3-4-fold 
decrease in carfilzomib sensitivity was in line with their 3-4-fold increase in proteasome 
catalytic activities [298].  Resistance of these HT-29 cell lines to bortezomib was attributed 
to increased proteasome activity, PSMB5 mutations, and the altered expression of genes 
associated with stress response and cell survival pathways [298]. 
In contrast to the unaltered inhibitory efficacy described by Kuhn et al. and Suzuki 
et al. for their bortezomib-resistant cell lines, 10 nM bortezomib was found slightly less 
effective in inhibiting the proteasome’s CT-L activity in bortezomib-resistant KMS-11 and 
OPM-2 multiple myeloma cell lines than in their respective parental cell lines [314].  
Accordingly, polyubiquitinated proteins accumulated to a lesser extent in the bortezomib-
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resistant cell lines than in the parental cell lines following bortezomib treatment.  This 
accumulation was transient in the bortezomib-resistant cell lines, with basal levels of these 
species being restored within 24 and 48 hours following bortezomib addition in 
bortezomib-resistant KMS-11 and OPM-2 cells, respectively [314].  Importantly, the 
suppressed polyubiquitinated protein accumulation was associated with the evasion of 
fatal ER stress.  These results led the authors to conclude that bortezomib’s slightly inferior 
inhibition of the CT-L activity in the bortezomib-resistant cell lines, which was concluded 
to partially result from a heterogeneous G322A point mutation in the PSMB5 gene, may 
have assisted in preventing polyubiquitinated proteins from accumulating to levels 
sufficient to induce cell death.  The results presented in this report are consistent with the 
conclusion that the G322A mutation in the PSMB5 gene contributes to a less robust 
accumulation of polyubiquitinated proteins following bortezomib treatment, which, by 
protecting against activation of a fatal ER stress response and suppressing subsequent 
apoptotic signaling, can contribute to acquired bortezomib resistance [314]. 
Polyubiquitinated proteins also accumulated more weakly, and returned to basal 
levels more rapidly, in bortezomib-resistant I-45 mesothelioma cells than in parental I-45 
cells after treatment with 40 nM bortezomib—the final selection concentration used in 
developing the bortezomib-resistant cell line [287].  However, since the levels of the 
constitutive catalytic subunits were concluded to remain unaltered, the basal CT-L activity 
was found to be slightly decreased rather than increased and was not resistant to 
bortezomib-mediated inhibition, and no mutations were identified in the coding region of 
the PSMB5 gene, the authors concluded that the resistance of this cell line to bortezomib 
was independent of the commonly-reported proteasome-dependent mechanisms [287].  
Instead, it was proposed that the reduced growth rate of these cells in comparison with 
parental I-45 cells may have been accompanied by a reduced rate of protein synthesis, 
potentially contributing to the reduced polyubiquitinated protein levels observed [287].  
Whatever the cause, bortezomib resistance in this cell line was attributed to reduced 
polyubiquitinated protein accumulation following bortezomib exposure, resulting in a 
failure to activate ER stress and the UPR and to stabilize the pro-apoptotic proteins Mcl-
1S, NOXA, and p53 [287].  Similarly, the ability of 15 nM bortezomib to inhibit the CT-L 
activity and induce polyubiquitinated protein accumulation remained unimpaired in two 
mantle cell lymphoma cell lines (Jeko-1 and Z-138) selected for resistance to 30 nM 
bortezomib [339].  The bortezomib resistance phenotypes of these cells were attributed to 
the Hsp90-assisted accumulation of the prosurvival chaperone BiP upon bortezomib 
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treatment, resulting in activation of the prosurvival arm of the UPR; accordingly, treatment 
with an Hsp90 inhibitor resensitized the bortezomib-resistant cells to bortezomib [339]. 
CT-L activity was also inhibited to a similar extent in parental and bortezomib-
adapted KMS-11 multiple myeloma cell lines following treatment with 32 nM bortezomib.  
It was therefore concluded that a mutation of the proteasome could not account for the 
resistance observed [340].  In bortezomib-adapted KMS-11 sublines, resistance to 
bortezomib was associated with low levels of XBP-1 mRNA, which may suggest a reduced 
dependence on the UPR and serve as a predictor of poor response to bortezomib in 
multiple myeloma cells [340].  Likewise, treatment with 10 nM bortezomib inhibited similar 
proportions of the CT-L, C-L, and T-L activities in parental and bortezomib-resistant U266 
multiple myeloma cells, with the T-L activity being, as expected, relatively resistant to 
inhibition by bortezomib.  Similar proportions of these activities were also inhibited by 
epoxomicin, MG132, or Tlck (an inhibitor of the T-L activity), respectively [290].  These 
results were again in agreement with the lack of substantial differences in β5, β1, and β2 
expression levels or basal CT-L, C-L, and T-L activities between the parental and 
bortezomib-resistant cells, as well as the absence of mutations in the PSMB5, PSMB6, or 
PSMB7 genes [290].  The authors concluded that neither differences in proteasome 
catalytic subunit levels or mutational status, nor in basal or residual proteasome activities, 
could account for the resistance phenotype of their model.  Instead, bortezomib resistance 
was attributed to enhanced elimination of ubiquitin-containing protein aggregates via the 
autophagy pathway, assisted by overexpression of the small heat shock protein HSPB8 
[290]. 
 
b. Epoxomicin and Carfilzomib Resistance 
In contrast to the many reports describing proteasome catalytic subunit expression 
levels and activity patterns in cell line models of acquired bortezomib resistance, 
information on these properties in epoxomicin- or carfilzomib-resistant cell lines is 
currently limited to just a few reports.  An early report showed increased proteasome 
subunit expression in epoxomicin-resistant variants of the A431 squamous cell carcinoma 
cell line relative to parental A431 cells, accompanied by an ~2.5-fold elevation of CT-L 
activity over parental levels.  Accordingly, exposure to even 20 nM epoxomicin did not 
cause polyubiquitinated proteins to accumulate in these epoxomicin-resistant cells, in 
contrast to the obvious accumulation of these species that occurred in the parental A431 
cells under these conditions [279].  In contrast to the epoxomicin-resistant KMS-11 cells 
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reported by Gutman et al. [278], the resistance phenotype of the epoxomicin-resistant 
A431 cell line was concluded to be P-glycoprotein independent [279].  Riz et al. found that 
the levels of the mRNAs encoding primary carfilzomib targets β5 and β5i were not 
substantially altered from parental levels in KMS-11 and KMS-34 multiple myeloma cell 
lines which had acquired resistance to 12 nM carfilzomib, indicating that the upregulation 
of these mRNAs is not necessary for acquisition of carfilzomib resistance.  However, the 
protein levels of these subunits were not reported [306].  
Compared with parental AMO-1 multiple myeloma cells, increased basal levels of 
active proteasome subunits, especially β2/β2i, were detected in carfilzomib-resistant 
AMO-1 cells, resulting in higher residual levels of these active subunits in the carfilzomib-
resistant cells than in the parental cells following treatment with proteasome inhibitors 
[184].  However, the proportion of the basal levels of these active subunits inhibited by 
bortezomib or carfilzomib was similar in the parental and carfilzomib-resistant cell lines, 
indicating that the binding of these inhibitors to the proteasome’s active sites was not 
impaired in the carfilzomib-resistant cells.  Consistent with this conclusion, no active site 
mutations in the β5 subunit were detected in the carfilzomib-resistant cell line.  These 
findings were similar to those obtained with bortezomib-resistant AMO-1 cells [184].  
Interestingly, co-treatment of the bortezomib- or carfilzomib-resistant cells with bortezomib 
or carfilzomib and the β2/β2i-selective inhibitor LU-102 achieved greater inhibition of total 
proteasome activity than treatment with bortezomib or carfilzomib alone, consistent with 
the synergistic cytotoxic effects of these combinations observed in the inhibitor-resistant 
cell lines.  Combining bortezomib or carfilzomib with LU-102 also had synergistic cytotoxic 
activity in primary malignant plasma cells that were resistant to bortezomib, at least two of 
which were also resistant to carfilzomib in vitro [184].  The mechanism by which combined 
treatment of bortezomib- or carfilzomib-resistant multiple myeloma cells with bortezomib 
or carfilzomib and LU-102 can overcome bortezomib or carfilzomib resistance was 
suggested to be a stronger and more prolonged inhibition of total proteasome activity, 
which causes greater accumulation of proteasome substrates and therefore a more robust 
activation of the UPR, leading to an increase in apoptosis [184].  This supports the notion 
that addition of a β2/β2i-selective inhibitor to bortezomib- or carfilzomib-containing 
therapeutic regimens may benefit patients resistant to these β5/β5i-selective inhibitors 
[184].  Although P-glycoprotein-mediated efflux has been found to contribute to carfilzomib 
resistance in other studies, its impact on carfilzomib resistance in the carfilzomib-resistant 
AMO-1 cell line was not assessed [184]. 
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In conclusion, adjustments in overall proteasome levels, subunit composition, and 
catalytic activities were seen in most cell lines following the onset of acquired proteasome 
inhibitor resistance, highlighting the adaptability of the proteasome complex itself as an 
important contributor to this resistance.  However, many permutations on this theme were 
observed.  Although the disparate results reported could have, in some cases, resulted 
from differences in the experimental methodologies applied, they collectively indicate that 
this adaptation can be achieved via multiple routes, so long as the end result allows the 
cell to maintain sufficient proteasome activity to carry out essential tasks required for 
continued survival and proliferation during proteasome inhibitor exposure.  As one would 
expect, proteasome adaptation does not appear to be the sole mediator of acquired 
proteasome inhibitor resistance, and the relative importance of this and other mechanisms 
may vary on a case-by-case basis.  Nevertheless, the frequency with which alterations in 
the proteasome complex were observed suggests that proteasome-mediated resistance 
mechanisms may be of paramount importance.   
 
1.8.5 Stability of Proteasome Inhibitor-Resistance Phenotypes 
Different conclusions were reached regarding the stability of the resistance 
phenotypes described above.  The bortezomib-resistance phenotype was maintained 
following a >2 month bortezomib withdrawal in the bortezomib-resistant Jurkat T 
lymphoblastic lymphoma/leukemia cells described by Lu et al., consistent with the finding 
that bortezomib-mediated inhibition of the proteasome’s CT-L activity in these cells was 
still inferior to that achievable in parental Jurkat cells.  However, the once increased 
PSMB5 mRNA levels and CT-L activity of the bortezomib-resistant cells had normalized 
over this time period [286, 312].  These findings suggest that the PSMB5 mutations 
identified in these cells are sufficient to maintain bortezomib resistance in the absence of 
sustained increases in β5 expression.  Furthermore, after removing bortezomib-resistant 
THP-1 myelomonocytic leukemia cells from bortezomib-containing culture conditions, no 
major changes in β5 mRNA levels were observed, but β5 protein levels were gradually 
reduced over a 7 day period  [246].  The increased proteasome gene expression detected 
in bortezomib-resistant THP-1 cells by microarray analysis had normalized during a 6 
month withdrawal period, indicating the transient nature of these changes [246].  The 
decrease in β5 protein levels was even more pronounced following the 6 month 
bortezomib withdrawal, but β5 upregulation could be rapidly reinduced at the mRNA and 
protein levels when the bortezomib-resistant cells were reexposed to bortezomib, 
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consistent with the >35-fold resistance reportedly retained in these cells.  Blocking 
bortezomib-induced β5 upregulation in the bortezomib-withdrawn cells via siRNA-
mediated silencing led to a more robust inhibition of cell growth and induction of apoptosis, 
further implicating the rapid induction of this (mutant) subunit in the stability of bortezomib 
resistance in this cell line model [246]. 
Similarly, β5 and β5i levels were reduced, but remained higher than parental levels, 
in bortezomib-resistant HT-29 colorectal adenocarcinoma cells after a 40 day bortezomib 
withdrawal.  β2 and β2i levels were also reduced to baseline levels, but the increased β1 
levels that had been observed after only a 14 day withdrawal period were maintained after 
the 40 day withdrawal [298].  Interestingly, the degree of bortezomib resistance increased 
rather than decreased over this 40 day withdrawal period, leading the authors to conclude 
that elevated levels of proteasome subunits only partially account for bortezomib 
resistance [298].  However, consistent with the observations of Oerlemans et al. regarding 
the β5 subunit, reintroducing bortezomib-resistant HT-29 cells to bortezomib-containing 
culture conditions reportedly again led to an increase in catalytic proteasome subunit 
levels in the bortezomib-resistant cells [298].  De Wilt et al. also indicated that bortezomib 
resistance remained stable in their bortezomib-adapted NSCLC cell lines following a 2 
month bortezomib withdrawal, consistent with PSMB5 gene mutations contributing to the 
bortezomib resistance mechanisms of these cell lines [289].  
  In contrast to the results obtained with bortezomib-resistant Jurkat, THP-1, and 
HT-29 cells, it was concluded that the altered expression levels of proteasome subunits 
observed in bortezomib-resistant HL-60 myeloid leukemia, ARH-77 plasmacytoid 
lymphoma, and AMO-1 multiple myeloma cells were not directly influenced by whether or 
not the cells were incubated in bortezomib-containing medium or not, or by removing the 
cells from bortezomib-containing medium for up to 7 days, which the authors suggested 
reflected adaptive changes rather than reactive ones [209].  Additionally, the altered 
proteasome activity patterns in the bortezomib-resistant HL-60 cell line were stable for at 
least 7 days after removal from bortezomib-containing medium.  Consistently, the authors 
indicated that resistance was stable in the bortezomib-resistant HL-60 cells after a 14 day 
bortezomib withdrawal [209].  As these cells were apparently devoid of PSMB5 mutations 
[184, 209, 338], these results suggest that stable resistance is achievable in the absence 
of such mutations.  In further support of this, the resistance phenotype was reportedly 
maintained in bortezomib-resistant I-45 mesothelioma cells—which lacked PSMB5 
mutations—following a 2 month bortezomib withdrawal period [287].  Additionally, 
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Stessman et al. reported that bortezomib resistance was stable for 1 year following 
bortezomib withdrawal in their mouse cell line model of acquired bortezomib resistance, 
which was also devoid of PSMB5 mutations [333].  On the other hand, acquired 
bortezomib resistance in cell culture models derived from the JEKO and HBL2 mantle cell 
lymphoma cell lines was found to gradually decrease after bortezomib was withdrawn, 
which, together with the gradual acquisition of resistance and the lack of PSMB5 gene 
mutations, was suggested to reflect a reversible adaptation to bortezomib-containing 
culture conditions [329].  
These observations indicate that PSMB5 mutations can mediate stable resistance 
to proteasome inhibitors, yet this can also be achieved without these mutations.  Perhaps 
other stable changes in the proteasome complex can account for the stability of 
bortezomib resistance in some instances of the latter (e.g., in the bortezomib-resistant HL-
60, ARH-77, and AMO-1 cells), or, perhaps other proteasome-independent mechanisms 
can be credited (e.g., in the bortezomib-resistant I-45 cells).  Alternatively, in some cases 
(e.g., in the bortezomib-resistant JEKO and HBL2 cells), transient cellular changes can 
lead to reversible bortezomib resistance.   
 
1.8.6 Cross-Resistance to Other Agents 
Significant cross-resistance of bortezomib-resistant cell lines to non-proteasome-
targeting chemotherapeutics was not observed in most cases in which it was reported 
[209, 246, 286, 287, 290, 314, 329, 330, 333].  No major change in sensitivity to 
daunorubicin was observed in bortezomib-resistant HL-60 myeloid leukemia or ARH-77 
plasmacytoid lymphoma cells, but some cross-resistance to this agent was observed for 
bortezomib-resistant AMO-1 multiple myeloma cells.  Despite the latter finding, the authors 
suggested these results to indicate that bortezomib resistance in these cell lines is likely 
not attributable to increased bortezomib efflux via multidrug resistance transporters [209].  
Conversely, Fuchs et al. reported that their bortezomib-resistant Namalwa Burkitt 
lymphoma cell line was cross-resistant to the pro-apoptotic effects of γ-irradiation and 
staurosporine.  This led the authors to suggest that, in the bortezomib-resistant cells, the 
upregulation of anti-apoptotic Hsp27 consequent to continuous bortezomib-mediated 
proteasome inhibition, as well as the reduced capacity to stabilize the pro-apoptotic protein 
p53 due to the elevated proteasome activities, conferred a general resistance to apoptosis 
[285]. 
71 
In contrast to the predominant lack of cross-resistance of bortezomib-resistant cell 
lines to non-proteasome-targeting chemotherapeutic drugs, cross-resistance to other 
proteasome-targeting agents was commonly reported.  Bortezomib-resistant cell lines 
were cross-resistant to several reversibly-binding proteasome inhibitors, including the 
peptide aldehydes ALLN [246] and MG-132 [246, 289, 290, 298, 313-315, 329], as well 
as the peptide boronate MG-262 [246].  While two bortezomib-resistant plasma cell lines 
derived by Stessman et al. from a mouse model of multiple myeloma were cross-resistant 
to the peptide boronate ixazomib, one of these cell lines was cross-resistant to MG-132 
but the other was not [333].  Bortezomib-resistant HT-29 colorectal adenocarcinoma cells 
also lacked cross-resistance to the peptide boronate LLL-Bor [298].  The observed cross-
resistance of bortezomib-resistant HL-60, ARH-77, and AMO-1 cell lines to reversibly-
binding proteasome inhibitors led Rückrich et al. to conclude that treating bortezomib-
resistant cancer cells with different proteasome inhibitors may be effective in cases where 
resistance is attributed to overexpression and/or active site mutations of β5, but, in those 
in which resistance is mediated by a general increase in proteasome components, this 
strategy may not be effective [209].  Bortezomib-resistant cell lines were also cross-
resistant to a variety of irreversibly-binding proteasome inhibitors, such as the peptide vinyl 
sulfones ZL3VS [209] and NLVS [209, 329], the β-lactones lactacystin [209, 285, 290] and 
marizomib [337], and the peptide epoxyketones epoxomicin [209, 290], carfilzomib [280, 
313, 333, 338], ONX 0912 [280, 289, 313], ONX 0914 [280, 313, 315], and PR-924 [318].   
Still, the levels of cross-resistance of bortezomib-resistant cell lines to alternative 
proteasome inhibitors were typically lower than the levels of resistance to bortezomib itself 
[246, 280, 285, 318, 329].  For example, bortezomib-resistant Namalwa cells were less 
resistant to the pro-apoptotic effects of lactacystin than to those of bortezomib [285].  This 
was consistent with the retained ability of lactacystin to inhibit the CT-L activity in the 
bortezomib-resistant cells, presumably due to its irreversible binding to the β5 subunit 
[285].   
A similar conclusion was reached by Suzuki et al., whose bortezomib-resistant HT-
29 cells remained relatively sensitive to carfilzomib, indicating that irreversible proteasome 
inhibitors can overcome bortezomib resistance.  Additionally, the authors noted that the 
3-4-fold decrease in carfilzomib sensitivity was in line with the 3-4-fold increase in 
proteasome catalytic activities observed in these cells [298].  Likewise, the 2-3-fold 
increase in the levels of constitutive catalytic subunits detected in bortezomib-resistant 
THP-1 myelomonocytic leukemia cells was suggested to contribute, together with amino 
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acid substitutions in the β5 active site, to the cross-resistance of these cells to other β5/β5i-
targeting inhibitors.  Cross-resistance to carfilzomib was observed in these cells, but to a 
lesser extent than that observed for the other inhibitors examined [280].  Also in accord 
with these findings, bortezomib-resistant JY B lymphoblast cells remained sensitive to 
carfilzomib and were only somewhat less sensitive to ONX 0914 and MG-132 [315].  
Multiple bortezomib-resistant cell lines also retained full sensitivity to the α7 subunit-
targeting proteasome inhibitor 5AHQ [289, 313], leading Franke et al. to recommend α7-
targeting inhibitors for efforts to overcome cases of bortezomib resistance mediated by 
upregulation of proteasomes containing a mutant β5 subunit [313]. 
The reduced sensitivity of the bortezomib-resistant CCRF-CEM acute 
lymphoblastic leukemia, THP-1 myelomonocytic leukemia, and RPMI 8226 multiple 
myeloma cell lines to PR-924 appeared to be at least partially attributed to the weaker 
inhibition of the catalytic activities of β5i and β5, the latter of which was, in turn, at least 
partially attributed to β5 active site mutations [318].  That cell lines harboring mutant β5 
subunits were less sensitive to both the β5-inhibitory and cytotoxic effects of PR-924 was 
in line with the finding that the cytotoxic effects of this β5i-selective inhibitor require co-
inhibition of β5, consistent with results reported by Parlati et al. [186, 318].  However, if 
reduced efficacy of β5 inhibition by bortezomib was the predominant mechanism 
underlying bortezomib resistance in the bortezomib-resistant cell lines, the reduced 
efficacy of β5 inhibition by PR-924 observed in these cell lines would be expected to lead 
to a higher level of cross-resistance to PR-924.  Instead, the levels of resistance to this 
inhibitor were much lower than those for bortezomib, which led the authors to suggest that 
much of the bortezomib-resistance phenotypes of these cell lines may be mediated by 
mechanisms independent of mutant β5 subunits [318].  Similarly, despite the reduced β5 
inhibitory efficacy of marizomib in bortezomib-resistant CCRF-CEM cells, it was still more 
effective in inhibiting the CT-L and (especially) T-L activities in these cells than bortezomib, 
which may be reflected in the much lower level of resistance to marizomib than to 
bortezomib [337]. 
Not all bortezomib-resistant cell lines displayed greater resistance to bortezomib 
than to alternative proteasome inhibitors.  While bortezomib-resistant KMS-11 multiple 
myeloma cells were less resistant to MG-132 than to bortezomib, a bortezomib-resistant 
variant of the multiple myeloma cell line OPM-2 displayed equivalent resistance to both 
inhibitors [314].  Additionally, bortezomib-resistant CCRF-CEM and RPMI 8226 cells were 
less resistant to most of the alternative proteasome inhibitors examined, including  
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MG-132, ONX 0912, and carfilzomib, than to bortezomib;  however, although bortezomib-
resistant CCRF-CEM cells were less resistant to ONX 0914 than to bortezomib, 
bortezomib-resistant RPMI 8226 cells were more resistant to the former inhibitor than to 
the latter [313].  The differences between the cross-resistance profiles of the bortezomib-
resistant CCRF-CEM and RPMI 8226 cell lines were suggested to possibly reflect different 
β-subunit-mediated mechanisms of proteasome inhibitor resistance [313].  Similarly, 
bortezomib-resistant A549 NSCLC cells displayed equivalent resistance to carfilzomib 
and equivalent or greater resistance to ONX 0912, and SW1573 NSCLC cells resistant to 
150 nM bortezomib were more resistance to ONX 0912 than to bortezomib [289].  Further 
differences in the cross-resistance profiles of the bortezomib-resistant NSCLC cell lines 
reported by de Wilt et al. were also observed.  For example, while bortezomib-resistant 
H460 cells were not cross-resistant to ONX 0914, SW1573 cells resistant to 150 nM 
bortezomib and bortezomib-resistant A549 cells were.  In addition, bortezomib-resistant 
H460 cells were not cross-resistant to carfilzomib, while A549 and SW1573 cells were.  
Finally, A549 cells resistant to 100 nM bortezomib and SW1573 cells resistant to 150 nM 
bortezomib were highly cross-resistant to ONX 0912 (to an even greater extent than to 
carfilzomib), while bortezomib-resistant H460 cells were cross-resistant to ONX 0912 to a 
much lesser extent [289]. 
Cell line models of resistance to second-generation proteasome inhibitors were 
also cross-resistant to other general and subunit-selective proteasome inhibitors.  Cal33 
and UMSCC-1 head and neck squamous cell carcinoma cell lines that had acquired 
resistance to 1 μM carfilzomib were highly cross-resistant to oprozomib [283].  They were 
also highly cross-resistant to paclitaxel—as were the carfilzomib-resistant NSCLC and 
colon adenocarcinoma cell lines previously developed in our laboratory [281]—but were 
only slightly cross-resistant to cisplatin [283].  Conversely, just as carfilzomib and 
oprozomib were found to retain considerable activity against cancer cells which have 
acquired bortezomib resistance [262, 266, 267, 274], the cell line models of acquired 
carfilzomib/oprozomib resistance employed in this study displayed only relatively low 
levels of cross-resistance to bortezomib, suggesting that bortezomib may retain clinical 
efficacy against cancers that have acquired resistance to carfilzomib and/or oprozomib 
[283].   
Collectively, these results suggest that carfilzomib-resistant cancer cells are more 
likely to be resistant to chemotherapeutic agents that do not target the proteasome than 
are those resistant to bortezomib due to the greater probability of P-glycoprotein 
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overexpression contributing to carfilzomib resistance.  Importantly, they also indicate that 
proteasome inhibitor-resistant cell lines differ in their cross-resistance profiles to 
alternative proteasome inhibitors, which may be mediated by differences in proteasome-
dependent mechanisms of resistance.  This is further supported by clinical observations 
demonstrating that second-generation proteasome inhibitors can be effective in treating 
bortezomib-resistant cancers and suggests that, as more proteasome inhibitors are 
developed for clinical use and our understanding of the resistance mechanisms to each 
inhibitor increases, identifying patients that will best respond to a given inhibitor may 
improve clinical outcomes.   
 
1.9 Summary and Study Rationale 
Much has been learned about the functions of the proteasome since the discovery 
of the UPP decades ago, in large part due to the development and discovery of both broad-
spectrum and subunit-selective proteasome inhibitors.  Furthermore, proteasomes were 
validated as anticancer targets when the first-in-class proteasome inhibitor bortezomib 
was approved by the FDA for use as an anticancer agent almost fifteen years ago.  
However, dose-limiting toxicities and intrinsic and acquired resistance have emerged as 
major clinical challenges associated with bortezomib treatment.  It is believed that 
bortezomib’s toxicity profile may result from off-target inhibition of nonproteasomal 
proteases and/or from inhibition of constitutive proteasomes in healthy cells.  On the other 
hand, largely based on findings obtained from cell line models of acquired bortezomib 
resistance, a number of proteasome-mediated and non-proteasome-mediated resistance 
mechanisms have been proposed.  Second-generation proteasome inhibitors such as 
carfilzomib and ixazomib were subsequently developed to overcome these limitations and 
have recently received the FDA’s approval.  Although they are generally more active than 
bortezomib against bortezomib-resistant cancer cells in both the laboratory and clinic, 
these inhibitors were designed to target the same active sites as bortezomib; this may limit 
their efficacy and may not prevent side effects that result from targeting proteasomes in 
healthy cells. 
The discovery of the immunoproteasome as a second proteasome subtype and 
findings implicating this subtype in the pathogenesis of autoimmune diseases and cancers 
inspired researchers to develop inhibitors that selectively target the immunoproteasome 
over its constitutive counterpart.  It was proposed that such inhibitors would target 
proteasomes present in diseased cells while sparing those in most healthy cells, thereby 
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creating a greater therapeutic window than that associated with inhibitors targeting both 
subtypes.  Selective inhibitors of immunosubunits β1i and β5i have been successfully 
developed and have been shown to be effective in laboratory models of autoimmune 
diseases and cancers. 
It is now understood that, in addition to constitutive proteasomes and 
immunoproteasomes, at least two additional proteasome subtypes comprising mixtures of 
constitutive subunits and immunosubunits are present in varying proportions across 
diverse tissues.  It also appears that the distinct catalytic subunit combinations of each 
subtype imparts its unique activity profile, which may be optimized for specialized cellular 
functions.  Furthermore, evidence demonstrating that proteasome inhibitors vary inhibitor-
dependently in their inhibitory efficacies against the different proteasome subtypes of 
murine tissues has been reported.  Together, these findings suggest that each subtype of 
proteasome carries out some discrete cellular functions and may be more effectively 
targeted by one inhibitor over another.  Importantly, the proteasome’s catalytic subunit 
expression levels and activities are frequently altered when cancer cell lines acquire 
bortezomib resistance; this is consistent with a shift in the ratios of discrete proteasome 
subtypes upon establishment of bortezomib resistance.  We hypothesized that such a shift 
plays a causative role in acquired resistance to proteasome inhibitors, and that the 
subtypes involved in conferring resistance vary inhibitor-dependently.  Evaluating which 
subtypes of proteasomes are present in diseased cells displaying resistance to a given 
proteasome inhibitor and identifying or developing inhibitor(s) that more effectively target 
those subtypes may provide necessary insight to ultimately improve the therapeutic 
efficacy of proteasome inhibitors. 
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2 HYPOTHESIS AND SPECIFIC AIMS 
The overall goal of this project is to elucidate the functions and adaptive responses 
of distinct proteasome subtypes in cancer cells.  It has become increasingly clear that 
mammalian cells contain at least four distinct proteasome subtypes in various proportions 
[186, 224-229, 233].  These subtypes are defined by their unique combinations of catalytic 
subunits and therefore differ in their activity profiles and effects on the MHC class I-
mediated presentation of certain antigenic peptides, including clinically relevant tumor 
epitopes [224-226, 229, 232, 236, 238].  However, aside from antigen presentation, much 
regarding the unique functions of each subtype, or their roles as drug targets, remains 
poorly understood.  This is in large part due to difficulties in differentiating between 
individual subtypes in complex biological samples, which frequently contain more than 
one subtype [224]. 
Changes in the levels of expression or activity of catalytic proteasome subunits are 
typically observed when cells acquire proteasome inhibitor resistance [184, 204, 209, 246, 
280, 285, 288, 289, 298, 313, 315, 329, 330, 332, 333] and are often associated with the 
incomplete suppression of proteasome activities by the inhibitor to which resistance was 
acquired [184, 204, 209, 246, 285, 289, 313, 337].  It has frequently been concluded that 
the reduced sensitivities of the proteasome complexes within these cells to inactivation 
results from overexpression of specific subunits or of proteasome complexes as a whole 
[209, 246, 285, 289, 313].  Considering the findings of these studies, together with the 
observed differences in proteasome inhibitor sensitivity between distinct proteasome 
subtypes isolated from murine tissues [231, 232], the changes in the expression levels 
and activity patterns of catalytic proteasome subunits detected upon acquisition of 
proteasome inhibitor resistance may reflect a relative increase in proteasome subtypes 
that are more resistant to inhibition by the inhibitor applied, and a relative decrease in 
those that are more sensitive.  We therefore hypothesized that changes in the relative 
abundances of individual proteasome subtypes serve as a mechanism of acquired 
proteasome inhibitor resistance.  Our study had the following aims: 
 
Aim 1. Develop a set of bifunctional activity-based probes for use in identifying 
distinct proteasome subtypes.  A lack of practical, straightforward techniques for 
identifying distinct proteasome subtypes has been an important factor limiting studies of 
their biological functions.  We therefore set out to develop new chemical probes for use in 
determining which proteasome subtypes are present within cell or tissue samples.  
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Building on earlier work by Moroder and colleagues [197] and Vidal, Reboud-Ravaux, and 
colleagues [198, 199], and utilizing several subunit-selective proteasome inhibitors, we 
developed a set of bifunctional activity-based probes capable of crosslinking specific pairs 
of catalytic proteasome subunits when they coexist within individual proteasome 
complexes and compatible with an immunoblotting-based readout of the crosslinked 
subunit pairs.  We hypothesized that the information gained from experiments conducted 
with these probes would allow us to deduce the identity of proteasome subtypes present 
in a given sample. 
 
Aim 2. Assess whether changes in the relative abundances of specific proteasome 
subtypes are associated with acquired resistance of cancer cells to bortezomib and 
carfilzomib.  We established non-small cell lung cancer cell line models of acquired 
bortezomib and carfilzomib resistance.  Proteasome activity assays and immunoblotting 
analyses were used to detect changes in proteasome complexes that had occurred upon 
acquisition of resistance to each inhibitor.  These assays also allowed us to assess 
whether, and to what extent, the individual catalytic activities of proteasomes were 
suppressed under bortezomib or carfilzomib exposure in the inhibitor-resistant cells and 
in the parental cell line from which they were generated.  We also conducted experiments 
with the bifunctional probes described in Aim 1 to determine whether changes in the 
relative abundances of particular proteasome subtypes had occurred during the 
development of bortezomib and carfilzomib resistance.   
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3 METHODS 
 
Some of the methods described in this chapter were previously reported [239]. 
 
3.1 Synthesis of Bifunctional Proteasome Probes 
Bifunctional proteasome probes were synthesized as reported [239, 341]. 
 
3.2 Proteasome Inhibitors 
Epoxomicin [169], YU-102 [177], Ac-nLPnLD-CHO, Ac-PAL-ek [239], NC-012 
[180], and PR-924 (IPSI) [186] were synthesized by following previously-reported 
procedures.  Bortezomib was purchased from LC Laboratories (Woburn, MA), and 
carfilzomib was synthesized by previously reported methods [174] or purchased from 
ChemieTek (Indianapolis, IN). 
 
3.3 Cell Culture and Whole Cell Lysis 
The U266 human multiple myeloma and H23 non-small cell lung cancer (NSCLC) 
cell lines were purchased from the American Type Culture Collection and cultured as 
recommended in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine 
serum (Atlanta Biologicals) and 1 mM sodium pyruvate (Sigma-Aldrich) at 37°C and 5% 
CO2.  The cells were collected by centrifugation and lysed in Passive Lysis Buffer 
(Promega) following the manufacturer’s protocol.  Protein concentrations of the resulting 
lysates were determined using the Bio-Rad Protein Assay.  
 
3.4 Treatment of Cell Lysates or Purified Proteasomes with Bifunctional 
Proteasome Probes  
Cell lysates were diluted in Passive Lysis Buffer (Promega) to a final concentration 
of 1 μg/μL, or purified human 20S constitutive proteasome or immunoproteasome 
preparations (Boston Biochem) were diluted in 20S proteasome assay buffer to a final 
concentration of 5-15 ng/μL.  The resulting samples were incubated with DMSO, 5 μM 
epoxomicin (a broadly-acting proteasome inhibitor used as a positive control for covalent 
modification of all catalytic proteasome subunits except for β1), 10 μM YU-102 (a β1/β1i-
selective inhibitor [177, 178] used as a positive control for covalent modification of β1), or 
1-10 μM of the indicated bifunctional probe for 4 h at room temperature.  Where indicated, 
the samples were pretreated with DMSO, 3 μM Ac-nLPnLD-CHO (β1-selective) [239],  
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3 μM NC-012 (β2/β2i-selective) [180], 0.02 μM carfilzomib (β5/β5i-selective) [262], 1 μM 
Ac-PAL-ek (β1i-selective) [239], or 0.1 μM IPSI (PR-924; β5i-selective) [186] for 1 h at 
room temperature before adding the bifunctional probes.   
 
3.5 Generating Cell Line Models of Acquired Bortezomib and Carfilzomib 
Resistance 
Proteasome inhibitor-naïve parental H23 cells were cultured in the presence of 
increasing concentrations of bortezomib (3.2-150 nM) over a period of ~15 mo, or 
increasing concentrations of carfilzomib (8.7-1,000 nM) over a period of ~6-8 mo.  
Replicate cell lines resistant to each inhibitor were generated to assess the consistency 
of experimental results.  Cells growing in the presence of 150 nM bortezomib (2 replicate 
cell lines) or 1 μM carfilzomib (3 replicate cell lines) were collected by centrifugation.  In 
addition, cells growing at these concentrations of bortezomib or carfilzomib were similarly 
collected following inhibitor removal and further culture in inhibitor-free medium for 7 d.  
Cell pellets were stored at -80°C until required for use, at which point the cells were lysed 
and their protein concentrations determined as described above.   
 
3.6 Treatment of Parental H23 Cells with Bortezomib or Carfilzomib 
Parental H23 cells were plated on 3 100-mm culture dishes and incubated at 37°C 
until they became ~80% confluent.  Separate dishes were then treated with DMSO, 150 
nM bortezomib, or 1 μM carfilzomib for 4 h.  Following the 4 h treatment, the cells were 
collected by centrifugation, and cell pellets were stored at -80°C until required for further 
use, at which point the cells were lysed and their protein concentrations determined as 
described above. 
 
3.7 Proteasome Activity Assays 
Purified human 20S constitutive proteasome or immunoproteasome (Boston 
Biochem) (50 ng/well) or cell lysates (5 μg of protein/well) were incubated in 96 well plates 
with DMSO, 20 μM epoxomicin, 10 μM YU-102, or increasing concentrations of each 
bifunctional proteasome probe in 20S proteasome assay buffer (20 mM Tris-HCl, pH 8.0, 
0.5 mM EDTA, 0.035% SDS) in a total volume per well of 90 μL for 1 h at room temperature.  
SDS was omitted from the 20S proteasome assay buffer in assays in which the β2/β2i-
selective substrate was used.  Each substrate was diluted in 20S assay buffer, and 10 μL 
of the resulting solutions were added to the appropriate wells to give a final volume per 
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well of 100 μL.  Substrates Ac-nLPnLD-AMC (β1-selective), Boc-LRR-AMC (β2/β2i-
selective), Suc-LLVY-AMC (β5/β5i-selective) [181], Ac-PAL-AMC (β1i-selective), and Ac-
ANW-AMC (β5i-selective) [76] were used at a final concentration of 100 μM, while Ac-
RLR-AMC (β2/β2i-selective) [181] and Ac-WLA-AMC (β5-selective) [76] were employed 
at a final concentration of 20 μM.  Fluorescence produced by AMC release was measured 
once per minute over a 1 h period with a SpectraMax M5 microplate reader (Molecular 
Devices) using excitation and emission wavelengths of 360 nm and 460 nm, respectively.  
Residual hydrolysis of each substrate measured in lysates treated with 20 μM epoxomicin 
(for all substrates except Ac-nLPnLD-AMC) or 10 μM YU-102 (for Ac-nLPnLD-AMC) was 
regarded as nonproteasomal and subtracted from each experimental measurement of 
proteasome activity.  Hydrolysis rates were determined by linear regression in GraphPad 
Prism, and those of the DMSO-treated controls were designated as 100%.  For the Ac-
RLR-AMC substrate, only data points collected within the first 20 min following substrate 
addition were analyzed for the H23 parental and bortezomib-resistant cell lines due to the 
early plateau of the reaction progress curves obtained for the bortezomib-resistant cell 
lines.  IC50 values of the bifunctional proteasome probes were determined by nonlinear 
regression in GraphPad Prism and represent the averages of three replicates. 
 
3.8 Immunoblotting 
Each sample was mixed with Laemmli Sample Buffer (2X; Sigma-Aldrich), and 
proteins were subsequently denatured at 100°C for 10 min.  Equivalent protein amounts 
of each sample were resolved by 14% SDS-PAGE (for experiments with bifunctional 
proteasome probes) or 12% SDS-PAGE (for evaluating expression levels of catalytic 
proteasome subunits), and proteins were subsequently transferred from the gels onto 
PVDF membranes (Bio-Rad).  Membranes were blocked in 5% non-fat dry milk (Bio-Rad) 
in Tris-buffered saline with 0.05% Tween-20 (TBST) for 1 h at room temperature.  Primary 
antibodies against β1 (Enzo Life Sciences; PW8140), β2 (Enzo Life Sciences; PW8145), 
β5 (Thermo Scientific; PA1-977), β1i (Abcam; ab3328), β5i (Abcam; ab3329), and β-actin 
(Novus Biologicals, NB600-501) were diluted 3% BSA in TBST.  The primary antibody 
against β2i (Santa Cruz, sc-133236) was diluted in 3% milk in TBST.  Membranes were 
incubated in the appropriate primary antibody solutions overnight at 4°C.  Anti-rabbit or 
anti-mouse horseradish peroxidase-conjugated secondary antibodies (GE Healthcare) 
were diluted in 3% milk in TBST, and membranes were incubated in the appropriate 
secondary antibody solutions for 1 h at room temperature.  Protein visualization was 
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facilitated by SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) 
and X-ray film (Thermo Scientific or GeneMate). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kimberly C. Carmony 2016  
82 
4 DEVELOPMENT OF BIFUNCTIONAL ACTIVITY-BASED PROBES FOR 
DETECTING DISTINCT PROTEASOME SUBTYPES 
 
Some of the contents of this chapter were previously published [239]. 
 
4.1 Introduction 
Due to technical difficulties in evaluating the catalytic subunit compositions of 
individual proteasome complexes, much about the cellular functions of each subtype, or 
their importance to the cellular response to proteasome inhibitors, remains to be 
determined.  So far, most researchers have evaluated the relative abundances of 
individual catalytic proteasome subunits via immunoblotting, 2D PAGE [191, 223, 227, 
231, 234, 342], or label-free LC-MS- or ELISA-based quantification [226, 228, 231, 233], 
and used the information obtained to draw conclusions regarding which subtypes may be 
present in a given cell or tissue sample.  However, drawing conclusions based solely on 
these types of studies is complicated by the typical coexistence of multiple distinct 
subtypes [224].  Characterizing individual proteasome subtypes in greater detail has 
typically involved separating purified 20S proteasome complexes by anion-exchange or 
hydrophobic interaction chromatographic procedures [224, 225, 229, 232, 235], free-flow 
isoelectric focusing electrophoresis [230], or immunoprecipitation of tagged forms of 
catalytic β-subunits that were exogenously expressed [223, 342], coupled with 
immunoblotting- [223, 224, 229, 230, 342] or 2D PAGE-based [225, 232, 235] readouts of 
catalytic subunit composition.  Additionally, Guillaume et al. developed antibodies that bind 
the native states of certain catalytic proteasome subunits, enabling proteasome subtypes 
to be separated via sequential immunoprecipitation steps for subsequent immunoblotting 
analysis of their catalytic subunit compositions [226].  They thereby confirmed the 
existence of two intermediate proteasome subtypes that had been previously identified in 
transfected cell lines and in cells derived from immunosubunit-deficient mice [220-223]: 
one containing immunosubunit β5i together with constitutive subunits β1 and β2, and 
another containing immunosubunits β1i and β5i together with constitutive subunit β2 [226].   
Investigations using all of these techniques have yielded valuable information that 
has greatly enhanced our understanding of 20S proteasome diversity.  We now know that 
there are at least four distinct 20S proteasome subtypes that differ in their catalytic activity 
profiles and contributions to producing a given antigenic epitope [224-226, 229, 230, 232, 
235, 236, 238].  The abundance of each subtype appears to be cell type- or tissue-specific, 
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with intermediate proteasome subtypes comprising a greater proportion of the proteasome 
population in many cell and tissue types than was previously appreciated [224, 226, 228, 
229, 233].  Specific subtypes of proteasomes may be associated with pathological 
processes and have been suggested to be of potential utility as disease biomarkers [190].  
They may also play a role in defining the cellular repercussions of treatment with a given 
proteasome inhibitor [231, 232].  However, while only the more detailed examinations can 
truly provide information regarding the identity of specific proteasome subtypes, the 
techniques used so far require multiple technically challenging steps, and the approach 
described by Guillaume et al. depends on the availability and affinity of antibodies that 
recognize the proteasome’s catalytic subunits in their native states. 
Our laboratory thus set out to develop more practical methods to examine the 
catalytic subunit compositions of individual proteasome subtypes contained within cell or 
tissue samples.  The first of these to be reported was a fluorescence resonance energy 
transfer (FRET)-based approach, which involves using pairs of fluorescently-labeled 
inhibitors that selectively bind to specific catalytic proteasome subunits to detect instances 
of catalytic subunit colocalization via a fluorescence readout [343].  Our second approach 
to be reported [239] will be the focus of this chapter.   
As described in Chapter 1.4.8, Moroder and colleagues [197] and Vidal, Reboud-
Ravaux, and colleagues [198, 199] developed several reversibly-binding bifunctional 
proteasome inhibitors with the goal of optimizing inhibitory potency.  Their work, combined 
with our ongoing interest in developing proteasome-targeting activity-based probes, 
sparked the idea of coupling pairs of irreversibly-binding, subunit-selective proteasome 
inhibitors to generate a series of bifunctional proteasome inhibitors with utility as activity-
based probes.  Therefore, building upon the designs of the bifunctional proteasome 
inhibitors previously described [197-199], we designed, synthesized, and characterized a 
set of bifunctional, activity-based proteasome probes that can be used to crosslink 
different pairs of catalytic subunits that coexist within discrete proteasome complexes.  We 
envisioned that treating cells or cell lysates with these bifunctional probes and the resulting 
catalytic subunit crosslinking would allow us to visualize the crosslinked subunit pairs via 
immunoblotting analyses, providing us with the direct information required to deduce 
which proteasome subtypes were present in the cell population under study (Figure 4.1). 
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Figure 4.1 Crosslinking strategy for proteasome subtype identification 
Bifunctional proteasome probes, composed of two peptide epoxyketone proteasome 
inhibitors coupled by a linker, crosslink different pairs of catalytic proteasome subunits 
when they are present within the same 20S core complex. Crosslinking efficiency of a 
particular subunit pair is determined by the subunit selectivity of the two inhibitors, as well 
as the length of the linker by which they are coupled. Following treatment of cell lysates 
or purified 20S proteasomes with a bifunctional proteasome probe, the crosslinked subunit 
pairs can be identified by immunoblotting analysis. This figure was published in our 
previous report [239]. 
 
4.2 Results 
4.2.1 Design of Bifunctional Proteasome Probes 
The most definitive evidence has been provided for the existence of four distinct 
proteasome subtypes: pure constitutive proteasomes of catalytic subunit composition β1-
β2-β5, two intermediate proteasome subtypes of compositions β1-β2-β5i and β1i-β2-β5i, 
and pure immunoproteasomes of composition β1i-β2i-β5i [220-224, 226].  Consistent with 
this, it has been shown that the formation of proteasome subtypes containing β5 with 
immunosubunits or β2i with constitutive subunits is prohibited during the proteasome 
assembly process [221-223].  Therefore, we set out to develop bifunctional proteasome 
probes that can be used to discriminate between these four subtypes.  The two β1-
containing proteasome subtypes are distinguishable by whether they also contain β5 or 
β5i, while the two β1i-containing proteasome subtypes are distinguishable by whether they 
also contain β2 or β2i.  It thus follows that probes capable of crosslinking the β1-type (β1 
and β1i) subunits with the β5-type (β5 and β5i) subunits, and those capable of crosslinking 
the β1-type subunits with the β2-type (β2 and β2i) subunits, should be sufficient to allow 
the detection of each individual subtype.  To generate such probes, we utilized several 
subunit-selective peptide epoxyketone proteasome inhibitors that had previously been 
developed in our laboratory and in others [101, 177, 180, 185, 186, 214, 343] (Figure 4.2).   
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Figure 4.2 Design of bifunctional proteasome probes 
Two of the depicted four subunit-selective proteasome inhibitors (left panel) were 
combined in various iterations via linkers of varying lengths and chemical compositions 
(right panel) to generate a series of bifunctional activity-based probes that target the 
proteasome’s catalytic subunits. 
 
UKP1-3 [343] was derived from the β1/β1i-selective inhibitor YU-102 [177, 178], and 
LKS01 [214] from the β5/β5i-selective inhibitor PR-924 (referred to in this chapter as IPSI) 
[186], by replacing their P4 glycine or P2 tryptophan side chains, respectively, with that of 
lysine to enable their coupling to a second inhibitor via amine-reactive linkers.  We also 
synthesized a derivative of the β5-selective inhibitor PR-825 [101, 185] (6Ahx-PR825) in 
which PR-825’s N-cap was replaced with a 6-aminohexanoyl group to allow linker 
attachment through its N-terminal amine.  Finally, we derivatized the β2/β2i-selective 
inhibitor NC-012 [180] to facilitate linker attachment at its N-terminus.  Different 
combinations of these inhibitors were coupled via linkers of varying lengths and chemical 
compositions to generate a set of 13 bifunctional probes (Table 4.1).  We used the 
distances between the catalytic threonine Oγ atoms of each targeted catalytic subunit pair, 
which were previously derived from X-ray structure data for mammalian 20S proteasome 
complexes [75, 344], to assist us in selecting linkers of the appropriate lengths to facilitate 
crosslinking of these subunits (Figure 4.1).  We chose peptide epoxyketone inhibitors 
because they form irreversible covalent bonds with the proteasome’s catalytic threonine 
residues [170], which would thereby allow us to detect instances of crosslinking between 
catalytic proteasome subunits via immunoblotting analyses.    
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Table 4.1 List of the 13 bifunctional proteasome probes generated in this study 
 
Probe R1 R2 Linker 
1 
UKP1-3 LKS01 
C6 
2 (PEG)9 
3 (PEG)494 
4 (PEG)8-SS-(PEG)8 
5 UKP1-3 6Ahx-PR-825 (PEG)494 
6 UKP1-3 NC-012 (PEG)4 
7 
LKS01 NC-012 
(PEG)94 
8 (PEG)494 
9 
UKP1-3 UKP1-3 
(PEG)9 
10 (PEG)8-SS-(PEG)8 
11 
LKS01 LKS01 
(PEG)9 
12 (PEG)494 
13 NC-012 NC-012 (PEG)494 
 
The two inhibitors comprising R1 and R2 and the linker of each bifunctional probe (see 
Figures 4.1 and 4.2) are listed. These probes were synthesized by Dr. Lalit Kumar Sharma 
and Do-Min Lee, with assistance from Dr. Ying Wu and Ji Eun Park. Probes 1, 4, 5, and 
6 were previously reported [239]. 
 
4.2.2 Probes for β1/β1i-β2/β2i Crosslinking 
a. Probe 1 
Design 
We began by making use of two inhibitors—the β1/β1i-selective inhibitor UKP1-3 
and the β5/β5i-selective inhibitor LKS01—that were readily available in our laboratory at 
the time in order to test the feasibility of our crosslinking approach to identifying 
proteasome subtypes.  UKP1-3 and LKS01 were coupled via a short hydrocarbon linker 
(C6, with an estimated length of ~11.4 Å) to yield the bifunctional probe UKP13-C6-LKS01 
(probe 1) (Figures 4.1 and 4.2, Table 4.1). 
 
Subunit Binding Preferences 
Prior to evaluating its crosslinking capabilities via immunoblotting analyses, we first 
wanted to confirm that probe 1 exhibited the proteasome inhibitory profile expected based 
on the known preferences of its parent compounds.  Activity assays with a series of 
subunit-selective fluorogenic peptide substrates [76, 181] were conducted in purified 
human 20S proteasomes and in lysates of U266 multiple myeloma cells, which abundantly 
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express all three constitutive catalytic subunits as well as all three immunosubunits [345].  
The results revealed that probe 1 does, in fact, preferentially inhibit the β1i and β5i 
subunits when incubated with the purified immunoproteasome, and the β1 and β5 subunits 
when incubated with the purified constitutive proteasome.  Conversely, inhibiting 50% of 
β2 or β2i activity required concentrations of 10 μM or higher (Table 4.2).  Probe 1 also 
selectively inhibits β1/β1i and β5/β5i activity in U266 cell lysates, with nearly complete 
inhibition being achieved at a concentration of 1 μM, while inhibiting β2/β2i activity by ~50% 
required a concentration of 10 μM (Table 4.3).   
 
Crosslinking Capabilities 
With probe 1 established as an active proteasome inhibitor displaying the expected 
inhibitory preferences, we conducted immunoblotting experiments with antibodies against 
individual catalytic proteasome subunits to examine whether this probe can crosslink one 
or more pairs of catalytic subunits.  All of the proteasome’s catalytic subunits fall within the 
molecular weight range of 20-30 kDa; therefore, covalent modification of a given subunit 
can be detected as an upward shift of an immunoreactive band within this molecular 
weight range.  On the other hand, we expected to visualize crosslinking in the form of 
immunoreactive bands with molecular weights between 40-60 kDa, representing the 
combined molecular weights of two catalytic proteasome subunits.  After treating the 
purified immunoproteasome with probe 1, a single immunoreactive band at ~45 kDa was 
detected upon immunoblotting with an antibody against immunosubunit β1i, suggesting 
that β1i had been crosslinked with another catalytic proteasome subunit (Figure 4.3 A).  
When we treated U266 lysates with probe 1 to confirm the consistency of these results 
within a more complex system, we detected two anti-β1i-immunoreactive bands at ~45-
50 kDa (Figure 4.3 B).  This latter result suggested that probe 1 had crosslinked β1i with 
two different catalytic subunits within the U266 lysate.  Despite the observed preference 
of this probe for inhibiting β5 and β5i over β2 and β2i (Tables 4.2 and 4.3), the apparent 
molecular weights of the crosslinked subunit pairs and the known molecular weights of 
each individual catalytic subunit led us to suspect that the two subunits crosslinked with 
β1i were actually β2 and β2i instead of β5 and β5i.  This was further supported by our 
failure to detect crosslinking of β5 or β5i in probe 1-treated U266 lysates (data not shown).  
These findings were not surprising, given that the linker used to couple the two inhibitors 
in probe 1 was likely too short to allow the probe to span the distance required for  
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Figure 4.3 Probe 1 crosslinks β1i with β2/β2i 
A) The purified 20S immunoproteasome (IP) was treated with DMSO, the broadly-acting 
proteasome inhibitor epoxomicin (Epx), or probe 1 prior to immunoblotting for β1i. B) U266 
cell lysates were treated with DMSO or epoxomicin, or were pretreated with DMSO or the 
indicated subunit-selective inhibitor prior to treatment with probe 1, as indicated. β1i was 
detected by immunoblotting. C) High-molecular-weight immunoblot signals detected 
following treatment with bifunctional proteasome probes result from crosslinking of 
catalytic proteasome subunits. Left panel. U266 cell lysates were treated with DMSO, 
epoxomicin, or probe 4 prior to immunoblotting for β1i. Right panel. U266 cell lysates were 
treated with probe 4, and proteins were subsequently denatured in sample buffer with or 
without β-mercaptoethanol (βME), which cleaved the internal disulfide bond of the linker. 
β1i was detected by immunoblotting. Irrelevant lanes were removed from the blot shown 
in the right panel of C. CL = crosslinked β-subunit, * = nonspecific band. Portions of this 
figure were published in our previous report [239]. 
 
crosslinking β1-type subunits with β5-type subunits.  We tested whether or not this was 
the case by pretreating U266 lysates with the proteasome inhibitor NC-012, which binds 
selectively to the β2 and β2i subunits, or with the β5i-selective proteasome inhibitor IPSI, 
before treating with probe 1.  Pretreating with NC-012 completely blocked probe 1-
mediated β1i crosslinking, as seen by the complete abolishment of the two ~45-50 kDa 
bands on the β1i immunoblot, whereas pretreating with IPSI did not (Figure 4.3 B).  These 
results confirmed our suspicion that probe 1 crosslinks β1i with both β2 and β2i, which, 
despite the finding that the β2 and β2i subunits are not the preferred targets of this probe, 
likely results from the C6 hydrocarbon linker restricting crosslinking to adjacent subunits 
within the 20S proteasome complex.  Importantly, our findings indicate the presence of 
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intermediate proteasome subtypes harboring immunosubunit β1i together with constitutive 
subunit β2 in U266 myeloma cells, substantiating previous results demonstrating that 
intermediate proteasomes are formed even under situations in which all of the 
proteasome’s catalytic subunits are simultaneously expressed [223].   
 
b. Probe 4 
To provide additional assurance that the anti-β1i-immunoreactive bands that 
appeared between ~45-50 kDa for probe 1-treated U266 lysates actually represent 
crosslinked β1i, a second bifunctional proteasome probe, UKP13-SS-LKS01 (probe 4), 
was synthesized in which we replaced the C6 linker of probe 1 with a poly(ethylene glycol) 
(PEG) linker containing a scissile disulfide bond (Figure 4.2, Table 4.1).  We anticipated 
that a reducing agent such as β-mercaptoethanol, when added to cell lysates following 
treatment with probe 4, would break the intersubunit crosslinks that the probe had formed, 
and that this could be visualized by the depletion of the higher-molecular-weight bands 
detected for probe 4-treated samples to which the reducing agent had not been added.  A 
proteasome activity assay demonstrated that, as observed for probe 1, probe 4 selectively 
binds β5i and β1i within the context of the purified immunoproteasome, and β1 and β5 
within that of the purified constitutive proteasome.  Substantially higher concentrations of 
this probe were required for inhibiting 50% of β2 or β2i activity (Table 4.2).  Additionally, 
we detected anti-β1i immunoreactive bands with molecular weights between 37-50 kDa 
upon immunoblotting analysis of probe 4-treated U266 lysates, indicating that, as 
observed with probe 1, probe 4 mediates β1i crosslinking (Figure 4.3 C, left panel).  We 
next incubated U266 lysates with probe 4 and denatured their proteins with or without β-
mercaptoethanol.  The two major anti-β1i-immunoreactive bands between 37-50 kDa that 
were detected for the probe 4-treated sample denatured without added β-mercaptoethanol 
could not be detected in the probe 4-treated sample denatured in the presence of β-
mercaptoethanol, providing further evidence supporting the conclusion that the higher-
molecular-weight bands observed represent crosslinked β1i (Figure 4.3 C, right panel). 
 
c. Probe 6 
Design and Subunit Binding Preferences 
Now that we had confirmed that our compounds were, in fact, capable of 
crosslinking pairs of catalytic proteasome subunits, we decided to synthesize a third 
bifunctional probe in attempt to improve upon the β1/β1i-β2/β2i crosslinking efficiency of 
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probe 1.  To this end, we replaced the LKS01 component of probe 1 with the β2/β2i-
selective inhibitor NC-012, and its C6 linker with a more flexible and water-soluble PEG 
linker.  The distance between the catalytic threonine Oγ atoms of β1/β1i and β2/β2i within 
each β-ring is relatively short (~28 Å) [75, 344] (Figure 4.1); we therefore chose a short 
(PEG)4 linker of an estimated length of ~23.2 Å for use in coupling the two inhibitors 
(Figure 4.2, Table 4.1).  Results of proteasome activity assays in purified constitutive 
proteasomes and immunoproteasomes confirmed that β1/β1i inhibition by the newly 
synthesized probe, UKP13-(PEG)4-NC012 (probe 6), is similar to that observed for probe 
1.  On the other hand, probe 6’s preference for inhibiting β2/β2i is greatly improved over 
that of probe 1, and its preference for inhibiting β5/β5i is reduced (Table 4.2).  Similar 
conclusions can be drawn from the results of proteasome activity assays with these 
probes in U266 lysates (Table 4.3). 
 
Crosslinking Capabilities 
Immunoblotting analysis showed that treatment of the purified constitutive 
proteasome with probe 6 produced an anti-β1-immunoreactive band just below 50 kDa, 
consistent with β1-β2 crosslinking (Figure 4.4 A).  A similar anti-β1-immunoreactive band 
was detected for U266 cell lysates following treatment with probe 6 (Figure 4.4 B).  Probe 
6 was also found to crosslink β1i with β2i, but not with β5i, in the purified 
immunoproteasome, as shown by the ability of the β2/β2i-selective inhibitor NC-012, but 
not the β5i-selective inhibitor IPSI, to attenuate the anti-β1i-immunoreactive band 
representing crosslinked β1i (Figure 4.4 C).  We also detected probe 6-mediated β1i 
crosslinking in U266 lysates.  In this case, two immunoreactive bands between ~45-50 
kDa were observed on a β1i immunoblot (Figure 4.4 D), as previously observed when 
U266 lysates were treated with probe 1 (Figure 4.3 B).  This latter result strongly indicates 
that probe 6, like probe 1, crosslinks β1i with both β2 and β2i in U266 lysates. 
 
Our results obtained with probes 1 and 6 collectively demonstrate that, despite 
their structural differences, both probes crosslink β1/β1i with β2/β2i.  They also highlight 
the presence of proteasome subtypes containing both β1i and β2i, and those containing 
both β1i and β2, in U266 cells.  Conversely, while our results reflect the presence of 
proteasome subtypes containing both β1 and β2 in these cells, they indicate the absence 
of proteasome subtypes containing both β1 and β2i.  The lack of evidence for the formation  
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Figure 4.4 Probe 6 crosslinks β1/β1i with β2/β2i 
A) The purified 20S constitutive proteasome (CP) was incubated with DMSO, the β1/β1i-
selective proteasome inhibitor YU-102, or probe 6 prior to immunoblotting for β1. B) U266 
cell lysates were incubated with DMSO, epoxomicin (Epx), or the indicated bifunctional 
probe prior to immunoblotting for β1. C) The purified 20S immunoproteasome (IP) was 
treated with DMSO, epoxomicin, or was pretreated with the indicated subunit-selective 
inhibitor prior to treatment with probe 6, as indicated. β1i was detected by immunoblotting. 
D) U266 cell lysates were incubated with DMSO, epoxomicin, or probe 6 prior to 
immunoblotting for β1i. Irrelevant lanes were removed. CL = crosslinked β-subunit. * = 
nonspecific band. These data were published in our previous report [239]. 
 
of proteasome subtypes containing the β1-β2i combination agrees with previous 
observations suggesting that β2i is efficiently incorporated into proteasome complexes 
only when it is co-incorporated with β1i [220, 221, 223].  
 
4.2.3 Probes for β1/β1i-β5/β5i Crosslinking 
a. Probes 3 and 5 
Design and Subunit Binding Preferences 
Our next goal was to generate a bifunctional proteasome probe capable of 
crosslinking β1 or β1i with β5 or β5i.  We therefore synthesized two UKP1-3-containing 
bifunctional probes: one in which the β5i-selective inhibitor LKS01 was used as the second 
inhibitory moiety, and another in which the β5-selective inhibitor PR-825 was used (Figure 
4.2).  The estimated length of the PEG linker we chose to incorporate into these probes is 
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~83.9 Å.  We felt this length would be more than sufficient to facilitate crosslinking of the 
targeted subunits, whose catalytic threonine residues are separated by ~62 Å [75, 344] 
(Figures 4.1 and 4.2).  The first of these two probes, UKP13-(PEG)494-LKS01 (probe 3) 
(Table 4.1), was found to selectively inhibit the β1-type and β5-type subunits in U266 
lysates, whereas >10 μM of this probe was required to inhibit the β2/β2i activity by 50% 
(Table 4.3).  The second of these probes, UKP13-(PEG)494-6Ahx-PR825 (probe 5) (Table 
4.1) selectively binds the β5 and β1 subunits and the β1i and β5i subunits of the purified 
constitutive proteasome and immunoproteasome, respectively (Table 4.2).  Furthermore, 
a 5 μM concentration of this probe completely inhibits the β1/β1i and β5/β5i activities in 
U266 lysates (Table 4.3). 
 
Crosslinking Capabilities 
1. Probe 3 
Following treatment of the purified immunoproteasome with probe 3, crosslinked 
β5i was detected on a β5i immunoblot as a single immunoreactive band with a molecular 
weight consistent with β5i-β1i crosslinking (Figure 4.5, left panel).  Providing further 
evidence for this species, we detected a band of approximately the same molecular weight 
on a β1i immunoblot (Figure 4.5, right panel).  Pretreating the purified immunoproteasome 
with the β5i-selective inhibitor IPSI effectively suppressed the emergence of this higher-
molecular-weight band following treatment with probe 3, verifying that this band represents 
crosslinked β5i (Figure 4.5, left panel).  Additionally, pretreating with the β1i-selective 
inhibitor Ac-PAL-ek produced the same effect, indicating that probe 3 crosslinks β5i with 
β1i (Figure 4.5, left panel).   
Pretreating with Ac-PAL-ek also blocked the appearance of the higher-molecular-
weight band on the β1i immunoblot, demonstrating that it represents β1i (Figure 4.5, right 
panel).  Conversely, pretreating with the β2/β2i-selective inhibitor NC-012 had no effect 
on this band, suggesting that probe 3, unlike probes 1 and 6, does not crosslink β1i with 
β2i (Figure 4.5, right panel).  Interestingly, although we expected that pretreating with IPSI 
would block the appearance of this crosslinked β1i band, this was not the case.  However, 
this band did appear to shift upward in molecular weight under these conditions (Figure 
4.5, right panel).  This suggests that the β1i-immunoreactive band seen for the DMSO- 
and NC-012-pretreated samples resulted from crosslinking of β1i with β5i, but that a 
different crosslinked species was formed when β5i’s active site is blocked.  Based on  
 
93 
 
 
Figure 4.5 Probe 3-mediated crosslinking of catalytic proteasome subunits 
The purified 20S immunoproteasome (IP) was incubated with DMSO or epoxomicin (Epx), 
or was pretreated with DMSO or the indicated subunit-selective inhibitor prior to treatment 
with probe 3, as indicated. β5i (left panel) or β1i (right panel) was detected by 
immunoblotting. Irrelevant lanes were removed. CL = crosslinked β-subunit. 
 
molecular weight, this new species is likely a β1i-β2i pair rather than a β1i-β1i pair, as β2i 
is of higher molecular weight than β5i, while β1i is of lower molecular weight.   
Collectively, these results suggest that probe 3 crosslinks β1i with β5i, and, if β5i’s 
active site is blocked, it crosslinks β1i with β2i instead.  Conversely, it does not appear to 
crosslink β5i with β2i when β1i’s active site is blocked.  It is unclear if this is due to the 
probe’s inability to reach the β2i active site when bound to that of β5i, or to the inefficient 
binding of one end of the probe (presumably the UKP1-3 end) to β2i.  Regardless, it 
appears that the long, flexible PEG linker can facilitate probe 3-mediated crosslinking of 
multiple subunit pairs within the purified immunoproteasome.  On the other hand, despite 
its ability to bind both of the constitutive subunits β1 and β5 individually, probe 3 was not 
able to perceptibly crosslink either of these subunits with one another, or with β2, when 
incubated with the purified constitutive proteasome (data not shown).  
 
2. Probe 5 
In contrast to the single band observed following treatment with probe 3, two anti-
β1i-immunoreactive bands were observed between ~40-50 kDa by immunoblotting 
analysis of the probe 5-treated purified immunoproteasome: one major band and one 
minor band (Figure 4.6 A, left panel).  We detected a band with a comparable molecular 
weight to that of the major crosslinked β1i band on a β5i immunoblot, suggesting that 
these bands arose from crosslinking of β1i with β5i (Figure 4.6 A, middle panel).  Based  
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Figure 4.6 Probe 5 crosslinks β1/β1i with β5/β5i and β2/β2i 
A) The purified 20S immunoproteasome (IP) was treated with DMSO, epoxomicin (Epx), 
or probe 5 prior to immunoblotting for β1i (left panel), β5i (middle panel), or β2i (right panel). 
B) The purified 20S immunoproteasome was treated with DMSO or epoxomicin, or was 
pretreated with DMSO or the indicated subunit-selective inhibitor prior to treatment with 
probe 5, as indicated. β5i was detected by immunoblotting. C) The purified 20S 
constitutive proteasome (CP) was treated with DMSO, YU-102, epoxomicin, or probe 5 
prior to immunoblotting for β1 (left panel) or β5 (right panel). D) The purified 20S 
constitutive proteasome was treated with DMSO, YU-102, probe 6, or probe 5 prior to 
immunoblotting for β1. E) The purified 20S constitutive proteasome was treated with 
DMSO or YU-102, or was pretreated with DMSO or the indicated subunit-selective 
inhibitor prior to treatment with probe 5, as indicated. β1 was detected by immunoblotting. 
Irrelevant lanes were removed from blots shown in A, C, D, and E. CL = crosslinked β-
subunit. These data were published in our previous report [239]. 
 
on the results of the β1i immunoblot and of one for β2i, the minor band on the β1i 
immunoblot appears to reflect crosslinking between β1i and β2i (Figure 4.6 A, right panel).  
Together, these results indicate that probe 5 crosslinks β1i preferentially with β5i, but also, 
to a lesser extent, with β2i.  The higher-molecular-weight β5i band was no longer 
detectable when the purified immunoproteasome was pretreated with the β5i-selective 
inhibitor IPSI before it was treated with probe 5, confirming that this band represents 
crosslinked β5i (Figure 4.6 B).  This band could also be attenuated by pretreating with the 
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β1i-selective inhibitor Ac-PAL-ek, providing further evidence that it resulted from 
crosslinking between β5i and β1i (Figure 4.6 B). 
Also contrasting probe 3-mediated crosslinking was the ability of probe 5 to 
crosslink catalytic subunits within the purified constitutive proteasome.  We detected two 
immunoreactive bands on a β1 immunoblot with the probe 5-treated constitutive 
proteasome that arose from β1 crosslinking (Figure 4.6 C, left panel).  A crosslinked band 
with a molecular weight comparable to that of the lower of these crosslinked β1 bands was 
detected on a β5 immunoblot, indicating that probe 5 crosslinks β1 with β5 (Figure 4.6 C, 
right panel).  On the other hand, the upper crosslinked β1 band was found to align with 
the crosslinked β1 band generated following treatment of the purified constitutive 
proteasome with probe 6.  Their comparable molecular weights suggested that the upper 
crosslinked β1 band observed for the probe 5-treated constitutive proteasome reflects 
crosslinking between β1 and β2 (Figure 4.6 D).  Both of the higher-molecular-weight β1 
bands could be substantially depleted by pretreating the purified constitutive proteasome 
with the β1-selective inhibitor Ac-nLPnLD-CHO before treating with probe 5, confirming 
that these bands arose from β1 crosslinking (Figure 4.6 E).  Only the lower of these bands 
was depleted by pretreating with the β5/β5i-selective inhibitor carfilzomib [262] (Figure 4.6 
E, left panel), while pretreating with the β2/β2i-selective inhibitor NC-012 depleted only 
the upper band (Figure 4.6 E, right panel).  These results confirm that probe 5 crosslinks 
β1 with both β5 and β2 and again indicate that the long, flexible PEG linker can mediate 
crosslinking of multiple pairs of catalytic proteasome subunits. 
 
4.2.4 Probes for β2/β2i-β5/β5i Crosslinking 
Design and Subunit Binding Preferences 
Although it was outside of our original goal of generating probes for crosslinking 
the β1-type subunits with the β2- or β5-type subunits, we also attempted to develop probes 
capable of crosslinking the β5-type subunits with the β2-type subunits.  We felt that adding 
such probes to our repertoire would be helpful in determining the catalytic subunit 
compositions of the various proteasome subtypes more conclusively.  Specifically, their 
use could provide the evidence required for deciding whether we could truly rule out the 
presence of mature proteasome complexes containing β2i together with β5 [220, 221, 223, 
226], and, if not, allow us to detect those subtypes as well.  We therefore synthesized 
probes 7 (LKS01-(PEG)94-NC012) and 8 (LKS01-(PEG)494-NC012), with the former having 
a shorter linker than the latter (estimated lengths: ~62.7 Å vs. ~83.9 Å) (Figure 4.2, Table 
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4.1).  Still, we anticipated that the length of either of these linkers would likely be sufficient 
for crosslinking of the targeted subunits, whose catalytic residues are separated by ~63 Å 
within each β-ring.  As observed for probe 6 (Tables 4.2 and 4.3), incorporating the β2/β2i-
selective inhibitor NC-012 into these bifunctional probes substantially increased their 
potency against these subunits (Table 4.3).  Both probe 7 and probe 8 prefer binding to 
β5, β5i, β2, and β2i over β1 and β1i in U266 lysates (Table 4.3). 
 
Immunoblotting Analyses 
Although immunoblotting analyses demonstrated that probe 7 does, in fact, 
covalently modify its preferred targets in U266 lysates—consistent with the activity assay 
results—crosslinking of these subunits could not be readily detected using their respective 
antibodies (data not shown).  Conversely, we did observe faint crosslinking of β1i, whereas 
no significant β1 crosslinking was detected (data not shown).  We did not go forward with 
discerning which subunit was crosslinked with β1i by probe 7, but, based on the molecular 
weight of the crosslinked β1i band, the unknown subunit is unlikely to be a β2-type subunit 
and likely to be either a β5-type or β1-type subunit (data not shown).  On the other hand, 
probe 8 did appear to weakly crosslink β5i (in addition to β1i) within the purified 
immunoproteasome, but it is unlikely that this probe crosslinks β5i with β2i (data not 
shown).  Our efforts to definitively determine the identity of the subunits crosslinked with 
β5i and β1i by this probe have so far been unsuccessful. 
 
4.2.5 Homobifunctional Proteasome Probes 
Finally, we synthesized five homobifunctional proteasome probes: UKP13-(PEG)9-
UKP13 (probe 9), UKP13-(PEG)8-SS-(PEG)8-UKP13 (probe 10), LKS01-(PEG)9-LKS01 
(probe 11), LKS01-(PEG)494-LKS01 (probe 12), and NC012-(PEG)494-NC012 (probe 13) 
(Figure 4.2, Table 4.1).  Given the variability in proteasome catalytic subunit composition, 
it has been questioned whether the two β-rings within a 20S proteasome complex need 
be identical, or whether so-called ‘asymmetric’ core particles containing two β-rings of 
differing catalytic subunit content can form [73, 225].  We reasoned that our 
homobifunctional probes would allow these possibilities to be further examined.   
 
Subunit Binding Preferences 
We found that probe 9 strongly inhibits β1 and β1i in U266 lysates; it also exhibits 
reduced potency toward β5 and β5i compared with probes in which UKP1-3 was combined 
97 
with LKS01 or PR-825.  Additionally, this probe poorly inhibits β2/β2i activity, with only 9% 
of this activity being inhibited at a probe concentration of 10 μM (Table 4.3).  Probe 10 
also completely inhibits β1i activity at a concentration of 1 μM.  This probe is a more potent 
inhibitor of β5/β5i activity than probe 9 (Table 4.3).  Probe 11 strongly inhibits β5/β5i 
activity and displays much weaker activity against β1/β1i and β2/β2i (Table 4.3).  Probe 
12 appears to inhibit β5/β5i activity more potently than probe 11, but it also shows 
increased inhibitory potency toward β1/β1i and β2/β2i (Table 4.3).  The results obtained 
with probes 9-12 suggest that coupling two UKP1-3 moieties, or two LKS01 moieties, via 
longer linkers gives rise to less specific probes than those in which the same inhibitory 
moieties are coupled by shorter linkers.  Lastly, probe 13 is the most potent β2/β2i inhibitor 
among the bifunctional probes.  Conversely, it poorly inhibits β1 and shows reduced β1i 
inhibitory potency compared with the UKP1-3-containing probes (Table 4.3).  
 
Crosslinking Capabilities 
1. Probes 9, 2, and 11 
Strong β1i crosslinking was observed when U266 lysates were treated with probe 
9 (Figure 4.7 A).  A competition assay confirmed the subunit crosslinked with β1i by this 
probe to be the β1i subunit on the opposing β-ring (Figure 4.7 B).  Surprisingly, similar 
results were obtained for probes 2 (UKP13-(PEG)9-LKS01) (Figure 4.7 C) and 11 (Figure 
4.7 D), suggesting that the (PEG)9 linker directs crosslinking between the two β1i subunits 
within a 20S core complex.  Conversely, probes 2 and 11 do not crosslink β5i or β5 (data 
not shown), consistent with their linker length (estimated to be ~35.8 Å), although longer 
than the C6 linker of probe 1, being insufficient for crosslinking between the β5-type and 
β1-type subunits (Figures 4.1 and 4.2).  Interestingly, the (PEG)9 linker of probe 2 leads 
to a loss of the β1i-β2/β2i crosslinking observed with probe 1, further demonstrating that 
properties of the linker can have a meaningful influence on the subunits crosslinked by 
bifunctional probes with identical inhibitory moieties (Figure 4.7 A).   
 
2. Probe 10 
Like probe 4, probe 10 was synthesized for use as a control to show that the 
higher-molecular-weight bands seen upon immunoblotting analysis of bifunctional probe-
treated samples resulted from crosslinking of two catalytic proteasome subunits (Figure 
4.2, Table 4.1).  Like probe 9, probe 10 produced strong bands on a β1i immunoblot that  
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Figure 4.7 Probes 9, 2, 11, and 10 crosslink β1/β1i with β1/β1i on the opposing β-
ring 
A) U266 cell lysates were treated with DMSO, epoxomicin (Epx), or the indicated 
bifunctional probe prior to immunoblotting for β1i. B-D) U266 cell lysates were treated with 
DMSO or epoxomicin, or were pretreated with DMSO or the indicated subunit-selective 
inhibitor prior to treatment with probe 9 (B), 2 (C), or 11 (D), as indicated. β1i was detected 
by immunoblotting. E) Left panel. U266 cell lysates were treated with DMSO, epoxomicin, 
or probe 10 prior to immunoblotting for β1i. Right panel. U266 cell lysates were treated 
with probe 10, and proteins were subsequently denatured in sample buffer with or without 
β-mercaptoethanol (βME), which cleaved the internal disulfide bond of the linker. β1i was 
detected by immunoblotting. F) U266 cell lysates were treated with DMSO or epoxomicin, 
or were pretreated with DMSO or the indicated subunit-selective inhibitor prior to treatment 
with probe 10, as indicated. β1i was detected by immunoblotting. G) U266 cell lysates 
were treated with DMSO, YU-102, or probe 10 prior to immunoblotting for β1. Irrelevant 
lanes were removed from blots shown in B-G. CL = crosslinked β-subunit. 
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appeared to represent crosslinked β1i (Figure 4.7 E, left panel).  This was confirmed by 
immunoblotting with probe 10-treated samples whose proteins had been denatured in the 
absence or presence of β-mercaptoethanol (Figure 4.7 E, right panel).  Despite its long 
and flexible PEG linker, β1i crosslinking by probe 10 seems to occur, based on competition 
assay results, exclusively with the β1i on the opposing β-ring (Figure 4.7 F); the multiple 
bands observed for crosslinked β1i appear to result from the non-reducing conditions 
under which this gel was run (Figure 4.7 E and F).  This probe also crosslinks β1, most 
likely with β1 on the opposing β-ring (Figure 4.7 G).  Although probe 10 was found to 
crosslink β1 (Figure 4.7 G), we did not observe crosslinking between β1i and β1 (Figure 
4.7 F); these results suggest that proteasomes in U266 cells are symmetric rather than 
asymmetric, at least with respect to their β1 and β1i content.     
 
3. Probe 12 
In contrast to probe 11, the longer linker of probe 12 facilitates crosslinking of β5i 
upon incubation of the purified immunoproteasome with this probe (Figure 4.8, left panel).  
This probe also crosslinks β1i (Figure 4.8, right panel).  Results of competition assays 
suggest that probe 12 crosslinks β5i with both β5i (likely the predominant species) and β1i 
(Figure 4.8).   
 
4. Probe 13 
Assessments with the purified constitutive proteasome and immunoproteasome 
showed that probe 13, like probe 8, covalently modifies all detectable β2 and β2i (data not 
shown).  It also binds β1i and β1 to a lesser extent, but does not bind β5i (data not shown).  
Unfortunately, however, we were unable to detect crosslinking of any subunit by this probe 
(data not shown). 
 
4.3 Discussion 
We designed and synthesized a set of bifunctional activity-based probes for use in 
a crosslinking-based strategy to elucidate the catalytic subunit compositions of individual 
proteasome subtypes (Figures 4.1 and 4.2, Table 4.1).  We conducted proteasome activity 
assays (Tables 4.2 and 4.3) and immunoblotting analyses (Figures 4.3-4.8) to 
characterize the subunit binding and crosslinking preferences of these probes within the 
context of the purified constitutive proteasome or immunoproteasome, or of lysates 
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Figure 4.8 Probe 12-mediated crosslinking of catalytic proteasome subunits 
The purified 20S immunoproteasome (IP) was incubated with DMSO or epoxomicin (Epx), 
or was pretreated with DMSO or the indicated subunit-selective inhibitor prior to treatment 
with probe 12, as indicated. β5i (left panel) or β1i (right panel) was detected by 
immunoblotting. Irrelevant lanes were removed. CL = crosslinked β-subunit. 
 
prepared from a multiple myeloma cell line (U266) that abundantly expresses all of the 
constitutive subunits and immunosubunits.  Our results revealed that the bifunctional 
proteasome probes maintain the subunit binding preferences of the individual parent 
inhibitors of which they are composed.  Additionally, they showed that all of the probes 
(except for the NC-012 homodimer [probe 13]) are capable of crosslinking pairs of catalytic 
subunits within intact proteasome complexes, allowing us to detect instances of catalytic 
subunit colocalization within these complexes via immunoblotting analyses.  A major 
advantage of this approach is that it does not necessitate proteasome purification or 
separation of individual proteasome subtypes from one another via chromatographic 
methods, free-flow isoelectric focusing electrophoresis, or immunoprecipitation [223-230, 
232, 235, 342]; it requires fewer processing steps, yet provides more information on the 
identity of individual proteasome subtypes than techniques simply assessing overall 
expression levels of individual catalytic subunits [191, 223, 226-228, 231, 233, 234, 342], 
most of which may exist in more than one proteasome subtype [224].  Additionally, when 
using our previously-reported fluorescent proteasome probes in a FRET-based strategy 
for identifying proteasome subtypes [343], one must be sure to use concentrations of 
these probes that are subunit-specific for the experimental results to be accurately 
interpreted; conversely, this limitation does not necessarily apply to the use of our 
bifunctional probes in the approach discussed here. 
We found that both the inhibitory moieties and the linker of a given bifunctional 
probe influence the subunits it preferentially crosslinks.  By joining different combinations 
of subunit-selective inhibitors via linkers of varying lengths and chemical compositions, we 
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were able to meet our goal of developing bifunctional proteasome probes that crosslink 
β1/β1i with β2/β2i (e.g., probes 1 and 6) or with β5/β5i (e.g., probes 3 and 5).  Using 
probes 1 and 6, we identified two β1i-containing proteasome subtypes in U266 cells: one 
containing β2i, consistent with a pure immunoproteasome, and one containing β2, 
consistent with intermediate proteasome subtype β1i-β2-β5i [226].  Conversely, subtypes 
containing β1 together with β2i were not detected, which is in accord with prior results 
demonstrating that formation of subtypes containing both of these subunits within a single 
complex is precluded by the proteasome assembly process [220, 221, 226].  These results 
demonstrate the utility of these probes in discerning the identities of the proteasome 
subtypes that can be formed in a given cell or tissue type.  We also developed bifunctional 
probes that crosslink β1/β1i with β1/β1i on the opposing β-ring within a single 20S 
proteasome complex (e.g., probes 2, 9, 10, and 11), and one (probe 12) that appears to 
crosslink β5i with β5i on the opposing β-ring.  These probes can be used to determine 
whether proteasome complexes are symmetric or asymmetric in terms of the catalytic 
subunit compositions of their two β-rings.  Results obtained with probe 10 in U266 cell 
lysates (Figure 4.7 F and G) indicate that, although both β1- and β1i-containing 
proteasome complexes are present in this cell line, both β-rings within these complexes 
are identical with respect to whether they contain β1 or β1i—that is, our results are 
consistent with a lack of asymmetric proteasome complexes, at least with respect to the 
β1-type subunits.  Whether this is true for other catalytic proteasome subunits or holds 
across multiple cell lines or tissue samples could be further explored using this approach, 
and the successful development of a probe that crosslinks the two β2-type subunits on 
opposing β-rings with one another would complete the set of bifunctional probes required 
for a full analysis.  Although this conclusion contrasts that of Klare et al., who, following 
IFNγ stimulation, detected both β1 and β1i in proteasomes purified via a tagged β1 subunit 
from transfected HeLa cells [225], it is in line with that of Guillaume et al., who, by 
analyzing proteasomes immunoprecipitated with an antibody recognizing β5 in its native 
state via β5i immunoblotting, were unable to detect asymmetric proteasome complexes 
containing both β5 and β5i in melanoma cells or in kidney [226]. 
Although our approach offers several advantages over others that are currently 
available, it has several limitations worth addressing.  First, the crosslinking efficiency of 
our probes stands to be improved.  This would provide a greater probability of detecting 
subtypes that may be present in low amounts, which can still be of biological importance 
[226].  Additionally, our bifunctional proteasome probes containing the longest PEG linkers 
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used in our study (~83.9 Å) tend to crosslink multiple pairs of catalytic subunits (e.g., 
probes 5 and 12), or appear to readily crosslink a given subunit with a non-preferred target 
when the active site of a preferred target is blocked (e.g., probe 3).  Unfortunately, this 
latter finding renders drawing definitive conclusions from the competition assays used to 
identify the subunit pairs crosslinked by these probes more difficult, especially when the 
next-preferred target for crosslinking is of similar molecular weight to the one whose active 
site was blocked.   
Further optimization of linker lengths or inhibitor sequences may overcome these 
barriers.  Additionally, our laboratory has been working to develop two modified 
approaches.  In one approach, biotin-labeled versions of the various bifunctional 
proteasome probes are used to facilitate streptavidin-mediated purification of the 
crosslinked subunit pairs.  This strategy would allow a mass spectrometry-based 
identification of the crosslinked catalytic subunits, bypassing the need for competition 
assays to confirm the identities of the subunits crosslinked by a given probe.  The other 
approach involves using monomeric subunit-selective proteasome inhibitors that have 
been functionalized with biorthogonal reactive groups.  Treatment of cells with these 
inhibitors, cell lysis, and incubation of the resulting lysates with a linker that has compatible 
reactive groups on either end to those of each inhibitor leads to joining of the two inhibitors 
by the linker.  It is hoped that using these smaller inhibitors will provide greater subunit 
selectivity compared with the large bifunctional probes, thereby assisting the more 
straightforward interpretation of experimental results.   
We anticipate that the bifunctional proteasome probes described here and the 
second-generation proteasome probes our lab is developing will continue to assist in 
answering many open yet important questions regarding proteasome biology.  For 
example, the development of probes that crosslink β2/β2i with β5/β5i will allow generation 
of the evidence required to firmly establish whether formation of proteasome subtypes 
containing β2i together with β5 is permissible.  Additionally, further experiments with the 
probes capable of crosslinking β1/β1i-β5/β5i may answer the question of whether 
proteasome complexes containing β1i together with β5 exist.  Improving our knowledge 
regarding which proteasome subtypes can and cannot form in specific cell types and/or 
under specific conditions will improve our collective understanding of proteasome 
structure and function in both normal and diseased cells.  Our probes can also be used in 
investigating the specific cellular functions of each proteasome subtype.  Finally, they can 
be used to determine whether specific subtypes can serve as disease biomarkers or 
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indicators of relative sensitivity to proteasome inhibitors.  If so, they may provide useful 
tools to screen for the relevant subtypes in patient samples.  If certain subtypes of 
proteasomes do in fact confer sensitivity or resistance to particular proteasome inhibitors, 
such an approach may ultimately allow the personalized selection of the proteasome 
inhibitor that will most effectively target the subtypes present in diseased cells of each 
patient. 
 
Table 4.2 Inhibitory potencies of bifunctional probes 1, 4, 5, and 6 towards individual 
catalytic subunits of the purified constitutive proteasome or immunoproteasome 
 
 IC50 (μM) 
Probe β5 β5i β1 β1i β2 β2i 
UKP13-C
6
-LKS01 (1) 0.895 0.349 0.655 0.402 10.64 >10 
UKP13-(PEG)8-SS-
(PEG)8-LKS01 (4) 
0.165 0.017 0.094 0.038 6.669 >10 
UKP13-(PEG)494-6Ahx-
PR825 (5) 
0.075 0.380 0.188 0.130 15.28 28.07 
UKP13-(PEG)4-NC012 
(6) 
3.93 4.35 1.153 0.803 0.128 0.03 
 
The purified constitutive proteasome or immunoproteasome was incubated with 
increasing concentrations of each bifunctional probe for 1 h. Proteasome activities were 
then assessed using fluorogenic peptide substrates selectively hydrolyzed by the 
indicated subunit. These data were obtained with the help of Ji Eun Park and were 
previously reported [239]. 
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Table 4.3 Subunit binding preferences of the bifunctional proteasome probes in 
lysates of U266 multiple myeloma cells 
 
  Relative Activity (% DMSO Control) 
Probe 
Conc. 
(μM) 
 β5/β5i β5 β5i β1 β1i β2/β2i 
UKP13-C6- 
LKS01 (1) 
 
0.5 N.D.   N.D.  N.D. N.D. N.D. 104% 
1 4%  N.D. 4% 3% 0% 91% 
5 0%  N.D. 0% 0% 0% 71% 
10 0%  N.D. 1% 0% 0% 47% 
UKP13-(PEG)9-
LKS01 (2) 
0.5 N.D. N.D. N.D. N.D. N.D. 107% 
1 2% N.D. 4% 13% 2% 108% 
5 0% N.D. 0% 0% 0% 97% 
10 0% N.D. 0% 0% 0% 70% 
UKP13-(PEG)494-
LKS01 (3) 
0.1 N.D. 4% 7% 2% 0% N.D. 
0.5 N.D. 2% 0% 0% 0% N.D. 
1 N.D. 2% 0% 0% 0% 108% 
5 N.D. 0% 0% 0% 0% 69% 
10 N.D. 0% 0% 0% 0% 65% 
UKP13-(PEG)494-
6Ahx-PR825 (5) 
0.5  N.D. 0% 5% 5% 0%  N.D. 
1  N.D. 0% 2% 3% 0%  N.D. 
5  N.D. 0% 0% 0% 0%  N.D. 
10  N.D. 0% 0% 0% 0%  N.D. 
UKP13-(PEG)4-
NC012 (6) 
1  N.D. 77% 101% 15% 7% 23% 
5  N.D. 33% 88% 2% 1% 6% 
10  N.D. 8% 61% 0% 0% 0% 
LKS01-(PEG)94-
NC012 (7) 
1 N.D. 0% 7% N.D. 70% 21% 
5 N.D. 0% 0% 81% 28% 0% 
10 N.D. 0% 0% 62% 12% 0% 
LKS01-(PEG)494-
NC012 (8) 
0.1  N.D. 28% 40% N.D. 95% 68% 
0.5 N.D. 1% 13% N.D. 72% 48% 
1 N.D. 1% 5% 106% 71% 41% 
5 N.D. 1% 0% 80% 31% 10% 
10 N.D. 1% 0% 72% 12% 0% 
UKP13-(PEG)9-
UKP13 (9) 
0.5 N.D. N.D. N.D. N.D. N.D. 102% 
1 34% N.D. 44% 0% 0% 106% 
5 2% N.D. 18% 0% 0% 97% 
10 1% N.D. 15% 0% 0% 91% 
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Table 4.3 (continued)  
 
  Relative Activity (% DMSO Control) 
Probe 
Conc. 
(μM) 
 β5/β5i β5 β5i β1 β1i β2/β2i 
UKP13-(PEG)8-
SS-(PEG)8-
UKP13 (10) 
1 3% N.D. N.D. N.D. 0% N.D. 
5 1% N.D. N.D. N.D. 0% N.D. 
10 1% N.D. N.D. N.D. 0% N.D. 
LKS01-(PEG)9-
LKS01 (11) 
0.5 25% N.D. 5% 89% 91% 105% 
1 4% N.D. 5% 90% 95% 108% 
5 1% N.D. 0% 73% 56% 87% 
10 1% N.D. 0% 45% 36% 61% 
LKS01-(PEG)494-
LKS01 (12) 
0.1 N.D. 1% 0% 59% 15% N.D. 
0.5 N.D. 1% 0% 35% 1% N.D. 
1 N.D. 0% 0% 23% 0% 88% 
5 N.D. 0% 0% 11% 0% 54% 
10 N.D. 0% 0% 8% 0% 27% 
NC012-(PEG)494-
NC012 (13) 
0.1 N.D. N.D. N.D. N.D. N.D. 32% 
0.5 N.D. N.D. N.D. N.D. N.D. 13% 
1 N.D. N.D. N.D. 110% 56% 0% 
5 N.D. N.D. N.D. 84% 29% 0% 
10 N.D. N.D. N.D. 60% 11% 0% 
 
Cell lysates were incubated with the indicated concentrations of each bifunctional probe 
for 1 h.  Proteasome activities were then assessed using fluorogenic peptide substrates 
selectively hydrolyzed by the indicated subunit(s). N.D. = not determined. Data for probes 
1, 4, 5, and 6 were previously reported [239]. 
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5 EVALUATING PROTEASOME COMPOSITION AND FUNCTION IN CELL LINE 
MODELS OF ACQUIRED BORTEZOMIB AND CARFILZOMIB RESISTANCE 
5.1 Introduction  
Despite the markedly improved clinical outcomes achieved with proteasome 
inhibitor-based treatment regimens, acquired resistance to these inhibitors has emerged 
as a major clinical challenge [257, 258, 260, 267].  While multifarious conclusions have 
been drawn from preclinical studies of proteasome inhibitor resistance mechanisms (as 
described in Chapter 1.8), distinct expression and activity patterns of catalytic proteasome 
subunits have frequently been observed in cancer cells displaying both intrinsic [204, 289, 
334, 346] and acquired [184, 204, 209, 246, 280, 285, 288, 289, 298, 313, 315, 329, 330, 
332, 333] resistance to these agents.  In cell line models of acquired bortezomib resistance, 
these properties are frequently accompanied by an inferior bortezomib-mediated 
suppression of proteasome activities [184, 204, 209, 246, 285, 289, 313, 337].  The 
consistency of these findings, especially those obtained with the same cell line before and 
after resistance was acquired, as well as previous findings linking distinct proteasome 
subtypes of murine cells with the differential inhibitory efficacies of bortezomib and other 
proteasome inhibitors [231, 232], led us to hypothesize that increases in the relative 
proportions of specific subtypes may serve as an important mechanism of acquired 
proteasome inhibitor resistance due to the inability of the proteasome inhibitors currently 
in clinical use to efficiently inhibit their activities.  Additionally, given the structural and 
mechanistic differences between inhibitors, we hypothesized that the subtypes conferring 
resistance would differ in a manner depending on the inhibitor to which resistance was 
acquired.  We therefore sought to test this hypothesis by following changes in proteasome 
composition and activities in a single, proteasome inhibitor-sensitive cell line once 
resistance to the clinically-relevant proteasome inhibitors bortezomib and carfilzomib was 
acquired, and assessing how these changes correlate with the effects of bortezomib and 
carfilzomib on the proteasome’s various catalytic activities.     
 
5.2 Results 
5.2.1 Cell Line Models of Acquired Proteasome Inhibitor Resistance 
We first generated cell line models of acquired bortezomib and carfilzomib 
resistance for use in testing our hypothesis.  The H23 non-small cell lung cancer (NSCLC) 
cell line was selected for this purpose for the following reasons: (1) While a number of 
research groups have investigated mechanisms of acquired bortezomib resistance using 
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hematologic cancer cell line models, only a few have examined these mechanisms in solid 
cancer cell lines, and therefore a greater knowledge gap exists in this area, (2) 
Encouraging results of preclinical and clinical studies have rationalized further examining 
the applications of proteasome inhibitors in NSCLC therapy [347, 348], (3) Prior 
immunoblotting analyses conducted by members of our laboratory showed that, in 
comparison with other NSCLC cell lines, H23 cells express immunosubunits β1i and β5i 
at relatively high levels; as the constitutive subunits are also expressed in H23 cells, this 
indicates their potential to form multiple proteasome subtypes, and (4) Cell viability assays 
previously conducted in our laboratory demonstrated that H23 cells are, in comparison 
with other NSCLC cell lines, relatively intrinsically sensitive to bortezomib and carfilzomib, 
therefore allowing a comparison of the changes that occur when an initially sensitive cell 
line becomes resistant to these inhibitors.  H23 cells were cultured in the continuous 
presence of gradually increasing concentrations of bortezomib or carfilzomib until they 
were able to survive and proliferate in the presence of a final concentration of 150 nM 
bortezomib or 1 μM carfilzomib.  These concentrations exceed the respective IC50 values 
of these inhibitors in parental H23 cells by ~28- and ~55-fold, respectively (Table 5.1).  We 
then collected the cells when they were growing in the presence of bortezomib or 
carfilzomib, or following a 7 day recovery period, for our analyses.  Replicate cell lines 
resistant to each inhibitor (referred to as bortezomib-resistant cell lines #1 and #2 [BtzR#1 
and #2] and carfilzomib-resistant cell lines #1-3 [CfzR #1-3]) were generated to evaluate 
the consistency of the experimental results.  
 
Table 5.1 Cell line models of acquired bortezomib (BtzR) and carfilzomib (CfzR) 
resistance 
 
Cell Lines Parental Cell Line IC50 (nM) Final Concentration (nM)  
H23 BtzR 5.4 150 (~28X parental IC50) 
H23 CfzR 18.3 1,000 (~55X parental IC50) 
 
The IC50 values of bortezomib and carfilzomib in parental H23 cells, and the final 
concentrations of each inhibitor to which resistance was established, are listed. Cell 
viability (IC50) data for the parental H23 cell line were acquired by Min Jae Lee.   
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5.2.2 Proteasome Catalytic Activities of Inhibitor-Exposed Cells 
While some cancer cells tolerate partial inhibition of proteasome activity better than 
others, prolonged exposure to inhibitor concentrations that achieve stronger inhibition of 
total proteasome activity should induce growth arrest and cell death even in relatively 
insensitive cells.  As a first step in determining how our bortezomib- and carfilzomib-
resistant cell lines are able to survive the continuous presence of high concentrations of 
bortezomib or carfilzomib, respectively, we first assessed which of the proteasome’s 
catalytic subunits were inhibited in these cell lines, and to what extents, under conditions 
of continuous exposure to 150 nM bortezomib or 1 μM carfilzomib, respectively, reasoning 
that insufficient proteasome inhibition could contribute to their survival under such 
conditions.  The use of fluorogenic peptide substrates that are selectively hydrolyzed by 
specific catalytic proteasome subunits [76, 181] allowed us to selectively measure the 
activities of individual subunits in lysates obtained from the parental, bortezomib-, and 
carfilzomib-resistant cells.  Each activity measured in the resistant cell lines was 
expressed as a percentage of that measured in untreated parental H23 cells.  For 
comparison, we treated parental H23 cells with these same concentrations of bortezomib 
or carfilzomib.  The treatment period for the parental cells was reduced to 4 hours to 
prevent the onset of cell death pathways [242].  We envisioned that any differences in 
activity patterns between the inhibitor-exposed parental and resistant cell lines could 
provide insight into underlying resistance mechanisms.  Additionally, as such differences 
could result from the enhanced formation of specific proteasome subtypes in the inhibitor-
resistant cell lines from those formed in the parental cell line, their detection would be in 
keeping with our hypothesis. 
 
a. Effects of Bortezomib Exposure 
As expected [174, 180, 207, 243-245], 150 nM bortezomib inhibited most of the β5 
and β5i activities in parental H23 cells (Figure 5.1 A).  It also almost completely inhibited 
the β1 and β1i activities, which were previously reported to be secondary targets that are 
bound at clinically relevant concentrations of bortezomib [200, 204, 207, 243] (Figure 5.1 
A).  In contrast, the β2/β2i activity was only inhibited by ~50%, which is in agreement with 
previous results showing the poor targeting of these subunits by bortezomib [174, 180, 
204, 207, 243-245] (Figure 5.1 A). 
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Figure 5.1 Effects of bortezomib or carfilzomib exposure on proteasome catalytic 
activities in the parental, BtzR, and CfzR H23 cell lines 
A) Activity profile of parental H23 cells exposed to 150 nM bortezomib. B) Activity profile 
of BtzR H23 cells continuously maintained in the presence of 150 nM bortezomib. C) 
Activity profile of parental H23 cells exposed to 1 μM carfilzomib. D) Activity profile of CfzR 
H23 cells continuously maintained in the presence of 1 μM carfilzomib. Values represent 
the averages of three replicates, and error bars indicate standard deviations. 
 
When we examined the activity profiles of the BtzR cells maintained under 
continuous bortezomib exposure, clear differences from that of the bortezomib-treated 
parental cells were observed.  Although secondary bortezomib targets β1 and β1i were 
fully inhibited in both BtzR cell lines (Figure 5.1 B), as observed in the bortezomib-treated 
parental cells (Figure 5.1 A), we detected residual activities of primary targets β5 and β5i 
(Figure 5.1 B), in contrast to the near complete inhibition of these activities by bortezomib 
in the parental cells (Figure 5.1 A).  β5 activity was even increased in bortezomib-exposed 
BtzR#1 cells relative to that of the untreated parental cells (Figure 5.1 B).  Strikingly, the 
β2/β2i activity of both BtzR cell lines was considerably increased over that of the untreated 
parental cells, despite the presence of bortezomib (Figure 5.1 B).  Although the responses 
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of the β5 and β5i activities to bortezomib differed between the two BtzR cell lines, the rank 
order of proteasome activities detected, ranging from strongly elevated to completely 
inhibited, was similar in both: β2/β2i > β5 > β5i > β1 = β1i (Figure 5.1 B).  These results 
indicate that enhanced β2/β2i activity and residual β5 and β5i activities may be important 
in surviving continuous bortezomib exposure. 
 
b. Effects of Carfilzomib Exposure 
In contrast to the effects of 150 nM bortezomib on parental H23 cells, which left 
the β2/β2i activity partially intact (Figure 5.1 A), treatment of parental H23 cells with 1 μM 
carfilzomib abolished all proteasome catalytic activity (Figure 5.1 C), on par with previous 
findings [174].  However, residual activities of all of the constitutive proteasome and 
immunoproteasome catalytic subunits were detected in all three CfzR cell lines, despite 
their prolonged exposure to carfilzomib (Figure 5.1 D).  As observed in both BtzR cell lines 
cultured in the presence of bortezomib (Figure 5.1 B), residual activities of primary 
carfilzomib targets β5 and β5i were detectable in all three CfzR cell lines (Figure 5.1 D).  
However, the suppression of β5 activity by at least 50% relative to parental levels in all 
three CfzR cell lines (Figure 5.1 D) contrasted the elevated β5 activity over parental levels 
detected in the bortezomib-exposed BtzR#1 cell line (Figure 5.1 B). 
While both the BtzR and the CfzR cell lines displayed residual β5 and β5i activities 
in the presence of bortezomib and carfilzomib, respectively, the activities of the remaining 
catalytic subunits were differentially impacted under these conditions in the CfzR cell lines 
than in the BtzR cell lines.  The β2/β2i activity, which was strongly increased over parental 
levels in both BtzR cell lines (Figure 5.1 B), remained similar to parental levels in all three 
CfzR cell lines (Figure 5.1 D).  β1 activity was elevated, while the activity of its 
immunosubunit counterpart, β1i, was incompletely suppressed, in all three CfzR cell lines 
in comparison with those of untreated parental H23 cells (Figure 5.1 D).  This contrasts 
the complete inhibition of both β1 and β1i activities by bortezomib in both BtzR cell lines 
(Figure 5.1 B).  Despite variations in the degree to which certain catalytic activities were 
altered in these cell lines in the presence of carfilzomib, the rank order of residual activities, 
ranging from elevated (<2-fold) to predominantly suppressed, was similar across all three 
cell lines: β1 > β2/β2i > β1i > β5 > β5i (Figure 5.1 D).  Of note, the preferred targets of 
carfilzomib were, in fact, those whose activities were suppressed to the greatest extent 
(Figure 5.1 D) (unlike what we observed for bortezomib [Figure 5.1 B]).  These findings 
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suggest that elevated β1 activity and fully retained β2/β2i activity may allow the CfzR cells 
to tolerate continuous carfilzomib exposure. 
 
5.2.3 Proteasome Catalytic Subunit Expression Levels of Inhibitor-Exposed Cells 
a. Bortezomib-Resistant Cells 
To determine whether the differential impacts of bortezomib on the various 
proteasomal catalytic activities in the parental and BtzR cell lines (Figure 5.1 A and B) 
may be attributed to the differential expression of the subunits responsible for these 
activities, we assessed the expression levels of these subunits via immunoblotting.  In 
comparison with untreated parental H23 cells, the most prominent changes observed were 
the upregulation of constitutive catalytic subunits β5, β1, and β2 in both BtzR cell lines 
(Figure 5.2 A).  The structural proteasome subunit α5 was also upregulated in both BtzR 
cell lines (Figure 5.2 A).  Alternatively, immunosubunit β5i was downregulated in BtzR#1 
and, to a lesser extent, in BtzR#2, while β1i was downregulated only in BtzR#1 (Figure 
5.2 A).  As the most striking result of the proteasome activity assays was the marked 
increase in β2/β2i activity in both bortezomib-exposed BtzR cell lines in comparison with 
that of parental H23 cells (Figure 5.1 B), we expected to see a strong increase in β2 and/or 
β2i levels in the BtzR cell lines.  In contrast, we observed a comparable increase in β2 to 
that observed for β5 and β1 (Figure 5.2 A), while β2i expression remained below readily 
detectable levels (data not shown).  Furthermore, the upregulation of β1 in both BtzR cell 
lines (Figure 5.2 A) apparently could not protect against its full inhibition by bortezomib 
(Figure 5.1 B).  Finally, despite the higher levels of proteasome subunit α5—which is 
common to all proteasome subtypes—in BtzR#2 than in BtzR#1 (Figure 5.2 A), overall 
proteasome activity under continuous bortezomib exposure was higher in BtzR#1 
(possibly indicating weaker inhibition) than in BtzR#2 (Figure 5.1 B).  Collectively, these 
results indicate that changes in the expression levels of the catalytic proteasome subunits 
had occurred in the BtzR cell lines during prolonged exposure to bortezomib, but that 
these changes alone cannot fully explain the proteasome activity profiles observed.   
 
b. Carfilzomib-Resistant Cells 
A comparison of the proteasome catalytic subunit expression levels between the 
parental and CfzR cell lines revealed that, despite the detection of residual β5 activity in 
all three CfzR cell lines under continuous carfilzomib exposure (Figure 5.1 D), β5 
expression appeared to remain largely unaltered from parental levels (Figure 5.2 B).  This  
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Figure 5.2 Effects of continuous bortezomib or carfilzomib exposure on the 
expression levels of catalytic proteasome subunits 
A) The expression levels of catalytic proteasome subunits are altered BtzR cells 
maintained under continuous bortezomib exposure relative to those of bortezomib-naïve 
parental H23 cells. B) The expression levels of catalytic proteasome subunits are altered 
CfzR cells maintained under continuous carfilzomib exposure relative to those of 
carfilzomib-naïve parental H23 cells.  
 
contrasts the overexpression of β5 seen in both BtzR cell lines (Figure 5.2 A) and indicates 
that overexpression of this subunit cannot explain the residual β5 activity observed.  
Furthermore, all of the β5 detectable by immunoblotting appeared to be covalently 
modified by carfilzomib, as indicated by the upward shift of the β5 band for the CfzR cell 
lines in comparison with that for the parental H23 cell line (Figure 5.2 B and data not 
shown).  As observed for both BtzR cell lines (Figure 5.2 A), β5i expression was decreased 
in all three CfzR cell lines in comparison with that of parental H23 cells (Figure 5.2 B).  
Like β5, all of the β5i detectable by immunoblotting appeared to be covalently modified by 
carfilzomib (Figure 5.2 B and data not shown).  Additionally, the failure of carfilzomib to 
completely inhibit the β1i activity (Figure 5.1 D) was not due to an upregulation of β1i, 
since the expression of this subunit was reduced in all three CfzR cell lines when grown 
under continuous carfilzomib exposure (Figure 5.2 B).  Decreases in these two 
immunosubunits appeared to be greater than those observed in the BtzR cell lines (Figure 
5.2 A and B).   
In contrast to the bortezomib-exposed BtzR cell lines (Figure 5.2 A), increases in 
β1 expression over parental levels in the carfilzomib-exposed CfzR cells were more 
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modest (Figure 5.2 B).  This indicates that the high residual β1 activity detected in these 
cell lines (Figure 5.1 D) cannot be attributed to a strong upregulation of the β1 subunit.  β2 
expression was also increased in all three CfzR cell lines relative to that of parental H23 
cells (Figure 5.2 B), similar to our observations in the BtzR cell lines (Figure 5.2 A).  We 
were again unable to readily detect the β2i subunit in the CfzR cells (data not shown).  
Finally, α5 expression levels were elevated (although only slightly) in all three CfzR cell 
lines (Figure 5.2 B), as observed in the BtzR cell lines (Figure 5.2 A).  In contrast to the 
BtzR cell lines, however, the rank order of α5 expression across the three CfzR cell lines 
(Figure 5.2 B) appeared to agree with the rank order of total residual proteasome activity 
in these cell lines in the presence of carfilzomib (Figure 5.1 D).  However, these results 
collectively indicate that, as for the bortezomib-exposed BtzR cell lines, the observed 
changes in expression of the individual catalytic proteasome subunits cannot fully account 
for the activity profiles observed for the CfzR cell lines maintained under continuous 
carfilzomib exposure.  Additionally, they confirm a lack of (at least complete) covalent 
modification of β1, β1i, and β2 by carfilzomib in the CfzR cell lines, which is consistent 
with the activity assay results and suggests that the binding of carfilzomib to these subunits 
is somehow impeded in the CfzR cell lines. 
 
Our activity assays revealed an incomplete suppression or an elevation of specific 
proteasome activities in the BtzR and CfzR H23 cells maintained under continuous 
inhibitor exposure (Figure 5.1 B and D).  Additionally, our immunoblotting analyses of 
these cells revealed that the expression levels of individual catalytic proteasome subunits 
were altered relative to those of the parental H23 cells, indicating a shift in the abundances 
of particular proteasome subtypes (Figure 5.2 A and B).  Although, for many of these cell 
lines, the immunoblotting data obtained may be consistent with an overall downregulation 
of immunoproteasomes (especially for the CfzR cell lines) and upregulation of constitutive 
proteasomes (especially for the BtzR cell lines), these data alone are insufficient to 
definitively determine which subtypes of proteasomes are formed in each cell line.  Since 
most of the catalytic proteasome subunits are incorporated into more than one 
proteasome subtype [226], a change in the level of a given subunit could reflect a change 
in the abundance(s) of one, or of more than one, subtype into which that subunit 
incorporates.  As the individual catalytic activities of distinct proteasome subtypes appear 
to be differentially impacted by proteasome inhibitors [231, 232], a relative increase in 
subtypes that are less efficiently inhibited by bortezomib or carfilzomib and a relative 
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decrease in those that are more efficiently inhibited could, at least partially, explain the 
incomplete inhibition of specific proteasome activities observed and, therefore, the 
reduced sensitivities of the BtzR and CfzR cell lines to bortezomib and carfilzomib, 
respectively. 
 
5.2.4 Proteasome Activity Profiles of Inhibitor-Resistant Cells 
Different subtypes of proteasomes have been shown to display different proteolytic 
activity profiles [224-226, 229-232, 235], and these differences may contribute to the 
apparent discrepancies between our activity assay and immunoblotting data.  However, 
such differences in activity profiles are difficult to identify in samples from inhibitor-exposed 
cells, as it is difficult to discern whether a particular activity is elevated or suppressed due 
to the effects of inhibitor binding, altered catalytic subunit composition, or both.  Therefore, 
to further examine whether the relative levels of particular subtypes may differ between 
the inhibitor-resistant and parental H23 cell lines, we again measured the various 
proteasome activities in the inhibitor-resistant cell lines, this time following a 7 day inhibitor 
withdrawal to exclude the effects of the inhibitors on these activities. 
 
a. Proteasome Activity Profiles of Bortezomib-Resistant Cells 
Following bortezomib withdrawal, we again noted differences in the regulation of 
β5 activity in the two BtzR cell lines: this activity returned to parental levels in BtzR#1, 
while it was elevated >2-fold over parental levels in BtzR#2 (Figure 5.3 A).  We also 
observed differences in the regulation of β5i activity, which, relative to parental levels, 
remained reduced in BtzR#1 to levels similar to those observed in the presence of 
bortezomib, but was increased in BtzR#2 (Figure 5.3 A).  Interestingly, the higher β5 and 
β5i activities following bortezomib withdrawal were observed for the cell line in which they 
were most suppressed in the presence of bortezomib (Figures 5.1 B and 5.3 A).  
Conversely, β1 activity, which was completely inhibited in the presence of bortezomib 
(Figure 5.1 B), was increased following bortezomib withdrawal in both BtzR cell lines 
(Figure 5.3 A).  However, in contrast to β1 activity, β1i activity, which was also completely 
inhibited in the presence of bortezomib (Figure 5.1 B), was differentially regulated 
following withdrawal in the two BtzR cell lines: this activity was decreased in BtzR#1, but 
increased in BtzR#2, relative to parental levels, following suit the trend observed for β5i 
activity (Figure 5.3 A).  Interestingly, β2/β2i activity remained highly elevated  
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Figure 5.3 Proteasome activity profiles in inhibitor-withdrawn BtzR and CfzR H23 
cell lines 
A) Proteasome activity profiles of BtzR H23 cells following a 7 d withdrawal from 
bortezomib. B) Proteasome activity profiles of CfzR H23 cells following a 7 d withdrawal 
from carfilzomib. Values represent the averages of three replicates, and error bars indicate 
standard deviations. 
 
relative to parental levels in both BtzR cell lines following bortezomib withdrawal (Figure 
5.3 A).  However, relative to the level of β2/β2i activity observed in each cell line in the 
presence of bortezomib (Figure 5.1 B), the level of this activity following withdrawal was 
decreased in BtzR#1 and further increased in BtzR#2 (Figure 5.3 A).  These results show 
that the proteasome activity patterns of the BtzR cell lines measured following bortezomib 
withdrawal remained altered in comparison with that of the parental cell line (Figure 5.3 
A), demonstrating that the effects observed in cells maintained under continuous 
bortezomib exposure (Figure 5.1 B) were not solely a direct result of inhibitor binding.  This 
is consistent with our hypothesis that the abundances of specific proteasome subtypes 
become altered when cells acquire resistance to bortezomib, and that these alterations 
persist after removal of this inhibitor.  Intriguingly, our findings obtained with the BtzR cell 
lines also demonstrate that, with respect to overall proteasome activity, stronger inhibition 
in the presence of bortezomib is associated with a larger increase following bortezomib 
withdrawal. 
 
b. Proteasome Activity Profiles of Carfilzomib-Resistant Cells 
A similar examination in the CfzR cell lines following carfilzomib withdrawal also 
revealed that the proteasome activity patterns of these cell lines remained altered in 
comparison with that of the parental cell line.  We found β5 activity to be increased in all 
three CfzR cell lines (Figure 5.3 B).  β1 activity, which was increased over parental levels 
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even in cells continuously exposed to carfilzomib (Figure 5.1 D), remained elevated in all 
three CfzR cell lines following carfilzomib withdrawal (Figure 5.3 B).  β1 activity was also 
increased in the BtzR cell lines following bortezomib withdrawal (Figure 5.3 A), albeit 
following substantial inactivation of this activity in the presence of bortezomib (Figure 5.1 
B).  β2/β2i activity, which remained similar to parental levels in all three CfzR cell lines 
under continuous carfilzomib exposure (Figure 5.1 D), did vary from parental levels in 
these cell lines following carfilzomib withdrawal.  The activity of these subunits was slightly 
decreased relative to parental levels in CfzR#1, but was increased in the other two CfzR 
cell lines (Figure 5.3 B).  This contrasts the more strongly enhanced β2/β2i activity 
observed in the BtzR cell lines cultured in both the presence and absence of bortezomib 
(Figures 5.1 B and 5.3 A).  Finally, β5i and β1i activities were both reduced relative to 
parental levels in CfzR#1 and CfzR#3, but remained similar to parental levels in CfzR#2, 
following carfilzomib withdrawal (Figure 5.3 B).  As observed for the BtzR cell lines 
(Figures 5.1 B and 5.3 A), the greater the β5 and β5i activities were suppressed in the 
presence of carfilzomib, the more they were increased relative to parental levels following 
carfilzomib withdrawal (Figures 5.1 D and 5.3 B).  The β1 and β1i activities followed this 
trend as well (Figures 5.1D and 5.3 B).  Collectively, these altered activity patterns are, 
again, in line with the hypothesis that the CfzR cells contain altered amounts of specific 
proteasome subtypes relative to those of the parental cells, and suggest that a greater 
suppression of proteasome activity during carfilzomib exposure leads to a greater 
elevation of proteasome activity following withdrawal of the inhibitor. 
 
5.2.5 Proteasome Catalytic Subunit Expression Levels of Inhibitor-Withdrawn 
Cells 
To determine whether these differences in proteasome activity profiles between 
parental and inhibitor-resistant cell lines were reflected by differences in the overall 
expression levels of the catalytic proteasome subunits that persisted following inhibitor 
withdrawal, we again analyzed the expression levels of these subunits in each cell line 
following the 7 day inhibitor withdrawal period via immunoblotting. 
 
a. Bortezomib-Resistant Cells 
We did, in fact, observe that proteasome catalytic subunit composition remained 
altered in the BtzR cell lines, relative to that of the parental cells, following bortezomib 
withdrawal, especially with respect to immunosubunits β5i and β1i.  The differential 
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regulation observed for the β5i and β1i activities in the two BtzR cell lines (Figure 5.3 A) 
was reflected by their expression levels, which both remained decreased relative to 
parental levels in BtzR#1 yet were increased above parental levels in BtzR#2 (Figure 5.4 
A).  β1 expression was also relatively consistent with the β1 activity data, with expression 
being higher in the cell line with higher β1 activity (BtzR#2) (Figures 5.3 A and 5.4 A).  
However, despite the observed differential regulation of β5 activity in the two BtzR cell 
lines following bortezomib withdrawal (Figure 5.3 A), their levels of expression of this 
subunit was similar (Figure 5.4 A).  As observed for the BtzR cell lines under continuous 
bortezomib exposure (Figures 5.1 B and 5.2 A), the β2 expression data obtained following 
bortezomib withdrawal is difficult to reconcile with the β2/β2i activity measured; while β2 
expression was slightly decreased and increased in BtzR#1 and BtzR#2, respectively, 
relative to parental levels (Figure 5.4 A), the β2/β2i activity remained elevated to ~330-
440% of parental levels (Figure 5.3 A).  In contrast to our observations obtained with the 
BtzR cells continuously exposed to bortezomib (Figures 5.1 B and 5.2 A), following 
bortezomib withdrawal, α5 expression remained elevated in the cell line with the highest 
overall proteasome activity (BtzR#2) but reverted to parental levels in the cell line with 
lower overall proteasome activity (BtzR#1) (Figures 5.3 A and 5.4 A).  Collectively, these 
findings indicate that the proteasome activity patterns of these cell lines are partially, but 
not solely, determined by their overall expression levels of each catalytic proteasome 
subunit.  That overall proteasome activity following bortezomib withdrawal was higher in 
the cell line in which it was most suppressed during continuous bortezomib exposure 
indicates that cellular mechanisms are in place to sense the extent to which proteasome 
activity is impaired and to adjust proteasome complexes accordingly to allow the 
appropriate degree of compensation following removal of the inhibitor. 
 
b. Carfilzomib-Resistant Cells 
As observed for the BtzR cell lines (Figure 5.4 A), the overall proteasome catalytic 
subunit composition in the CfzR cell lines, when compared against that of the parental cell 
line, also remained altered following carfilzomib withdrawal.  Again, there were some 
discrepancies between the expression levels and activities of certain catalytic proteasome 
subunits.  For instance, the sustained increase in β1 activity detected in all three CfzR cell 
lines following carfilzomib withdrawal (Figure 5.3 B) was apparently not obtained by an 
increase in β1 expression under these conditions (Figure 5.4 B).  Additionally, while the 
increased β5 activity observed in CfzR#3 following carfilzomib withdrawal was paralleled  
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Figure 5.4 Expression levels of catalytic proteasome subunits in inhibitor-
withdrawn BtzR and CfzR H23 cell lines 
A) Expression levels of catalytic proteasome subunits and structural proteasome subunit 
α5 in the BtzR cell lines following a 7 d bortezomib withdrawal are compared with those of 
bortezomib-naïve parental H23 cells. B) Expression levels of catalytic proteasome 
subunits and structural proteasome subunit α5 in the CfzR cell lines following a 7 d 
carfilzomib withdrawal are compared with those of carfilzomib-naïve parental H23 cells. 
 
by an increase in β5 expression, a comparable increase in β5 activity was observed in 
CfzR#2 in the absence of a similar β5 upregulation (Figures 5.3 B and 5.4 B).  Conversely, 
the reduced β5i activities, relative to that of the parental cells, observed in CfzR#1 and 
CfzR#3, and the near parental levels of this activity in CfzR#2, following carfilzomib 
withdrawal (Figure 5.3 B) were reflected at the protein level (Figure 5.4 B).  Like the β5i 
activity, β1i activity was reduced relative to parental levels in CfzR#1 and CfzR#3, but 
remained similar to parental levels in CfzR#2, following carfilzomib withdrawal (Figure 5.3 
B).  This was also in relatively good agreement with the levels of the β1i protein; however, 
the similar levels of β1i activity in CfzR#1 and CfzR#3 were not reflected by similar levels 
of β1i expression, which were lower in CfzR#3 than in CfzR#1 (Figures 5.3 B and 5.4 B).  
The levels of β2/β2i activity observed in the CfzR cell lines following carfilzomib withdrawal 
did not correlate with the expression levels of the β2 subunit.  Although the β2/β2i activity 
was increased to differing extents in CfzR#2 and CfzR#3, and was slightly decreased in 
CfzR#1, relative to parental levels (Figure 5.3 B), β2 expression was elevated to a similar 
extent above parental levels in all three of these cell lines (Figure 5.4 B).  Conversely, β2i 
expression remained below readily detectable levels (data not shown).  Finally, α5 
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expression was increased above parental levels to a similar extent in CfzR#1 and CfzR#2, 
but was increased to a greater extent in CfzR#3 (Figure 5.4 B).  Collectively, these results 
indicate that, as observed for the bortezomib-withdrawn BtzR cells, the expression levels 
of each catalytic proteasome subunit in the carfilzomib-withdrawn CfzR cells, taken at face 
value, are only partially consistent with the activity profiles observed.  This suggests that 
other factors aside from the overall cellular levels of each subunit modulate their catalytic 
activities.  Additionally, these results, too, are consistent with the ability of the CfzR cells 
to sense the degree of proteasome inhibition and to compensate accordingly following 
carfilzomib withdrawal. 
 
5.2.6 Identifying Proteasome Subtypes 
Our activity assay and immunoblotting analyses clearly demonstrated that the 
emergence of bortezomib and carfilzomib resistance in H23 cells was accompanied by 
changes in the overall levels of expression and activity of the various catalytic proteasome 
subunits.  While this supports a shift in the relative abundances of specific proteasome 
subtypes in the inhibitor-resistant cell lines, the identity of the subtypes formed in each cell 
line remained elusive.  We thus began experiments with the bifunctional proteasome 
probes described in Chapter 4 to identify, and to determine the relative abundances of, 
the discrete proteasome subtypes present in the parental and inhibitor-resistant cells.  
First, we treated lysates from the parental, BtzR#1, and CfzR#2 cell lines with UKP13-
(PEG)4-NC012 (probe 6).  U266 cell lysates were also treated with this probe for use as a 
positive control for detecting catalytic subunit crosslinking.  Upon immunoblotting analysis, 
we found that probe 6 crosslinks β1i in all three H23 cell lines with a single catalytic subunit 
(Figure 5.5).  The band representing crosslinked β1i migrated similarly on the SDS-PAGE 
gel to the top crosslinked β1i band detected for the U266 cell line, which represents a β1i-
β2 crosslinked subunit pair [239] (see also Chapter 4).  However, the intensity of this band 
varied across the three cell lines in a manner that was relatively consistent with the 
expression level of β1i itself—it was lower than that detected for the parental cells in 
BtzR#1 and higher in CfzR#2—consistent with most or all β1i-containing subtypes in all 
three H23 cell lines also containing β2.  If, as indicated by previous findings [221-223], 
β1i-β2-containing subtypes also contain β5i and not β5, then our results indicate that all 3 
cell lines predominantly or exclusively harbor β1i-containing subtypes of the β1i-β2-β5i 
variety but vary in their levels of this subtype.   
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Figure 5.5 Differential regulation of an intermediate proteasome subtype in BtzR 
and CfzR cell lines 
Lysates obtained from the H23 parental, BtzR#1 and CfzR#2 cell lines cultured in the 
absence of inhibitor for 7 d were treated with probe 6 to crosslink β1i with β2 and/or β2i, 
and the identity and abundance of the crosslinked subunit pair was evaluated via 
immunoblotting. A probe 6-treated lysate obtained from U266 cells, which are known to 
harbor β1i-containing proteasome subtypes containing either β2 or β2i [239], served as a 
positive control, while untreated H23 cells (lane 1) served as a negative control. 
Crosslinked β1i is represented by the band(s) just below 50 kDa. The top crosslinked β1i 
band detected for the U266 cell line results from β1i-β2 crosslinking, while the bottom 
crosslinked β1i band results from β1i-β2i crosslinking [239]. The single crosslinked β1i 
band for the three H23 cell lines aligns with the top crosslinked β1i band detected for the 
U266 cell line, indicating that the majority of the β1i-containing proteasome subtypes 
present in the H23 cell lines also contain β2 rather than β2i. Irrelevant lanes were removed. 
CL = crosslinked β-subunit. * = nonspecific band. Data acquired with the assistance of Min 
Jae Lee. 
 
Our failure to detect β1i-containing subtypes that also contain β2i in any of the H23 
cell lines is in agreement with our difficulty in detecting the β2i subunit in these cell lines 
via immunoblotting with an anti-β2i antibody (Figure 5.5 and data not shown).  Whether 
these cell lines fail to assemble detectable levels of proteasome subtypes containing both 
β1i and β2i due to their inability to express sufficient levels of β2i remains unknown.  As 
β5i can more promiscuously incorporate into proteasome subtypes containing multiple 
combinations of catalytic subunits (i.e., β1-β2-β5i, β1i-β2-β5i, and β1i-β2i-β5i) [220-223], 
it would be interesting to determine whether the relative levels of these β5i-containing 
subtypes differ between the parental and resistant cell lines, especially since all three cell 
lines detectably express all of the subunits of the former two subtypes.  Although we 
attempted to evaluate this, we have so far been unable to obtain clear results due to 
technical difficulties that arose during the immunoblotting experiments.  This may be 
further pursued by other members of our laboratory in the future.  Based on the lack of 
detectable β2i expression, one may expect to find one or two β5i-containing subtypes in 
these cell lines—β1-β2-β5i and/or β1i-β2-β5i [226]—and, if the relative levels of these 
121 
subtypes are altered in the inhibitor-resistant cells, this would indicate that whether β5i is 
preferentially assembled into β1- or β1i-containing proteasomes when all of these subunits 
are co-expressed may play a causal role in the resistance phenotypes observed.    
 
5.3 Discussion 
We conducted the experiments described in this chapter to test the hypothesis that 
the altered abundances of specific proteasome subtypes serve as a mechanism of 
acquired bortezomib and carfilzomib resistance.  We were able to establish variants of the 
H23 NSCLC cell line that survive exposure to a concentration of bortezomib that almost 
completely inhibits the activities of four of the six catalytic proteasome subunits, and 
inhibits half of that of the β2-type subunits, in the parental cell line.  Additionally, we 
successfully established variants of this cell line that are resistant to a concentration of 
carfilzomib that fully inactivates all proteasome activities in the parental cells.  We 
identified specific alterations in the levels of expression and activity of the various catalytic 
proteasome subunits that were associated with acquired resistance to each inhibitor.  
These changes were accompanied by the retention of substantial levels of specific 
proteasome activities in the resistant cell lines under exposure to these inhibitors, 
consistent with our hypothesis that changes in proteasome composition contribute to 
acquired proteasome inhibitor resistance. 
The most obvious changes in proteasome composition emerging in the BtzR H23 
cells following prolonged bortezomib exposure were increases in β5, β1, and β2 
expression.  We also observed decreased β5i expression in these cells (Figure 5.2 A).  
These findings are consistent with those obtained with other bortezomib-resistant cell lines 
[209, 246, 280, 285, 288, 289, 298, 313, 315, 329, 330, 332, 333], indicating that these 
changes may be generally important in conferring bortezomib resistance. 
As observed in bortezomib-exposed parental H23 cells, full inactivation of the β1 
and β1i subunits was achieved under continuous bortezomib exposure in both BtzR cell 
lines (Figure 5.1 A and B).  However, residual activities of primary targets β5 and β5i, and 
especially of weakly-targeted β2 and β2i, appear to compensate for this loss (Figure 5.1 
B).  Notably, while β5 activity was partially impaired in the bortezomib-exposed BtzR#2 
cell line, this activity was in fact elevated over that of untreated parental cells in the BtzR#1 
cell line, despite the presence of bortezomib (Figure 5.1 B).  The increased rather than 
suppressed β5 activity detected in BtzR#1 may be attributed in part to upregulation of the 
β5 subunit; however, a similar effect on β5 activity was not observed in BtzR#2 under 
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these conditions, despite a comparable degree of β5 upregulation (Figures 5.1 B and 5.2 
A).  It is possible that BtzR#1 cells could harbor a β5 mutation that impairs bortezomib 
binding to the β5 active site [246, 289, 298, 311, 313-315], although such a mutation may 
be expected to similarly impair substrate binding, an effect that has, in fact, been reported 
for the β5/β5i-selective substrate Suc-LLVY-AMC by other research groups [246, 289, 
313].  Therefore, the finding that our BtzR#1 cell line displayed enhanced and not reduced 
hydrolysis of this substrate may argue against a β5 mutation.  Nevertheless, this effect 
may differ depending on the specific mutation as well as on the substrate used to measure 
the β5 activity.  As inhibitors with different structural properties from those of bortezomib 
have been suggested to retain greater efficiency in binding mutant β5 subunits than 
bortezomib itself [246, 280, 298, 315, 318, 337], perhaps the ability of our BtzR cells to 
hydrolyze the Ac-WLA-AMC substrate could remain largely intact, even if a β5 active site 
mutation that impairs the hydrolysis of Suc-LLVY-AMC is present.  Despite this possibility, 
bortezomib also inhibited the β5i activity of BtzR#1 more weakly than that of BtzR#2 
(Figure 5.1 B), perhaps suggesting a more general mechanism of resilience of these two 
activities.   
We were surprised to find that bortezomib completely inhibited the activities of its 
secondary targets (β1 and β1i), but not those of its primary targets (β5 and β5i) (Figure 
5.1 B).  Presuming that bortezomib binding to β5 and β5i is not impaired, and, because 
free β5 and β5i subunits are not active in the cell (their active forms are instead confined 
to intact proteasomes, which also contain β1 or β1i), our results may suggest that 
bortezomib is able to dissociate more readily from the active sites of β5 and β5i than from 
those of β1 and β1i in the BtzR cell lines.  Furthermore, upregulation of β1 in both BtzR 
cell lines (Figure 5.2 A) was insufficient to prevent the complete depletion of the catalytic 
activity of this subunit under continuous bortezomib exposure (Figure 5.1 B).  This 
suggests that the upregulation of specific catalytic proteasome subunits alone is 
insufficient to prevent their full inhibition by exogenous inhibitors, which in turn implies that 
the upregulation observed may merely be part of a general stress response to proteasome 
inhibition rather than a cause of resistance.  However, the up- and downregulation of 
specific catalytic proteasome subunits may promote the increased assembly of specific 
proteasome subtypes whose activities are more resistant to total inhibition by the 
proteasome inhibitor applied and thereby indirectly contribute to the mechanism of 
resistance. 
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Although the observed increase in β2/β2i activity over parental levels in the 
bortezomib-exposed BtzR cell lines is itself unsurprising, its scale is somewhat surprising.  
Previously-reported increases in this activity in bortezomib-exposed cells were typically 
<2-fold [245, 246], whereas we observed an ~4-fold increase (Figure 5.1 B).  Additionally, 
in bortezomib-naïve H23 cells, such an increase was not observed; instead, 150 nM 
bortezomib partially reduced the β2/β2i activity in the parental cells (Figure 5.1 A).  
Furthermore, despite the strong elevation of β2/β2i activity above parental levels in both 
bortezomib-exposed BtzR cell lines (Figure 5.1 B), the increase in β2 expression under 
these conditions was comparable to that of β1 and β5, and we were still unable to readily 
detect expression of β2i (Figure 5.2 A and data not shown).  This is in further agreement 
with the conclusion that β2 and β2i expression levels alone cannot account for the 
observed alterations in β2/β2i activity; other factors likely contributed.  For example, it has 
been reported that inhibiting the proteasome’s C-L activity (which is attributed to the β1 
subunit) leads to an increase in its T-L activity (which is attributed to the β2 and β2i 
subunits), an effect that directly results from binding of an inhibitor to the β1 active site 
[349].  It is possible that such an effect could have contributed to the observed increase in 
β2/β2i activity in our BtzR cell lines, although, if this were the case, it is unclear why a 
similar effect was not observed in the parental cell line.  Alternatively, an increase in the 
abundances of proteasome subtypes with high T-L activity, or the association of 
proteasomes within these cells with a factor that activates this activity, may also account 
for our observations. 
While the higher α5 expression detected for bortezomib-exposed BtzR#2 than for 
bortezomib-exposed BtzR#1 (Figure 5.2 A) may seem inconsistent with this cell line’s 
comparatively lower proteasome activity (Figure 5.1 B), the latter observation may simply 
result from stronger proteasome inhibition in BtzR#2 than in BtzR#1.  However, unlike the 
catalytic β-subunits, the α5 subunit is not synthesized with an N-terminal propeptide that 
is cleaved during the proteasome assembly process, and the unincorporated versus 
proteasome-incorporated α5 subunits therefore do not differ in molecular weight and are 
indistinguishable based on immunoblotting.  As a result, it is possible that some of the 
detected α5 has not yet been incorporated into proteasome complexes.  Either way, the 
increased α5 expression of BtzR#2 compared with that of BtzR#1 could indicate that 
BtzR#1 cells are attempting to compensate for their greater suppression of proteasome 
activity by further upregulating proteasome expression.  This is consistent with the higher 
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overall expression levels and activities of catalytic proteasome subunits observed in 
BtzR#2 than in BtzR#1 following withdrawal from bortezomib (as discussed below). 
Collectively, these results suggest that the BtzR cells can survive and proliferate 
without the catalytic activities of β1 and β1i.  Perhaps this is only possible due to their high 
β2/β2i activity and residual β5 and β5i activities, which appear to be important in surviving 
continuous bortezomib exposure.  Residual proteasome activities were also concluded to 
be important for surviving bortezomib exposure by other research groups [184, 204, 209, 
246, 285, 289, 311-313, 337].  Our results also demonstrate that the expression levels of 
the various catalytic proteasome subunits are altered in bortezomib-resistant cells cultured 
under continuous bortezomib exposure in comparison with those of untreated parental 
H23 cells, but that these changes alone cannot account for the observed changes in 
proteasome activities.  These findings are consistent with our hypothesis that changes in 
proteasome composition contribute to the resistance phenotype by ensuring that 
substantial catalytic activity is maintained during bortezomib exposure.   
We were initially surprised to find that H23 cells could acquire resistance to a 
concentration of carfilzomib that renders the proteasome completely inactive in the 
parental cells (Figure 5.1 C).  However, the ability of carfilzomib to produce such a 
profound effect in parental H23 cells was clearly not retained in the CfzR cell lines.  As 
was the case for our BtzR cell lines (Figure 5.1 B), our CfzR cell lines were able to maintain 
significant proteasome function while under carfilzomib exposure (Figure 5.1 D), although 
this end was achieved through different means.   
All three CfzR cell lines maintained some residual β5 and β5i activities under 
continuous carfilzomib exposure (Figure 5.1 D), as did both bortezomib-exposed BtzR cell 
lines (Figure 5.1 B).  The finding that β5 expression remained largely similar to parental 
levels in the three carfilzomib-exposed CfzR cell lines (Figure 5.2 B) contrasts the elevated 
expression of this subunit observed in our bortezomib-exposed BtzR cell lines (Figure 5.2 
A) and demonstrates that β5 overexpression cannot account for the residual β5 activity 
detected under these conditions.  Likewise, the residual β5i activity is not attributable to 
an upregulation of β5i in the CfzR cells (Figure 5.2 B).  Also inconsistent with the residual 
β5 and β5i activities was our finding that all of the β5 and β5i in these cells detectable by 
immunoblotting analysis was covalently modified by carfilzomib (Figure 5.2 B).  It is 
therefore possible that these subunits remain completely bound by carfilzomib in the CfzR 
cell lines, and the perceived residual β5 and β5i activities are, in fact, mediated by non-
specific hydrolysis of the substrates used to measure their activities by the uninhibited 
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subunits.  This would be consistent with the notion that uninhibited subunits can 
compensate for the impaired catalytic activities of those that are inhibited.  A similar 
analysis of bortezomib binding could not be performed for the BtzR cells because, as a 
consequence of bortezomib’s irreversible binding mode, it dissociates from the 
proteasome’s active sites during immunoblotting sample preparation.   
Unlike the marked increase in β2/β2i activity detected in our BtzR cell lines cultured 
under continuous bortezomib exposure (Figure 5.1 B), the activity of these subunits was 
not upregulated in the carfilzomib-exposed CfzR cell lines (Figure 5.1 D), despite the 
elevated levels of β2 (Figure 5.2 B).  This can be highlighted as a major difference in the 
responses of H23 cells to the doses of bortezomib and carfilzomib to which resistance 
could be acquired: β2/β2i activity was only partially inhibited in the parental cells and was 
strongly increased in our BtzR cell lines, even in the presence of bortezomib (Figures 5.1 
A and B), whereas β2/β2i activity was fully inhibited by carfilzomib in the parental cells and 
remained at approximately parental levels in our CfzR cell lines (Figure 5.1 C and D).  
Although β2i has been reported as a secondary binding target of carfilzomib, our collective 
immunoblotting data seem to indicate a lack of significant levels of β2i-containing subtypes 
in any of these H23 cell lines.  Therefore, β2i binding by carfilzomib may not measurably 
impact the β2/β2i activity detected in our CfzR cell lines.  Unfortunately, a better 
discrimination of catalysis by β2 versus β2i awaits the development of substrates or 
inhibitors that can effectively distinguish between their two highly similar active sites [75]. 
In contrast to the unaltered β2/β2i activity, we did observe that β1 activity was 
elevated above parental levels in the CfzR cell lines, despite the presence of carfilzomib 
(Figure 5.1 D), an effect associated with only slight increases in β1 expression (Figure 5.2 
B).  This is also a major difference between the influence of bortezomib and carfilzomib 
on proteasome activities in the inhibitor-resistant cell lines, as bortezomib completely 
inhibited this activity in the BtzR lines (Figure 5.1 B).  Alternatively, the β1i activity was 
reduced in comparison with that of the parental cells, although it was not completely 
suppressed (Figure 5.1 D), unlike the complete inhibition of this activity in the BtzR cell 
lines under continuous bortezomib exposure (Figure 5.1 B).  Finally, the only slight 
increase observed in α5 levels in the CfzR cell lines (Figure 5.2 B) contrasts the more 
pronounced upregulation observed in the BtzR cell lines (Figure 5.2 A) and indicates that 
these cell lines are not compensating for impaired proteasome activity by massively 
overproducing proteasomes in general. 
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While activities of shared primary bortezomib and carfilzomib targets β5 and β5i 
were not those exhibiting the greatest degree of inactivation in our bortezomib-exposed 
BtzR cell lines (Figure 5.1 B), these were indeed the activities suppressed to the largest 
extent in our carfilzomib-exposed CfzR cell lines (Figure 5.1 D).  This could be due to the 
irreversible binding mode of carfilzomib, in contrast to the reversible one of bortezomib.  
Alternatively, it could be due to changes in the proteasome complexes in the BtzR cell 
lines that lower bortezomib’s binding affinity for the β5 and β5i subunits.  Also notable is 
the finding that, despite complete inhibition of all proteasome activities in parental cells 
treated with 1 μM carfilzomib (Figure 5.1 C), none of these activities were completely 
inhibited by carfilzomib in the CfzR cell lines (Figure 5.1 D).  These results may be 
consistent with the extrusion of carfilzomib from the CfzR cells by an efflux transporter 
such as P-glycoprotein, as we have previously observed in an independently generated 
carfilzomib-resistant H23 cell line [281] and has been reported as a resistance mechanism 
to carfilzomib [281-283] and epoxomicin [278].  Additionally or alternatively, they may be 
consistent with other cellular mechanisms operating to similarly prevent sufficient levels 
of carfilzomib from reaching the proteasome’s active sites to achieve a more complete 
proteasome inhibition in the CfzR cell lines (e.g., altered carfilzomib metabolism).  
However, our results suggest that at least enough carfilzomib is maintained within the 
CfzR cells to suppress the activities of its preferred binding targets by a considerable 
extent.  While selectively suppressing these activities was found to be cytotoxic to 
hematologic cancer cell lines [186], it was found in another study to poorly correlate with 
proteasome inhibitor-induced cytotoxicity [244].  It is therefore probable that inhibition of 
only the CT-L activity of the CfzR cell lines—especially while the T-L activity remains 
unaffected and the C-L activity is activated—is insufficient to arrest cell growth or induce 
cell death.  To what extent the inferior inhibition of proteasome activity in these cell lines 
results from P-glycoprotein-mediated efflux of carfilzomib, thereby only allowing sufficient 
levels to accumulate within these cells to inhibit β5 and β5i, from structural changes in 
proteasome complexes that lower carfilzomib’s binding affinity for the β1-type and β2-type 
subunits, or from some other mechanism, is worth further investigating. 
Taken together, our results suggest that increased β1 activity and full retention of 
β2/β2i activity (perhaps together with residual activities of primary carfilzomib targets β5 
and β5i) may be important in surviving continuous exposure to high concentrations of 
carfilzomib.  However, the increased β1 activity of the CfzR cells was not as pronounced 
as the increased β2/β2i activity observed in the BtzR cells.  Perhaps this is due to the 
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more selective reduction of β5 and β5i activities by carfilzomib in the CfzR cell lines (aside 
from those of β5 and β5i, carfilzomib did not inhibit any other catalytic activities in the CfzR 
cells beyond 20-40%) than by bortezomib in the BtzR cell lines (β1 and β1i activities were 
completely inhibited by bortezomib in the BtzR cells).  Therefore, the large increase in one 
particular activity appears to be less important in maintaining sufficient proteasome activity 
in the CfzR cells than in the BtzR cells, as, in the CfzR cells, substantial levels of the β1, 
β1i, β2, and β2i activities remain.   
Our findings also confirm that, as for the BtzR cell lines, catalytic proteasome 
subunit expression levels, in comparison with those of untreated parental H23 cells, are 
altered in the CfzR cell lines maintained under continuous carfilzomib exposure.  
Decreased expression of immunosubunits β1i and β5i was perhaps the most pronounced 
difference observed.  This is consistent with a recent report suggesting that 
immunosubunit expression is important for the cytotoxic effects of carfilzomib in mantle 
cell lymphoma cells [346].  Furthermore, as observed for the BtzR cell lines, the expression 
levels of individual catalytic subunits alone cannot account for the observed proteasome 
activity patterns of the CfzR cells cultured in the continuous presence of carfilzomib.  
Based on our collective observations, we conclude that these results are consistent with 
the hypothesis that changes in proteasome composition contribute to the apparently 
inferior inhibition of total proteasome activity by carfilzomib in the CfzR cell lines, and, 
therefore, to carfilzomib resistance.  However, it is very possible that P-glycoprotein-
mediated efflux of carfilzomib also plays a role in dampening its inhibitory efficacy by 
reducing its intracellular concentrations. 
Altered proteasome activity patterns and catalytic subunit expression levels 
remained apparent in the BtzR and CfzR cell lines following a 7 day inhibitor withdrawal.  
Since this withdrawal period was sufficient to allow full recovery of the proteasome’s 
catalytic activities, the activity patterns observed under these conditions were 
uninfluenced by bound inhibitor and, therefore, the level of each catalytic activity 
measured represents the average level of that activity conferred by the various 
proteasome subtypes present [224]. 
The individual proteasome activities of the two BtzR cell lines, relative to those of 
the parental cell line, were differentially altered: all proteasome activities were increased 
in BtzR#2, whereas only specific activities (β1 and β2) were elevated in BtzR#1, following 
bortezomib withdrawal (Figure 5.3 A).  Some of the activity assay results did not appear 
to be in accord with the immunoblotting results obtained.  Most notably, although a strong 
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increase in β2/β2i activity over parental levels was maintained in both BtzR cell lines 
(Figure 5.3 A), this does not appear to result from a marked overexpression of β2 (Figure 
5.4 A).  This disparity is also unlikely to be attributed to a large increase in the β2i subunit, 
since expression of this subunit remained below readily detectable levels (data not shown).  
Furthermore, we were unable to detect proteasome subtypes containing both β1i and β2i 
in BtzR#1 (Figure 5.5), and the formation of proteasome subtypes containing β2i 
combined with constitutive catalytic subunits is disfavored during proteasome assembly 
[220, 221, 223].  Therefore, other factors in addition to β2 and β2i expression levels likely 
contributed to the increased β2/β2i activity observed. 
As observed for the BtzR cell lines (Figures 5.3 A and 5.4 A), proteasome activity 
patterns and catalytic subunit expression levels in all three CfzR cell lines following 
carfilzomib withdrawal differed from those of the parental cell line.  Again, some of the 
immunoblotting results appear to be inconsistent with those obtained via proteasome 
activity assays.  For example, the β1 activity measured following carfilzomib withdrawal 
(Figure 5.3 B) may be higher than suggested based on β1 expression (Figure 5.4 B).  
Additionally, despite their differential regulation of β2/β2i activity (Figure 5.3 B), β2 was 
similarly overexpressed in all three CfzR cell lines following carfilzomib withdrawal (Figure 
5.4 B), while we were still unable to readily detect β2i expression (data not shown).  
Furthermore, our crosslinking results indicate that, in CfzR#2, the cell line with the highest 
β1i and β5i expression levels and activities and therefore the most likely candidate to 
harbor β2i-containing proteasomes [221, 223], all detectable β1i-containing subtypes 
contain β2 rather than β2i (Figure 5.5).  Another inconsistency is that, while both CfzR#1 
and CfzR#3 displayed equivalent β1i activity following carfilzomib withdrawal, higher 
levels of the β1i subunit were detected in CfzR#1 than in CfzR#3 (Figure 5.4 B), with both 
cell lines having an equivalent level of β1i activity (Figure 5.3 B).  Interestingly, the β5i 
expression in these two cell lines was found to bear an inverse relationship to that of β1i—
it was higher in CfzR#3 than in CfzR#1 (Figure 5.4 B).  This is consistent with the 
conclusion that these discrepancies are, at least in part, caused by differences in the 
activity profiles of the more abundant proteasome subtypes formed in each of these cell 
lines against the fluorogenic peptide substrates used in our study.   
Interestingly, in both the BtzR and CfzR cell lines, the more strongly overall 
proteasome activity was suppressed under inhibitor exposure, the higher overall 
proteasome activity became following inhibitor withdrawal (Figures 5.1 B and D and 5.3 A 
and B).  However this was achieved (e.g., by a general upregulation of proteasomes, 
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assembly of altered proteasome subtypes with higher overall activity, association with 
specific regulatory factors, etc.), it suggests that cells can detect to what extent 
proteasome activity is suppressed and can respond accordingly to ensure that 
proteasome activity is increased to the extent required to regain protein homeostasis once 
the inhibitor has been removed.  The finding that BtzR#2 maintained elevated α5 levels, 
while the levels of this subunit returned from their elevated state back to parental levels in 
BtzR#1, following bortezomib withdrawal is in line with the conclusion that the greater 
overall proteasome inhibition by bortezomib in BtzR#2 resulted in a general increase in 
proteasome components; this is further supported by the higher levels of expression and 
activity of all proteasome catalytic subunits in BtzR#2 than in BtzR#1 following bortezomib 
withdrawal (Figure 5.3 A and 5.4 A).  Additionally, that CfzR#2 was, following carfilzomib 
withdrawal, the cell line with the greatest expression levels and activities of 
immunosubunits β1i and β5i is consistent with the notion that immunosubunit-containing 
proteasomes may assist in restoring protein homeostasis following withdrawal from 
proteasome inhibitors [289]. 
These data indicate that the catalytic subunit composition of proteasomes remains 
altered in the BtzR and CfzR cell lines after bortezomib and carfilzomib withdrawal.  
Additionally, they show that the proteolytic activity profiles observed in these cells under 
these conditions cannot be fully accounted for by the expression levels of each active 
subunit.  These discrepancies may arise from differences in the overall architecture of 
each proteasome subtype that result from the incorporation of catalytic subunits in distinct 
permutations; such differences could result in each subtype interacting uniquely with each 
of the fluorogenic substrates, thereby impacting overall proteasome activity in a manner 
that does not solely correlate with the expression levels of each individual subunit.  Based 
on these findings, we conclude that the ratios of the various proteasome subtypes are 
altered in the inhibitor-resistant cell lines from those found in the parental cell line, which 
supports our hypothesis that such changes may contribute to the reduced efficacy with 
which proteasome activity is inhibited by bortezomib and carfilzomib.  Our crosslinking 
results are consistent with a reduction in intermediate proteasome subtype β1i-β2-β5i in 
BtzR#1, which may indicate a relative increase in constitutive proteasomes and/or 
intermediate proteasomes of composition β1-β2-β5i (Figure 5.5).  Alternatively, they 
indicate an increase in the levels of intermediate proteasome subtype β1i-β2-β5i in 
CfzR#2, potentially reflecting inhibitor-dependent effects (Figure 5.5).  It is therefore 
possible that differences in the relative levels of distinct proteasome subtypes in each cell 
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line may contribute to their disparate activity profiles as well as their ability to maintain 
substantial proteasome activity in the presence of bortezomib and carfilzomib and to 
regain adequate proteasome activity following inhibitor withdrawal.   
In summary, our cell line models of acquired resistance to the proteasome 
inhibitors bortezomib and carfilzomib exhibited altered proteasome activities and catalytic 
subunit expression patterns compared with those of the parental cell line from which they 
were generated, both in the presence or absence of these inhibitors.  The changes in 
these properties seen in the BtzR cell lines differed from those seen in the CfzR cell lines, 
which is consistent with the different mechanisms by which these inhibitors bind to the 
proteasome’s active sites as well as their different subunit binding preferences.  In both 
BtzR and CfzR cells, these changes appear to reflect a reorganization of proteasome 
composition, resulting in a shift in the relative ratios of particular proteasome subtypes.  
Our findings also indicate that the changes observed help to protect the inhibitor-resistant 
cells from an intolerable extent of proteasome inactivation.  That these alterations were 
observed in all of the inhibitor-resistant cell lines and differed inhibitor-dependently 
supports the hypothesis that they play a role in conferring bortezomib and carfilzomib 
resistance.  Finally, in both BtzR and CfzR H23 cells, a more pronounced inhibition of 
proteasome activity was associated with a stronger elevation of total proteasome activity 
following inhibitor withdrawal, further highlighting the adaptability of the proteasome 
complexes within these cells.     
It is highly likely that multiple mechanisms contribute to the proteasome inhibitor-
resistant phenotypes of our BtzR and CfzR cell lines.  If P-glycoprotein or other efflux 
pumps contribute, the effect is not pronounced enough to prevent sufficient accumulation 
of bortezomib within the BtzR cell lines to fully inactivate their β1 and β1i subunits and 
partially impair the activities of their β5i (and, for BtzR#2, β5) subunit(s), or to prevent 
sufficient accumulation of carfilzomib within the CfzR cell lines to cause substantial 
inhibition of primary carfilzomib targets β5 and β5i.  If β5 active site mutations contribute, 
we may also expect them to impair β5 activity, which we did not observe, and such 
mutations cannot account for the impaired suppression of β5i activity that was also 
observed in the inhibitor-exposed BtzR and CfzR cells.  Additionally, nonproteasomal 
proteolytic pathways such as autophagy may also help cells survive when their 
proteasome activities are reduced [290, 303-306].  However, the ability of our proteasome 
inhibitor-resistant cells to enhance the activities of the weakly-targeted proteasome 
subunits—while maintaining at least residual activities of others—suggests that 
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proteasome activity remains important for their continued survival and proliferation under 
the continuous pressure exerted by these inhibitors.  Future studies of these cell lines 
should be conducted to evaluate the contribution of each of these other potential 
resistance mechanisms.  Additionally, they should further evaluate whether specific 
subtypes of proteasomes play a causative role in resistance to each of these inhibitors.  
The use of the bifunctional probes described in Chapter 4, and of the second-generation 
probes our laboratory is currently developing, can assist in these studies.  Other members 
of our laboratory are using genetic approaches to evaluate the influence of specific 
proteasome subtypes on proteasome inhibitor resistance.  Finally, determining whether 
inhibiting the β2/β2i activity in the BtzR cell lines, or inhibiting the β1 activity in the CfzR 
cell lines, can sensitize them to bortezomib or carfilzomib, respectively, should shed 
further light upon the relative importance of the upregulation of these activities in acquiring 
resistance to these inhibitors.  The findings from these analyses could provide a rationale 
for the further development of β2/β2i- and/or β1-selective inhibitors to overcome or 
circumvent proteasome inhibitor resistance.  
The mammalian proteasome is a highly evolved and exquisitely specialized 
complex that provides critical assistance to a massive array of essential cellular functions.  
It is therefore not surprising that residual proteasome activities are typically detected in 
cell line models of acquired proteasome inhibitor resistance upon exposure to their 
selective inhibitor concentrations.  Armed with the ability to recruit different combinations 
of proteolytically active subunits into assembling 20S core particles, to remain unbound or 
to associate with a variety of activator complexes at one or both ends, to be allosterically 
regulated by its substrates or inhibitors, and to have its subunits be upregulated by a 
feedback loop when its activities have been inhibited, the proteasome is well suited to 
adapt itself to meet the needs of the cell in the face of a diverse range of cellular insults.  
Gaining a better understanding of the adaptive responses of the proteasome complex to 
inhibition of specific proteasome activities will in turn guide the development of 
proteasome-targeting approaches to block these responses and thereby thwart the onset 
of proteasome inhibitor resistance.   
 
 
 
 
Copyright © Kimberly C. Carmony 2016  
132 
6 SUMMARY 
It is now well-understood that proteasome inhibitor resistance is a major limitation 
associated with the clinical use of these agents in treating cancers, yet there is currently 
no consensus regarding the most important factors contributing to clinical cases of this 
resistance.  Mounting evidence has demonstrated that proteasome populations are 
diverse and can adapt to meet cellular demands.  This would be expected to pose 
challenges for proteasome inhibitor-based therapies.  In fact, this is supported by results 
from an increasing number of studies demonstrating that alterations in proteasome 
composition and catalytic activities occur when cancer cells acquire proteasome inhibitor 
resistance, and that these changes are associated with greater proteasome functionality 
when exposed to these inhibitors.  It thus follows that proteasome composition may play 
an important role in such adaptive responses, since the up- and downregulation of specific 
proteasome subunits may result in a relative increase in the abundances of proteasome 
subtypes that are more resilient to inactivation by the drug applied, and a relative decrease 
in the levels of those that are less resilient.  We set out to test this hypothesis in cell line 
models of acquired bortezomib and carfilzomib resistance derived from the H23 NSCLC 
cell line. 
Methodologies to identify distinct proteasome subtypes were limited when we 
began our study.  We therefore sought to develop new chemical tools to aid us in this 
process.  We generated a series of bifunctional activity-based probes that can crosslink 
distinct pairs of catalytic proteasome subunits within intact proteasome complexes and 
facilitate immunoblotting-based detection of the crosslinked subunit pairs.  These probes 
proved useful in detecting proteasome subtypes with distinct combinations of catalytic 
subunits.  Additionally, results obtained using these probes provided further evidence to 
support previously drawn conclusions regarding which combinations of catalytic subunits 
are permissible and which are discouraged when all six of these subunits are coexpressed.  
Our bifunctional proteasome probes should be useful not only in associating specific 
subtypes with sensitivity or resistance to a particular proteasome inhibitor, but also in other 
studies of proteasome function in both normal and diseased cells. 
We also derived cell line models of acquired bortezomib and carfilzomib resistance 
from the H23 NSCLC cell line in order to test our hypothesis that proteasome catalytic 
subunit composition is an important mediator of resistance to these inhibitors.  We 
identified changes in the expression levels and activities of individual catalytic proteasome 
subunits that were associated with the onset of acquired resistance to each inhibitor.  
133 
These changes were consistent with a shift in the relative abundances of the various 
proteasome subtypes, and their inhibitor-dependency and consistency across cell lines 
support a causative role in the resistance phenotypes observed.  Additionally, we 
observed a graded response to inhibition across these cell lines in which stronger 
inhibition of total proteasome activity was associated with a greater enhancement 
following inhibitor withdrawal, highlighting the ability of the proteasome complex to adapt 
to the appropriate degree to restore protein homeostasis when it is no longer under attack.  
Finally, the initial dataset obtained using one of our bifunctional proteasome probes 
indicates that β1i-containing proteasome subtypes in the parental and inhibitor-resistant 
H23 cells are predominantly intermediate proteasomes that also contain the constitutive 
catalytic subunit β2.  We found that this subtype was downregulated in a bortezomib-
resistant cell line, and upregulated in a carfilzomib-resistant cell line.  Taken together, our 
results indicate that alterations in the levels of specific proteasome subtypes occur when 
cells acquire resistance to either bortezomib or carfilzomib, and support the hypothesis 
that these changes play a role in conferring resistance to these inhibitors. 
Although we initiated experiments to examine the relative abundances of specific 
proteasome subtypes in our parental and inhibitor-resistant cell lines, additional efforts are 
needed in this realm to gain a true understanding of which specific proteasome subtypes 
are important in conferring resistance to each inhibitor.  Experiments involving the use of 
our bifunctional probes in inhibitor-sensitive and -resistant cell lines, as well as those 
involving genetic approaches, are underway in our laboratory to further investigate this.  
Additionally, our laboratory is working to determine whether the elevated proteasome 
activities detected in inhibitor-resistant cell lines can serve as co-targets for inhibitors and 
thereby allow improved anticancer activity to be achieved.  Furthermore, it is unlikely that 
changes in the proteasome complex serve as the sole mediator of bortezomib or 
carfilzomib resistance.  Moving forward, it will therefore be important to evaluate to what 
extent each potential resistance mechanism contributes to the resistance phenotypes 
observed.  If specific subtypes involved in conferring resistance to each inhibitor can be 
identified, the development of inhibitors that specifically target those subtypes, rather than 
a specific subunit or set of subunits, may be worthwhile. 
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